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With  the  recent  developments  in  biotechnology,  associated  patent  law 
issues  have  been  a  growing  concern  since  the  1980s.  Among  all  the 
subcategories  within  the  general  field  of  biotechnology,  human  embryonic 
stem  cell  research,  as  one  of  the  most  controversial,  is  receiving  different 
patent system treatment  in different countries. China explicitly opposes the 
patentability  of  hESCs  in  its  patent  regulations  on  the  basis  that  patenting 
hESCs  is  contrary  to  morality  and  the  public  interest.  Similarly,  the  EPO, 
relying  on  ambiguous  language  in  the  European  Patent  Convention   [EPC], 
excludes  hESCs  from  patentability  by  broadly  interpreting  the  morality 
clause  of  the  EPC.   In  contrast,  the  United  States  has  become  the  main 
progenitor of hESC patents. By analyzing the reasons to grant or deny patents 
on  hESCs,  and  considering  patent  law  doctrines  and  justifications,  this 
dissertation reaches  two conclusions. First, patent  law should not  include a 
morality clause and should only  take  into consideration  technical  concerns. 
Moral issues should be left to other mechanisms such as administrative law. 
This is an approach deeply rooted in the American patent system, but not in 
China  or  the  EPO.  Second,  by  reviewing  the  requirements  of  patentability 
such as novelty, non‐obviousness and utility, it can be concluded that hESCs 
themselves  are  not  patentable  because  they  lack  a  specific  concrete  utility 






In 2006,  two  crucial plans  regarding human embryonic  stem cell  [hESC] 
research were issued in China. The first of these was the Outline of National 
Medium and Long Term Science  and Technology Development Plan  (2006‐
2020)  issued  by  the  State  Council  of  the  People’s  Republic  of  China.  It 
adopted innovation as the new national strategy and established the goal of 
advancing  China  into  an  innovation‐oriented  country  by  2020.1 In  order  to 
reach  this  target,  the  outline  called  for  China  to  increase  its  investment  on 
research and development, encourage  indigenous  innovation, and adjust  its 
patent  laws  to  implement  the  new  goal  of  becoming  an  “an  innovation 
oriented  country,” 2  which  means  a  country  that  promotes  social  and 
economic  development  by  enhancing  science  and  technology  and  by 
increasing its globally influential scientific and technological achievements.3 
The  second  plan  called  the  National  Eleventh  Five‐Year  Science  and 
Technology Development Plan (11th), was authoritative between the years of 
2006  and  2010  and  was  promulgated  by  the  Ministry  of  Science  and 
Technology  [MOST].  It  called  for  the  establishment  of  a  bank  of  human 
embryonic  stem  cells  as  well  as  embryonic  stem  cells  derived  from  non‐
human primates,  the development of a differentiation model  for embryonic 
stem  cells,  and  progress  on  tissue  engineering  and  animal  cloning 















In  addition,  the  plan  demonstrated  China’s  specific  commitment  to 
nourishing biotechnological research, including hESC. 
In 2010, the MOST issued the Application Guideline for the National Basic 






maintain  the  same  developmental  pace.  Chinese  patent  law  was  recently 
amended in 2008 in an effort to embrace the Outline of National Medium and 
Long  Term  Science  and  Technology Development  Plan  (2006‐2020). While 
the  amendment  addresses  the  scope  of  the  novelty  requirement,  it  fails  to 
address  either  procedure  or  patent  right  enforcement.  The  revised  patent 
law does not specifically discuss the protection of biotechnology innovation. 
Meanwhile,  the  Chinese  Examination  Guidelines,  which  regulate  the 
patentability  of  biotechnological  innovations,  state  that  hESCs  and  their 
production  are  not  patentable  according  to  Article  5  in  patent  law6.  This 
conflicts with  the policies established  in  the  two above‐mentioned national 
plans. Encouraging innovation in science and technology is only one aspect of 
building an  innovation‐oriented  country. Proper  legal protection,  especially 











There are many articles  that discuss  the hESC research policy  in China, but 
very  few  articles  focus  on  the  patent  issues  directly  related  to  hESC 
innovation.  In  order  to  fill  this  gap,  I  analyzed  other  countries’  laws,  and 










This  dissertation  focuses  on  patent  law  issues  because  patent  law  is 
designed  to  be  a  stimulus  to  scientific  and  technological  progress.7 The 
mechanism  of  patent  law  is  to  reward  inventors  with  monopoly  rights  in 
order  to  encourage  scientific  innovation. While  simple  in  concept,  it  is  the 
burden  of  patent  law  to  adjust  the  degree  of  these monopolies  in  order  to 
maintain  a market with  fair  competition.  The  patent  laws  and  practices  in 
China have been gradually approaching those of developed countries due to 
international  treaties,  such  as  the  World  Trade  Organization’s  [WTO] 
Agreement  on  Trade‐Related  Intellectual  Property  Rights  [TRIPS 
Agreement]. However,  the goal of Chinese  legislation and policy concerning 










end‐product  industries.  With  respect  to  essential  tools  of  discovery  and 
research in biotechnology, one primary concern regarding the patent system 
is  the  side  effect  of  stifling  developmental  innovations  due  to  royalty 
requirements and negotiation time.8 Therefore, while patent protection is an 
important  tool  for encouraging  inventors, patent  rights are not absolute.  In 
order  to  enhance  the  progress  of  biotechnology,  the  scope  of  patentable 
subject matter should be restrained and research tool and experimental use 
exception should be sustained.9  
Granting  patent  protection  to  biotechnology  inventions  is  not  only 
intended to benefit public health, medical science and the drug industry, but 
also to enable states to maintain their competitiveness in the global market 
and  remain  independent  from  their  partners  in  trading.  Opponents  of  this 
viewpoint  argue  that  patent  protection  stifles  further  development  and 
innovation  by  awarding  a  monopoly,  thereby  limiting  competition.    In 
addition,  they  believe  that  it  causes  ethical  issues  due  to  the  close  relation 




Considering  the  importance  of  hESCs  to medicinal manufacture,  therapy 














patent  legislation  on  biotechnology  covers  almost  the  entire  field  of 
biotechnological  research  and  expresses  China’s  stance  on  some  ethically 
controversial issues. On the topic of patenting hESCs, China holds that hESCs 
and  their  production  are  not  patentable  under  morality  clauses  in  the 





institutes  or  public  universities  and  is  therefore  carried  out  with  a  high 
degree of rigor and professionalism. This is beneficial in three ways. First, the 
research  is  conducted  either  by  government  agencies  or  under  the 
supervision of the government, which may diminish the possibility of misuse 
or  illegal  conduct.  Second,  it  dispels  worries  about  future  research  being 
impeded by high royalties and lengthy negotiations. Because the government 
can  supervise  licensing  and  assignment  activities  in  the  interest  of  the 
country  as  a  whole,  there  is  no  need  to  be  concerned  about  research 
monopolies  hampering  further  downstream  development.  Third,  research 
results  can  be  utilized  and  applied  under  the  government’s  control  for  the 
public  interest.  In  the  case  of  emergencies,  such  as  those  involving  public 
safety,  decisions  can  be  made  more  quickly  and  measures  can  be 
implemented more thoroughly.  
Countries  utilize  the  patent mechanism  to  stimulate  science.  Along with 
the benefits  that  patenting hESC  inventions  can bring,  such  as  encouraging 
research,  there  are  a  number  of  concerns.  It  is  possible  to  misuse  or 
monopolize  research  results,  which  may  stifle  competition  and  lead  to 




does  not,  on  the  surface,  seem  globally  critical  since  such  laws  have  only 
territorial legal force. Nonetheless, non‐uniformity of patent laws may impact 
the international trade business in the global market and stifle the circulation 
of  product  innovations.  Facing  increasingly  fierce  industrial  and  scientific 
competition  and  an  increasingly  globalized market,  it  is  crucial  to  consider 
the role of scientific  innovation  in patent  law  in order  to avoid making bad 
decisions  that  will  adversely  affect  industry  and  science.  As  for  the  U.S., 
hESCs are presently patentable subject matter. If these inventions are, in the 
future,  deemed  unpatentable  and  opened  to  the  public,  the  licensees  who 
spent  tremendous  time  and money  negotiating  license  agreements  will  be 
unfavorably  impacted which will  bring  about  instability  in  the  industry.  In 
contrast, with  respect  to  those countries  that do not presently patent hESC 
innovations,  if  their  bans  on  patenting  hESCs  are  removed  in  the  future, 
countries  patenting  hESCs  all  along,  like  the US, will  take  advantage  of  the 
priority  right  in other  countries based on  international  treaties  such as  the 
Paris  Convention  for  the  Protection  of  Industrial  Property,  the  Patent 
Corporation  Treaty  [PCT]  and  bilateral  agreements.10 Because  hESC  patent 

















Along  with  the  rapid  development  of  biotechnology,  patent  laws  have 
been challenged substantially. Patent‐eligibility  issues on biotechnology are 
always contentious and sensitive. Which subjects are patentable, and which 
are not? Should patent  law extend  to new categories  like hESCs?  If  so, how 
should patent law be applied to them? Should patent law be altered for new 
types of subject matter? How should patent laws be utilized to maintain the 
balance  between  scientific  and  industrial  benefits  and  social  morality 
concerns generated by new technology? Investors and researchers urgently 
require  answers  to  these  and  other  questions.  Therefore,  these  difficult 
issues  should  be  solved  as  rapidly  as  possible  in  order  to  guarantee  and 




historical  debates  regarding  hESC  inventions  in  the  European  Patent 
Organization,  the  United  States  and  China,  this  dissertation  comes  to  the 
conclusion  that  hESCs  themselves  should  not  be  considered  patentable. 
While hESCs fail to meet the novelty and utility requirements of patent law, 
production methods and derivative products are found to be patentable. It is 
suggested  that  current  patent  rules  be  adjusted  to  consider  only  technical 
issues in the patent law. It is also suggested that the definitions and scopes of 
the  novelty  and  utility  requirements  be  altered  in  order  to  eliminate  the 
conflicting  rules  regarding  hESCs  across  the  relevant  countries.  This  study 
finds that the patent system is  indispensable to biotechnological  innovation 
and  research  goals,  such  as  the  development  of  methods  for  culturing, 
differentiating,  and  utilizing  hESCs,  and  the  development  of  downstream 
products from hESCs. 
This dissertation is divided into six chapters. Chapter 2 provides a general 
scientific  background  regarding  stem  cells with  an  emphasis  on  embryonic 
8 




related  innovations  in  the  United  States,  the  European  Patent  Office  and 
China,  respectively.  Chapter  VI  summarizes  the  differences  in  patent  rules 













renewing  indefinitely  and  differentiating  into  a wide  variety  of  specialized 
cells.11 Self‐renewal is the ability to produce a pool of identical cells12, which 
is  also  called  symmetric  cell  division13 (Figure  2.1).  In  addition,  stem  cells 
may  differentiate  into  more  specialized  cells,  such  as  red  blood  cells  or 
muscle cells,  in a process called asymmetric cell division14 (Figure 2.2  is an 
example of asymmetric cell division in the nervous system). When stem cells 
divide,  they  may  self‐renew  or  differentiate  into  specialized  cells  with 




























Stem  cells  can  be  divided  into  five  categories  based  on  their  potency,  a 
measure of their differentiation potential into specific cell types.16 In order to 
explain  the  various  types  of  stem  cells,  it  is  necessary  to  discuss  the  early 
development of the embryo. 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As  shown  in Figure 2.3, human embryos begin with  the  fusion of an egg 
and sperm, which forms a zygote,18 after which cell division begins. When the 










blastocyst  segregates  into  trophoblast  cells  and  an  inner  cell mass  [ICM],20 
also  known  as  the  embryoblast.  The  trophoblast  cells  develop  into  the 
placenta while the ICM forms the three germ layers of embryo.21 
Totipotent stem cells give rise to all embryonic cells and extraembryonic 
cell  types.22 Zygotes  are  the  prototype  of  totipotent  cells.23 Stem  cells  with 
the ability to form all of the cell types of the body are classified as pluripotent 


































Fetal  stem  cells  can  be  extracted  from  fetuses  five  to  nine  weeks  after 
conception. These stem cells are responsible for the initial development of all 
tissues.33 Both  fetal  and  embryonic  stem  cell  research  triggers  a  similar 
ethical debate. 
Adult stem cells, also called somatic stem cells, are undifferentiated cells 
found  in  certain  organs  and  tissues  that  can  renew  themselves  and 




other  cell  types  under  some  special  conditions,  grants  adult  stem  cells  an 
important  role  in  cell‐based  therapy.37 Generally  speaking,  this  category  is 





















Stem  cells  have  tremendous  scientific  and  therapeutic  value  thanks  to 
their ability to proliferate indefinitely and differentiate.40 An example of this 
value  is  their  ability  to  repair  and  regenerate  damaged  tissues  and  organs 
from  a  variety  of  diseases.41 Great  efforts  have  been  made  to  utilize  the 




marrow  cells  contain  blood  and  immune  system  stem  cells,  which  may 
broaden  their  therapeutic  uses  for  other  diseases.43 Stem  cells  also  have 
potential therapeutic value in Parkinson’s disease, spinal cord injury, retinal 
degeneration,  diabetes,  brain  tumors,  and  cardiovascular  and  metabolic 
diseases.44  
However, immune rejection of transplanted tissues can arise during stem 
cell  therapy,  as  the  immune  system  of  the  recipient  may  identify  the 
transplanted  cells  as  foreign.45 In  the  case of bone marrow  transplantation, 
the graft, which is the actual bone marrow that is being given to the patient, 
can  also  reject  or  react  against  the  host,  because  bone  marrow  is  the 
substance containing  the  immune  system  that  produces  the  rejection 
response. This is known as graft‐versus‐host disease (GVHD).46 To solve this 
problem,  there  are  several  theoretical  solutions,  including  genetically 















to  generate  embryonic  stem  cells  genetically  identical  to  the  patient  by 
somatic  cell  nuclear  transfer  [SCNT],  a  process  by  which  the  nucleus  of  a 
donor  egg  is  replaced with  the  nucleus  from  a  somatic  cell  taken  from  the 
patient.48 But considering the public’s discomfort with cloning and the vague 
line  between  reproductive  cloning  and  therapeutic  cloning,  this  method  is 
ethically controversial. 
In  addition  to  repair  and  regeneration,  stem  cells  offer  an  alternative 
method  of  pharmaceutical  testing.  During  an  investigational  new  drug 
application  [IND  application]  in  a  nation—take  the  U.S.  as  an  example—
applicants are required to submit safety reports49 to demonstrate the safety 
and  effectiveness  of  new  drugs.50 Historically  applicants  have  relied  upon 
animals testing. However, due to the significant differences between human 
and  other  animals,  a  drug’s  effectiveness  and  toxicity  results  from  animals 
cannot be directly applied to human beings with confidence.51 For improved 
effectiveness and toxicity studies, applicants could test new drugs on actual 
human  tissues  or  organs  derived  from  stem  cells.  The  application  of  stem 
cells  in  pharmaceutical  testing  could  theoretically  assure  drug  safety  and 
efficiency.52 The acceptance of  in vitro  testing  is  confirmed  in  the U.S. Food 
and Drug Administration’s [FDA] new rule, entitled Investigational New Drug 
Safety Reporting Requirements for Human Drug and Biological Products and 












Studies  in  Humans, which  adds  in  vitro  study  results  as  another  source  of 
information in safety reports.53  
Currently,  generally  speaking,  stem  cell  research  enhances  public  health 
and  welfare  by  creating  new  treatments  for  human  disease  in  the  central 
nervous  system.54 In  addition,  it  benefits  the  drug  industry  by  improving 
therapeutic efficacy.55 
3.   Global Investments on Stem Cell Research 
 





Unlike  the  private  sector,  governments  are  willing  to  play  the  role  of 
investor  for  two  prime  reasons.  First,  as  previously  discussed,  stem  cell 
research promotes national health and improves public welfare by delivering 
health  benefits  to  the  population.  Second,  since  the  era  of  a  biotechnology 
economy  has  arrived,  people  understand  how  large  and  competitive  the 
business will be in the global market. No country wants to fall behind in this 
biotechnology race.  
































$643  $968  $938  $1231  $1182  $1100 
Stem Cell Research 
     Human 
$38  $74  $88  $143  $137  $126 
Stem Cell Research 
     Nonhuman 
$110  $120  $150  $177  $161  $155 
Stem Cell Research 
     Nonembryonic Human 








Beyond  federal  appropriations,  states  input  millions  of  dollars  toward 
stem  cell  research  as well.  New  Jersey  invested  10 million  USD  in  January 
















report,  providing  up  to  600  million  USD  over  11  years  for  stem  cell 
research. 62  Connecticut  provided  100  million  USD  in  state  funding  for 
embryonic stem cell research over 10 years. Illinois granted 10 million USD 
to stem cell projects over 10 years in 2005 and added an extra 5 million USD 
in 2006. Maryland handed out 9 million USD  to 24  institutions  for a  three‐
year project.63 
In other countries, Canada is estimated to invest 40 million CAD per year 
on  stem  cell  research on  average,  and Germany  allocated 61.9 million EUR 




























(the  ectoderm,  mesoderm,  and  endoderm). 67  There  are  currently  two 
techniques  used  to  obtain  embryonic  stem  cells.  The  main  technique, 
originally  conceived  by  Dr.  James  Thompson  in  1998, 68  is  to  derive 
embryonic  stem  cells  from  the  inner  cell  mass  [ICM]  of  blastocysts. 69 





technical  problems  hinder  their  effective  and  routine  use  in  cell‐based 
therapies.  For  instance,  no  standardization  in  techniques  for  culture, 
maintenance  and  derivation  of  hESCs  has  been  achieved.  Recently,  some 
researchers  demonstrated  that  methods  of  culturing  hESCs  affect  their 
potentiality  of  differentiation  and  integrity  of  genomic  imprinting. 72 
























destruction of  embryos,  in practice,  the main  sources  from which  to derive 
ESCs  are  excess  embryos  produced  by  assisted  reproductive  techniques. 
Most commonly, these are in vitro fertilization [IVF]75 embryos left in fertility 
clinics.  In  the  US,  only  a  small  number  of  embryos  produced  by  IVF  are 
transferred  into  a  woman’s  uterus;  therefore,  many  embryos  are  kept  in 
freezers. Supporters of embryonic research claim that when  these embryos 
are  discarded by parents  and  are not  going  to  become human beings,  they 
are better used in hESCs research rather than simply being destroyed.  
It is theorized that undifferentiated ESCs fertilized by sperm and egg may 
be more  immunologically  compatible with any  recipient  than other mature 
stem  cells.76 However,  since  the  cells  carry  the  specific DNA of  the  embryo 
from which they were derived, they have different DNA than the recipients. 
Due  to  antigenic  differences,  immunological  rejection  will  happen  after 
transplantation.77 One  possible  solution  to  this  problem,  enabling  ESCs  to 
















immunological  rejection.78 SCNT  is  a  laboratory  technique  that  creates  a 









a  blastocyst,  grown  and  further  differentiated  into  particular  cell  types  as 
required for therapeutic uses.  
Reproductive  cloning  is  prohibited  by  most  international  organizations 
including the United Nations, and in most states because of ethical concerns, 
while therapeutic cloning is allowed, or even encouraged in some countries, 
like  Iraq,  China  and  the  United  Kingdom.  In  therapeutic  cloning,  scientists 
make  hESCs  following  SCNT,  cultivate  them,  and  differentiate  them  into 
particular needed cell types. These differentiated cells can be implanted into 
the DNA donor’s body  to  repair or  replace damaged cells,  tissues and even 
organs. However, therapeutic cloning is still somewhat theoretical. 81 Korean 


















scientists  have  been  investigating  other  methods  to  obtain  cells  with  the 
same pluripotent characteristics. Pluripotent stem cells can be obtained from 
parthenogenically  activated  eggs,  named  human  Parthenote  stem  cells 
[hPSCs], by artificially activating eggs with electrical pulses and several types 
of chemicals.85 HPSCs have  the same characteristics as other stem cells:  the 
capability  of  endless  self‐renewal  and  cell  division. Most  importantly,  they 
have been demonstrated to develop tissues from all germ layers but are not 





Another  development  is  induced  pluripotent  stem  cells.  In  2007,  Shinya 
Yamanaka  of  Kyoto  University  in  Japan  reported  that  he  and  his  colleague 
successfully turned skin cells into embryonic stem [ES]‐like cells, which were 
believed  to  be  pluripotent  and  might  have  the  capacity  to  grow  into  any 


















into  all  cell  types  of  the  body.  This  is  a  huge  step  in  stem  cell  research 
because  if  that  characteristic  is  proven,  people may not need hESCs, which 
are highly controversial, for disease treatment or drug testing any longer, as 
iPSCs may have the same function as ESCs without triggering ethical issues.91 
However,  whether  iPS  cells  will  replace  ESCs  is  still  an  open  question. 
Recently, two Chinese researchers created live mice from iPS cells, although 
one of  the researchers, Qi Zhou, emphasized that “it  is not  intended to be a 
first step towards using iPS cells to create a human being.”92 This is one step 
to  help  discover  the  differences  between ESCs  and  iPSCs.  Even  if  scientists 
can prove that the iPSCs can replace ESCs, iPSCs may have a more restrictive 
























body.  Sometimes,  rather  than  repairing  dysfunctional  cells,  whole  organ 
replacement  is  required.  In  these  cases,  hESCs  can  be  cultivated  and 
differentiated  under  certain  conditions  until  they  become  the  organ  or 
particular cells that are needed. For example, in the case of diabetes, insulin‐
producing  pancreatic  cells  do  not  function  well;  therefore,  scientists  could 
inject  ESCs‐derived  pancreatic  cells  into  the  body.  In  heart  attack  cases, 
physicians could repair the damaged heart by using heart cells differentiated 
from ESCs in a laboratory.  




injuries,  which  has  been  approved  by  the  FDA  in  2010.93 The  trials,  using 
hESC  therapy,  mark  the  beginning  of  a  new  era  of  tissue  and  organ 
regeneration by ESC‐derived cells.  
In  addition  to  therapeutic  applications,  ESCs  can  also  be  used  for 
pharmaceutical testing in the field of disease research.94 ESCs can be used for 
safety and effectiveness evaluations during an IND application. At the present 
time,  researchers  test  new  drugs  on  animals  initially,  and  implement  a 
second stage of trials on healthy volunteers and a small number of diseased 
people  if  the  animal  results  are  satisfactory.  But  due  to  the  inherent 
differences between animal and human tissues, the drug under test may have 
dramatically  different  results  when  tested  on  humans.  Due  to  the 
unpredictability  of  the  results,  a  test  program  modeled  on  the  above 
described  protocol  can  place  the  human  test  subjects  at  undue  risk.  By 







the  risk  taken  by  the  human  subjects  might  be  dramatically  reduced. 
Researchers need a sample that is similar, or even exactly the same as human 












genetic  diagnosis  made  during  in  vitro  fertilization  [IVF]96 to  vet  embryos 
before using them to derive ESCs in practice.97  
After  acknowledging  the  scientific  background  of  hESCs,  and  their 
pharmaceutical and therapeutic value,  it  is nonetheless clear that the use of 
hESCs  gives  rise  to  a  serious  ethical  debate.  Because  of  its  intimate 
relationship  with  human  embryos  and  its  unclear  moral  status,  the 
legitimacy  of  hESC  research  is  a  values  and  culture  based  issue.  Although 













Chapter 3: Ethical,  Religious  and  Philosophical  Viewpoints  on 
Human Embryonic Stem Cell [hESC] Research 
 
No  matter  how  amazingly  hESCs  may  function,  in  practice,  there  are  a 
number of unresolved  issues  in  the  field. This chapter explores a variety of 





overall  fabric of  legal and political  factors  that have a bearing on the actual 







within  society. The main debate  is  focused on  the moral  status of  embryos 










Given  this  ethical  controversy,  discarded  frozen  embryos  from  IVF 
procedures are used to reduce the moral debate and therefore  increase the 
general  acceptance  of  hESC  research.  In  a  2010  survey  of  public  attitudes 
toward  human  embryo  research  in  the  United  States,  72%  respondents 
supported research utilizing excess embryos.100 As mentioned above, couples 





infertile  couples  or  have  them  destroyed.  As  a  result,  these  embryos  from 
clinics are considered perfect resources for ESC research because they will be 
destroyed  and  never  have  the  chance  to mature  into  human  beings  in  any 



















embryo  research  is  thought  to  impose  an  unfair  burden  on  “an  innocent 
human being”104 (the embryo) for the exclusive benefit of others.105  
Research  on  embryos  obtained  through  other methods,  such  as  somatic 
cell nuclear transfer, or research‐purpose IVF, is more controversial because 
it  involves  another  question:  the moral  status  of  human  embryos.  At what 
point is a human being entitled to dignity and the protection of the law? Since 
hESCs are derived  from blastocysts,  the status of blastocysts  is  the  focus of 
the debate concerning hESC research.  
Proponents  of  ESC  research  have  various  reasons  from  a  scientific 




somatic cells.   For example,  in  female ESCs, both X chronosomes are active.  
During embryonic development, one X chromosome is inactivated. Even after 







blastocyst  (the  five day pre‐embryo),  the nervous system and brain system 












ESCs  from SCNT,  Some people  claim  that  these  cells have  little potential  to 
develop  into  human  beings  because  they  lack  the  attributes  of  normal 
embryos  and  harbor  fundamental  biologic  deficiencies;  therefore,  using 
SCNT  to  produce  embryonic  stem  cells  is  morally  justified.110 An  intention 
argument can also be made for weighting human beings over hESCs obtained 
by  SCNT  since  SCNT  is  a manufacturing  process  that  focuses  on  producing 
cells instead of infants, and therefore the embryos made by SCNT differ from 
early human embryos and are not human beings.111  
Opposing  the  above  viewpoint,  some  people  consider  that  since  human 
life  starts with  fertilization,  zygotes are also persons.112 Human dignity and 
























zygotes  produced  by  both  the  IVF  process  and  SCNT.118 According  to  this 
view, hESC extraction from embryos infringes on their human dignity.  
 
B.  The Start‐line of Personhood and Ethics of hESC Research  from  the 
Perspectives of Religion and Philosophy  
 
1.  Religious  Viewpoints  on  Human  Embryo’s  Status  and  hESC 
Research 
 
Similar  to  the  ethical  debates  described  previously,  hESC  research  has 
prompted debates  in  the religious sector as well. One of  the primary  issues 
driving  the debates  is  concerned with  the moral  status of human embryos: 
whether  the  embryos  maintain  human  dignity  at  the  same  level  as  an 
advanced fetus or child. This topic is closely related to questions concerning 
abortion and human life. A technique to mitigate this question is to establish 
a  timeline  for  the  embryo  that  defines  specific  epochs  and  milestones  of 
development.  
Historically,  human  embryos  did  not  always  have  the  same  status  as 
persons in Christianity. The Septuagint version of the Bible119 compiled in the 
third  century  BCE,  commonly  used  by  “the  early  Christian  fathers,” 120 
stipulated  that  the  fine  for  hurting  a  pregnant woman  is  dependent  on  the 
stage  of  the  fetus.  If  the  fetus  is me  exeikonismenon—not  yet  formed  as  a 
human portrayal,  the punishment  is  in the form of a payable fine, but  if  the 
fetus  is  exeikonismenon,  the  punishment  is  elevated  to  execution  with  the 








utilized  the quickened status122 of  the  fetus  to determine  the eligibility of  a 
priest to maintain his duties as a minister in the event he was involved in a 
forced miscarriage.123 Pope Gregory  XIV  affirms  this  conception  in  1591.124 
The  method  of  rating  the  protection  level  on  the  stages  of  a  human’s 
development  is  maintained  in  some  religions,  but  overturned  by  others 
including Catholicism. Table 3.1 demonstrates the start‐line of personhood125 





the  religions  chosen  for  most  studies  on  religious  perspectives  of  hESC 
























Catholicism  Conception  Opp  N/A 
Protestantism 
Methodism  Conception  Pro  N/A 
Presbyterian  None  Pro  N/A 
Episcopalian  None  Pro  N/A 
Lutheranism  Conception  None  Opp 
Eastern Orthodoxy  Conception  Opp  N/A 
Buddhism 
Theravada  Conception  None  Unresolved 
Mahayana  Conception  None  Pro 













 Christianity  has  three  mainstream  variants,  Catholicism,  Protestantism 












destruction  in  an  official  statement. 128  The  U.S.  Conference  of  Catholic 
Bishops also opposes any  research  that deliberately destroys human  life  at 
any  stage,  including  embryonic  stem  cell  research  that  destroys  human 
embryos.129 But  even  Catholics  admit  that  there  is  not  a  simple,  single 
opinion  in  the  Catholic  community  on  topics  such  as  hESC  research130 that 
are based on different interpretations of the moral status of human embryos 
and fetuses.131 Some Catholics allege that embryos should be protected at the 
same  level  as  a  person  and  not  be  created  or  destroyed  for  research 
purposes; research on human embryos should be banned, they say, because 
it  spurs  on  embryo  creation  or  abortion.132 However,  others  support  hESC 
research because they believe that embryos in early states do not possess the 



























 The  Presbyterian  Church  does  not  explicitly  state  when  human  life 
begins.135 The 213th General Assembly of the Presbyterian Church (U.S.A.) in 
2001  voted  in  favor  of  scientific  research  such  as  embryonic  stem  cell 
research  because  the  goal  of  the  research,  which  is  saving  lives,  is  so 
compelling and unachievable by other methods.136 The policy was reaffirmed 
by the 216th Assembly in 2004.137    
The Episcopal  Church  also does not have  an  explicit  statement  on when 
human life begins.138 Its governing body, the General Convention, declared its 
support  for  hESC  research  with  embryos  left  over  from  IVF  and  other 
fertilization  procedures  as  long  as  the  embryos  are  no  longer  required  for 
their  original  purposes  or  created  for  research  purposes  or  sale,  and  the 
donors have given prior informed consent.139  





















the Church Wide Assembly and proposed  that a  social  statement should be 
produced by 2011. 141 Individually,  some people  consider hESC research on 
extra  IVF  embryos  or  from  abortion  to  be  justified  considering  its 




all  human  lives  should  be  entitled  to  the  same  level  of  protection,  hESC 
research  that  involves  destruction  of  embryos  should  be  banned  to  avoid 
immoral  and  fundamental  violations  of  human  life.144 Orthodox  Christians 
also  believe  that  embryonic  stem  cell  research  should  be  forbidden  out  of 
respect for human life except in the case of spontaneous miscarriage.145  
Adherents of Buddhism believe  that  the  transmigration of consciousness 





























embryonic  stem  cell  research  because  it  benefits  the  whole  society.  In 
Theravada  Buddhism,  no  official  stance  is  taken  and  arguments  are 
formulated  both  advocating  and  opposing  hESC  research.148 In  Mahayana 
Buddhism, the idea is to achieve self‐emptying, and to return help for those 
in  need.  From  this  viewpoint  embryonic  stem  cell  research  has  a  rational 
basis.149  
While  there  is no official  ruling on hESC research, Hinduism asserts  that 
life begins at conception.150 In Hinduism, which is based on the principles of 




as  the  beginning  of  human  life,  IVF  and  embryonic  research  are  allowed 
because  therapeutic  benefits  of  hESC  research  outweigh  the  damage  of 
sacrificing blastocysts. 151  
It is hard to find an authoritative body to represent a single Islamic stance 

























In  general,  religious  groups  have  diverse  viewpoints  concerning  hESC 




























Unlike  religions,  which  usually  have  governing  bodies,  philosophical 
theories  are  more  varied  and  there  is  an  absence  of  authority  to  unify 
different  thoughts.  Hence,  almost  all  philosophical  schools  can  be  divided 
into  favor‐hESC  research  and  against‐hESC  research  factions.  For  instance, 
embryonic stem cell research can find both advocates and opponents within 
Kantianism. Some Kantian followers argue that the denial of the humanity of 
zygotes  by  declaring  that  humanity  begins  at  birth  is  “scientifically 
obscurantist,”  and  one  principle  of  Kantianism,  defined  in  the  phrase  “it  is 
impermissible for anybody at will to use force upon another” applies to both 
the born and unborn.160  Another group of Kantian followers believes that the 
state  of  personhood  is  not  established  at  the  time  of  conception  because  a 
Kantian  person  is  transcendental  and  intelligible  rather  than  the  empirical 
being. 161  Based  on  this  theory,  some  Kantian  followers  believe  that 
embryonic stem cell research is beneficial to human health and life.162  
In  contrast  to  the  Kantian  views,  a  number  of  alternative  philosophical 
schools  are  more  aligned  with  a  supportive  stance  toward  hESC  research 
based on its value in a modern society.  
As  an  example,  most  feminists  do  not  consider  embryos  as  having  the 
moral  or  legal  status  of  full‐fledged  persons.163 From  a  feminist  viewpoint, 















human  embryo.  However,  according  to  the  successor  of  Confucius—
Mencius—humans  possess  four  moral  capacities  to  be  distinguished  from 
animals:  righteousness  (yi),  propriety  (li),  wisdom  (zhi)  and  humanity 
(jen).165 Based on  this premise,  embryos can hardly be  considered persons. 
From  a  Confucian  perspective,  the  family  and  society,  instead  of  the 
individual,  are  the  center of health  care decision‐making;166 therefore,  even 
though  there  is no explicit  statement on embryonic stem cell  research,  it  is 
justified under the Confucian principles. 
Similarly,  followers of Utilitarianism  identify goodness not as  the agent’s 
own  happiness,  but  as  “the  greatest  amount  of  happiness  altogether.”167 
Some utilitarians insist that only autonomous creatures should be taken into 
account.168 Using this view, embryos have no moral standing since they have 
























was  brought  against  a  Texas  criminal  abortion  law,  which  prohibited 
abortion  at  any  stage  of  pregnancy  except  when  necessary  to  save  the 
mother’s life. The Supreme Court admitted that when life begins is a question 
about  which  “those  trained  in  the  respective  disciplines  of  medicine, 
philosophy, and theology are unable to arrive at any consensus,” and decided 
that the judiciary is not the right place to answer it.171 However, it held that 
the word  “person”  as used  in  the Fourteenth Amendment does not  include 
the unborn.172 In order to balance the state’s interest in protecting potential 
human life and the liberty interest of women, a trimester based schedule was 
devised,  rejecting  any  legislation  limiting  a  woman’s  choice  regarding  the 
disposition  of  an  embryo  during  the  first  trimester.173 In  conclusion,  the 
Court  held  that  the  Texas  criminal  abortion  statute  failed  to  recognize  the 
interests  of  the  mother  and  violated  the  Due  Process  Clause  of  the 
Fourteenth Amendment.174 It states,  
“For  the stage prior  to approximately  the end of  the  first  trimester, 
the abortion decision and its effectuation must be left to the medical 
judgment of  the pregnant woman's attending physician.  .  .  . For  the 
stage subsequent to approximately the end of the first trimester, the 
State, in promoting its interest in the health of the mother, may, if it 
chooses,  regulate  the  abortion  procedure  in  ways  that  are 
reasonably related to maternal health.  .  .  . For the stage subsequent 








except  where  necessary,  in  appropriate  medical  judgment,  for  the 
preservation of the life or health of the mother.”175  
The  Supreme  Court  rejected  the  idea  that  embryos  have  a  right  to  life 
protected by the Fourteenth Amendment.  
Planned Parenthood v. Casey, 505 U.S. 833 (1992) reaffirmed the judgment 
of Roe  v. Wade  and  held  that  states’  interest  in  protecting  life  fell  short  of 
justifying  the  override  of  human  liberty  claims.  In Stenberg v. Carhart,  530 
U.S.  914  (2000),  the  Supreme  Court  reaffirmed women’s  right  to  abortion, 
and held that “the state's interest in regulating abortion previability of a fetus 
is considerably weaker than postviability of a fetus,“ manifesting its intention 
to  distinguish  fetuses  without  the  capacity  of  maintaining  a  separate 
existence  from  fetuses  with  that  capacity.  Davis  v.  Davis,  842  S.W.2d  588 
(1992)  held  that  fetuses  were  not  human  beings  under  the  Tennessee 
Wrongful  Death  Statute,  and  were  not  entitled  to  the  same  protection  as 
“persons.”  Jeter  v.  Mayo  Clinic  Ariz,  211  Ariz.  386  (2005)  held  that  pre‐
implantation fertilized human eggs were not “persons” under Ariz. Rev. Stat. 
§ 12‐611. After President Obama opened the gate to federal appropriation on 






China  [GPCL]  (1986),  Article  9  stipulates  that  “a  citizen  shall  have  the 
capacity  for  civil  rights  from birth  to  death  and  shall  enjoy  civil  rights  and 
assume civil obligations in accordance with the law,” which means that China 






no civil  legal capacity or  legal responsibility. However,  the fetus has certain 
rights  of  inheritance  in  civil  law.  In  the  Law  of  Succession  of  the  Peoples 
Republic of China (1985),177 Article 28 provides unborn children a reserved 
share  at  the  time  of  the  estate  partitioning.  In  the  event  that  the  baby  is 
stillborn,  the  share  shall  be managed  according  to  statutory  succession.  In 
China, abortion is permitted, especially under the One Child Policy since the 
1980s,  according  to  which  one  couple  shall  have  only  one  child  except  in 
exceptional  conditions  that  are  promulgated  in  regulations. 178  But  any 
abortion  performance  is  under  the  nation’s  supervision.  Any  one  who 
conducts an illegal abortion will receive an administrative penalty, fines and 
even criminal punishment.179  
In  Europe,  the  countries maintain  various  laws  concerning  the  status  of 
embryos  and  the  beginning  epoch  of  human  rights  in  the  embryo  or  fetus 
timeline. As  in China, according to Section 1 of German Civil Code,  the  legal 
capacity  of  a  human  being  starts  at  the  completion  of  birth.  The  Federal 
Constitutional Court  in Germany has ruled  that abortion within  the  first 12 
weeks  of  pregnancy  is  allowed.180 In  the  French  Civil  Code,  Art.  725  states 
that  a  fetus’  right of  inheritance  is protected provided he/she  is born alive 
subsequently.181 In contrast, some countries in Europe give unborn children 
more  protection.  Article  15  of  the  Spanish  Constitution  sets  forth  that 














human  life  in  the womb;  Ireland also  recognizes  the  right  to  life of unborn 
children.182 Among European countries, fetuses and embryos receive various 
amounts of  legal protection.  It  is  too absolute to say that a  fetus or embryo 
has no legal rights, but it is also incorrect to claim that a fetus or embryo has 
the same legal rights as living people.  
In  European  regional  organizations,  there  is  no  official  statement  about 
the  status  of  embryos  considering  the  divergence  of multiple  cultures  and 
traditions.  Article  2  of  the  European  Convention  on  Human  Rights  [ECRH] 
provides  that  everyone’s  right  to  life  shall  be  protected.  But  whether 
“everyone”  includes human embryos was questioned  in  the case of Evans v. 
the United Kingdom in 2007. The case focuses on whether the member states 
of the ECHR have the obligation to protect the right to life of embryos under 
Article  2.  In  a  unanimous  judgment,  the  Grand  Chamber  ruled  that  no 
European  wide  consensus  has  been  established  on  the  level  of  legal 
protection  to  grant  a  human  embryo;  therefore  in  this  case,  under  English 
law, an embryo has no right to life as a person.183 Instead of interpreting and 
defining  the  protecting  scope  of  the  ECHR,  the  court  chose  to  evade  the 
hardcore issue at bar and left the ambiguity to member states. 
In  the European Union,  the  status of human embryos  is  also blurry. The 
Charter of Fundamental Rights of the European Union also promises the right 
to life to “everyone” in its Article 2, but the definition and scope of “everyone” 
is  not  clear  in  this  document  either.  None  of  the  constitutional  courts  in 
Europe  have  defined  the  legal  status  of  human  embryos  in  practice.184 The 
Convention on Human Rights and Biomedicine (1997) prohibits the creation 
of  human  embryos  solely  for  research  purposes,  but  allows  research  on 
embryos  in  vitro when  adequate  protection  is  given  under  Article  18.  The 






Council  on  the  Legal  Protection  of  Biotechnological  Inventions 
[Biotechnology  Directive]  forbids  patenting  the  human  body  at  various 
stages  and  considers  the  use  of  embryos  for  industrial  or  commercial 
purpose to be a violation of morality  in Article 6.185 However, the definition 
and scope of the term human embryo as used in the Biotechnology Directives 
are  ambiguous,  and  the  scope  of  commercial  or  industrial  purpose  is 











Another  ethical  debate  beyond  the  beginning  of  human  life  is  about 
policies  and  strategies  of  controlling  human  creation.  There  is  a  fear 
reflecting  distrust  of  science  and  technology.  Some  people  do  not  trust 
scientists  or  government  oversight  of  science.  Therefore,  suspicions  that 
scientists  may  misuse  cloning  techniques  to  create  humankind  arise. 








After President Obama opened  the door  for  federal  government  funding 
support  to  hESC  research  on  March  9,  2009,186 the  National  Institutes  of 
Health,  an  agency  of  the  Department  of  Health  and  Human  Services, 
promulgated  the  "National  Institutes  of  Health  Guidelines  for Human  Stem 
Cell  Research"187 [Guidelines  for  Human  Stem  Cell  Research].  According  to 
the  Guidelines  for  Human  Stem  Cell  Research,  federal  funding  is  only 
available  to  research with  ESCs  derived  from  human  embryos which were 
created  by  IVF  for  reproductive  purpose  but  were  no  longer  needed,  and 
were donated by the parents with written consent. The Guidelines for Human 























conditions. 189  The  creation  of  embryos  solely  for  research  purpose  is 
conditionally  allowed  (Article  4,  §1),  but  reproductive  cloning  of  human 
beings is prohibited (Article 6). 190  
In  contrast,  the  United  Kingdom,  along  with  many  other  European 
countries,  conditionally  supports  hESC  research  but  limits  the  sources  of 
embryos.  It  states  that  fundamental  research  on  embryonic  stem  cells  is 
necessary  at  present,  even  though  the  situation  may  be  changing  in  the 
future.191 The source of embryonic stem cells for research is limited to extra 
embryos  created  for  IVF  treatment  because  embryos  may  not  be  created 
solely  for  research  purposes.192 The  government‐financed  stem  cell  bank 
provides embryonic stem cells for scientists both domestically and abroad.193  
























Slovenia  have  all  implemented  legislation  authorizing  research  on  human 
embryos under certain conditions. 196 
Among  other  European  countries,  Lithuania,  Poland  and  the  Slovak 
Republic prohibit human embryo research. No specific regulations regarding 
embryonic  research  exist  in  Luxembourg,  Portugal,  Cyprus,  Malta  and  the 
Czech Republic.197 
Like most European countries, Canada has prohibited all  types of human 
cloning,  including  therapeutic  cloning  under  the  Assisted  Human 
Reproduction Act. It also governs all types of stem cell research and regulates 
acceptable  practices  in  embryonic  stem  cell  research  including  the 
permissible sources of human embryos.198 
Similarly,  Japanese  legislation  permits  stem  cell  research  on  surplus 
embryos and prohibits reproductive cloning; however, there is a sign of the 
Japanese  government  opening  the  door  for  therapeutic  cloning  and  hESC 
research  on  additional  embryos,  by  allowing  the  creation  of  new  cloned 
embryos for research under specific conditions.199  
While  nations  such  as  the United  States  can  easily  change  their  policies, 
international  organizations  usually  take  a  slower  step  forward  because 
consensus  is harder to achieve among their member countries with diverse 
cultural, historical and religious backgrounds. The United Nations has a long 
history  of  prohibiting  reproductive  cloning.  In  Article  11  of  the  Universal 











states  that  any  practice  contrary  to  human  dignity  is  prohibited,  including 
reproductive  cloning. The United Nations Declaration on Human Cloning at 




unclear.  The  European  Union  has  a  very  clear  viewpoint  on  reproductive 
cloning  expressed  in  Article  3  of  the  Charter  of  Fundamental  Rights  of  the 
European Union, which states  that reproductive cloning of human beings  is 




Regardless  of  the  various  attitudes  of  regional  institutes,  philosophical 
schools,  governments  and  international  organizations  towards  the  human 
body  and  embryonic  stem  cell  research,  the  trend  toward  developing  such 

















dramatic  modifications.  In  1996,  Congress  voted  in  favor  of  the  Dickey‐
Wicker Amendment which prevents the use of federal funds for any research 
activity  that  involves  "the  creation  of  a  human  embryo  or  embryos  for 
research  purposes”  or  “research  in  which  human  embryo  or  embryos  are 
discarded,  destroyed,  or  knowingly  subjected  to  a  risk  of  injury  or  death 
greater  than  that  allowed  for  research  on  fetuses  in  utero  under  45  C.F.R. 
208(a)(2)  or  42 U.S.C.  289g(b).”203 The  term embryo  in  the  clause  includes 
any embryo that is “derived by fertilization, parthenogenesis, cloning, or any 
other means  from one or more human gametes.”204 45 C.F.R. 208(a)(2) and 
42  U.S.C.  289g(b)  are  both  rules  regarding  fetal  research.205 However,  the 
Dickey‐Wicker  Amendment  expanded  the  scope  of  the  restriction  on 
research from fetuses to embryos. 
In  1999,  the  Clinton  Administration  interpreted  the  Dickey‐Wicker 
Amendment as inapplicable to derived hESC research since the cells used are 
already derived and not embryos.206 Harriet Rabb, the National Institutes of 
Health  [NIH]  general  counsel,  released  a  legal  opinion  stating  that  federal 
funds  could  not  be  used  to  derive  stem  cell  lines  which  may  cause  the 










restricted  under  the  Dickey‐Wicker  Amendment. 207  After  that,  the  NIH 
promulgated guidelines regarding research using hESCs.208  
But  this  policy  did  not  last  long. On August  9  of  2001,  former President 
George  W.  Bush  announced  that  federal  funds  would  not  be  awarded  for 
hESC research until the following criteria were met: the isolating process of 
hESCs, including the destruction of human embryos, must have been initiated 
before  9:00  pm.  EDT  on  August  9,  2001;  the  stem  cells  must  have  been 
derived  from embryos produced for reproductive purposes and not needed 
for further procreation; and the informed consent from the donor would be 
required without  involving any  financial  inducement.209 The announcement 
banned research involving embryos produced after 9:00 pm. EDT on August 
9,  2001  from  receiving  federal  appropriation.  In  other  words,  after  the 
announcement,  researchers  could not get  federal  support on  their  embryo‐





President  under  his  executive  authority. 210  The  Constitution  does  not 

















duty  to  execute  laws  under  Article  II,  Section  3,  Clause  4.212 Because  the 
power  to  issue  executive  orders  is  based  on  the  President’s  constitutional 
power,  executive  orders  have  full  legal  force.213 Order  13435  iterates  the 
policy that hESC research is encouraged as long as it does not destroy human 
embryos  or  fetuses  or  create  human  embryos  for  research  purposes.214 
Obviously,  the  resources  available  for  hESC  research  were  still  strictly 
limited.  




research  on  alternative  embryonic  sources,  but  prohibited  embryos  to  be 
created for any purpose,217 because the destruction of life, including embryos 
and  fetuses,  for  research  or  commercial  purposes,  violates  the  principle  of 
“no life should be used as a mere means for achieving the medical benefit of 
another.”218  The  main  idea  of  the  Executive  Order  was  consistent  with 
President  Bush’s  statement:  no  embryo  production  for  whatever  purpose. 
But,  it  did  not  illustrate  what  alternative  embryo  resources  would  be 
permitted.  
On  March  9,  2009,  President  Obama  issued  Executive  Order  13505 
(hereinafter  referred  to  as  “Order  13505”),  removing  the  governmental 
financial  constraints on  scientific  research  involving hESCs,  considering  the 













and  ordered  the  NIH  to  issue  new  guidance  consistent  with  this  new 
policy.221 Most importantly, Order 13505 revoked the presidential statement 
of August 9, 2001, which limited federal funding on hESC research; instead, it 
allows  for  funding  research  using  hESCs  derived  from  superfluous  IVF 
embryos  created  for  reproductive  purposes  but  no  longer  needed  for  their 




to  implement  this  new  presidential  policy.  The  NIH,  as  a  part  of  the  U.S. 
Department  of  Health  and  Human  Services,  is  the  primary  federal  agency 
responsible  for supervising medical research, with  its primary aim being to 
improve human health.224 As a federal agency, it implements the President’s 
policy  and  plays  a  critical  role  in  conducting  hESC  research.  The  NIH 
maintains the hESC registry, which lists all hESC lines eligible for use in NIH‐
funded research.  
Shortly  after  the  Executive  Order  13505,  the  NIH  promulgated  the 
National  Institutes  of  Health  Guidelines  for  Human  Stem  Cell  Research  to 
implement Order 13505.225 According to the Guidelines for Human Stem Cell 
Research,  federal  funding  is  only  available  for  research  on  hESCs  derived 
from human embryos, which were created by IVF for reproductive purposes 
but  no  longer  needed,  and  discarded  by  the  parents with written  consent. 










government  supported  hESC  research  using  SCNT  because  this  process 
involves  complex  ethical  issues  and  does  not  have  a  consensus  yet.  It  also 
defines hESC as “cells that are derived from the inner cell mass of blastocyst 
stage  human  embryos,  are  capable  of  dividing without  differentiating  for  a 
prolonged period in culture, and are known to develop into cells and tissues 
of  the  three primary germ  layers,” and articulates  that despite  the  fact  that 
hESCs  are  derived  from  embryos,  they  are  not  human  embryos 
themselves.226  
These  attempts  to  spur  hESC  research  ran  into  many  obstacles  later. 
However,  this  is  not  the  end  of  the  story.  Because  the  Dickey‐Wicker 
Amendment  is  still  in  force,  some  challengers  represented  by  James  L. 
Sherley,  a  stem  cell  scientist,  sought  a  preliminary  injunction  agains  the 
Department of Health and Human Services  [HHS]  to prevent  the Guidelines 
for  Human  Stem  Cell  Research  from  taking  effective  on  the  basis  that  the 
Guidelines  violated  the  Dickey‐Wicker  Amendment.  On  August  23,  2010,  a 
district  court  granted  a  preliminary  injunction.  The  court  reasoned  that 
during  hESC  research,  ESCs  have  to  be  derived  from  embryos,  which 
unavoidably  results  in  the  destruction  of  human  embryos;  thus,  hESC 
research  results  in  the  destruction  of  human  embryos  and  should  not  be 
granted  federal  funding  according  to  the  Dickey‐Wicker  Amendment.227 
Considering  the  injury  that  the public  interest and the plaintiff may receive 
from the enforcement the Guideline, a preliminary injunction is granted.228  
The  changes  in  the  legal  status  of  hESC  research  funding  have  had  a 
dramatic  effect  on  patent  application  and  issuance.  Figure  4.1  charts  the 
number  and  fluctuation of human  cell  (435/366) patents  filed  in U.S.  since 
1992.  Since  the  survey  only  includes  issued  patents,  the  data  cuts  off  after 













one  can  see  that  since  1996,  there  was  a  drop  of  both  issuance  and 
application  of  human  cell  patents.  The  reason  behind  this  could  be  that  in 
1995,  the  U.S.  Congress  voted  in  favor  of  the  Dickey‐Wicker  Amendment, 






































technique was under development worldwide. The birth of  the  first  cloned 
mammal “Dolly” in 1996 is one example.  
In  1999,  the  Clinton  Administration  interpreted  the  Dickey‐Wicker 
Amendment as banning federal funds for stem cell derivation from embryos, 
but allowing funding for research on cells that had already been derived,231 




Since  the  survey  only  includes  patents  issued  before  2004,  the  trend  of 










from  the  original  thirteen  American  Colonies.232 But  patent  customs  were 







general  patent  statute with  exclusive  rights  or  a  patent  period.233 After  the 
Revolution, the United States was formed, which finally triggered a uniform 
patent system.234 On September 5, 1787,  the power of Congress to promote 
the  progress  of  science  and  useful  arts  was  proposed  and  later  passed 
unanimously.  This  is  embodied  in  Article  1,  Section  8,  Clause  8  of  the 




by  the  Secretary  of  State,  the  Secretary  of  War  and  the  Attorney  General, 
based on the invention’s utility.237 At that point, there were no specific rules 
about  procedure  or  patent  requirements,  which  made  patent  examination 
difficult.238 Once  the  patent was  issued  the  patent  lifetime was  14  years.239 
However, In order to address the deficiency created by the lack of procedural 
and substantive rules in the Patent Act of 1790, the Patent Act of 1793 was 
created, which  set up a  registration  system at  the State Department, under 
which  patents  would  became  effective  as  soon  as  they  were  registered.240 


















To  solve  this  problem,  the  Act  of  1836  was  passed.242 The  Act  of  1836 
distinguished  the  patent  office  from  the  Department  of  State  as  an 




some  new  statutory  rules  and  addressed  related  court  decisions.  For 
instance, Section 103 overturned the “flash of creative genius”245 standard as 
a  patent  requirement.  Instead,  it  set  the  standard  of  nonobviousness  at  an 
ordinary level, which is “a person having ordinary skill in the art.”246 The Act 
of  1952  was  codified  as  Chapter  35  of  the  U.S.  Code.  Since  then,  several 























the  Department  of  Commerce.249 The  USPTO  is  responsible  for  examining 
and  issuing  patents  and  disseminating  information  to  the  public  with  the 
mission  of  promoting  innovation  and  competitiveness  in  the market.250 To 
carry out its responsibility, the USPTO is entitled to issue regulations under 
its  authority. 251  Therefore,  all  regulations  the  USPTO  issues  under  its 
authority are legally binding. To implement the Patent Act [Chapter 35 of the 
U.S.  Code,  hereinafter  35  U.S.C.]  and  Chapter  37  of  the  Code  of  Federal 
Regulations [hereinafter 37 C.F.R.], the USPTO set forth the Manual of Patent 
Examining Procedure [MPEP]. 
The USPTO consists of  the Under Secretary of Commerce  for  Intellectual 
Property  and  Director  of  the  USPTO,  the  Deputy  Under  Secretary  of 
Commerce  for  Intellectual  Property  and  Deputy  Director  of  the  USPTO,  a 
Commissioner  for  Patents,  a  Commissioner  for  Trademarks,  and  other 
officers  and  employees.252 Under  the  Commissioner  for  Patents,  there  is  a 
Deputy  Commissioner  for  Patents,  a  Deputy  Commissioner  for  Patent 
Examination  Policy  and  a  Deputy  Commissioner  for  Patent  Resources  and 
Planning. 253  In  addition,  the  USPTO  also  has  a  Patent  Public  Advisory 
Committee and a Trademark Public Advisory Committee, as watchdogs over 
policies, performance, and budget.254  
To  apply  for  a  patent,  an  applicant  files  an  application with  the  USPTO. 
The  application  is  published  and  made  available  to  the  public  within  18 
months after  the  filing date.255 After  the USPTO examines  the application,  it 












non‐obviousness and usefulness  requirements,  the disclosure  requirements 
and other  requirements of  the  law.  If  the application  is  finally  rejected,  the 
applicant  can  appeal  to  the  Board  of  Patent  Appeals  and  Interferences.256 




examiner  to  the  Board  of  Patent  Appeals  and  Interferences.  Patentees  and 
the  third  parties  can  also  appeal  the  final  decision  of  patent  examiners.258 
The  Board  of  Patent  Appeals  and  Interferences  [BPAI]  is  the  appeal  body 
within  the  USPTO,  which  comprises  the  Director,  the  Deputy  Director,  the 
Commissioner  for  Patents,  the  Commissioner  for  Trademarks,  and  the 
administrative  judges.259  The  BPAI  reviews  the  appeals  from  the  patent 
applicant  against  the  examiner’s  decisions  and  determines  patentability  of 
inventions and priority in interferences.260  
If  the BPAI decision  is adverse  to  the patent applicant,  the applicant can 
appeal  the  decision  to  the  U.S.  Court  of  Appeals  for  the  Federal  Circuit 
[CAFC],261 or  file a civil action against  the Director  in  the U.S. District Court 
for  the  District  of  Columbia.262 In  addition,  a  patent  owner  involved  in  any 
reexamination  proceedings,  or  a  third  party  involved  in  an  inter  partes 
reexamination proceedings who is dissatisfied with the decision of the BPAI, 
















In  1982,  The  Federal  Court  Improvements  Act  created  the  CAFC  as  a 
unified  forum  for  patent  appeals,  aiming  at  achieving  uniformity  on  patent 





Article  1,  Section  8,  Clause  8  of  the  Constitution  is  the  basis  for  federal 
patent law in the U.S. It states that Congress has the power to “promote the 
progress of science and useful arts, by securing for limited times to authors 
and  inventors  the  exclusive  right  to  their  respective  writings  and 
discoveries.”267  
Title 35 of the U.S. Code is the current Patent Act.  It addresses all patent 
issues,  including eligible subject matter, patent  requirements, patent  rights, 
enforcement,  remedies  and  so  forth.  To  be  patented,  an  invention  must 















with  “any  new  and  useful  improvement  thereof.”268  Sidney  A.  Diamond, 
Commissioner of Patents and Trademarks, v. Ananda M. Chakrabarty et al.  in 
1980,  which  held  that  “anything  under  the  sun  that  is  made  by  man”  is 
patentable  subject  matter  under  patent  law,269 is  a  milestone  in  patenting 
biotechnology.  The  issue  in Diamond  v.  Chakrabarty was whether  a  patent 
claiming  a  human‐made,  genetically  engineered  bacterium,  which  was 
capable of breaking down crude oil, was valid. The court upheld the patent’s 
validity and opened the gate to patenting vital inventions.  
After  Diamond  v.  Chakrabarty,  the  scope  of  patentable  subject  matter 
expanded to  include  living  things. Furthermore, as  the  first patent claim on 
animals,  U.S.  Patent  No.  4,736,866  (1988)  [hereinafter  Harvard  Mouse] 
started  the  era  of  animal  patents.270 Later,  stem  cell  patents  extended  to 




However,  this  broad  understanding  of  the  patentable  subject  matter 
requirement  was  challenged  in  a  recent  judgment  made  by  a  U.S.  District 













possessing  “a  new  or  distinctive  form,  quality,  or  property.”273  But  the 
claimed  DNA  failed  that  requirement,  being  “the  physical  embodiment  of 
laws  of  nature;”274 therefore,  the  genes  were  held  to  be  unpatentable.  The 
defendant patentee appealed. However,  the reasoning of  the district court’s 
judgment  has  challenged  the  patentable  subject  matter  criterion  that  has 
lasted  for  thirty  years.  If  the  judgment  is  confirmed,  there  will  be  a  new 




from  cells  and  cell  lines  including  hESCs.  In  the  history,  the  USPTO 
announced  a  policy  that  human  body  is  not  patentable  subject  matter  in 
1987.275 Claims  encompassing  human  beings  at  any  stage  of  development, 
including embryos and fetuses, have not been patentable.276 But human stem 
cells,  including  hESCs,  have  been  successfully  patented  and  upheld  by  the 
USPTO,277 which manifests  their  patentability.  Considering hESC’s  ability  to 
differentiate into all of the three germ layers of an embryo, the line between 
human body at early stages and hESCs is not clear. As a process, procedures 



















products  of  hESC  research  and  procedures  are  confirmed  to  constitute 
patentable  subject  matter  as  well,  as  long  as  they  do  not  claim  “human 







granted,  any  patent  application  must  be  useful.  To  clarify  the  utility 
requirement, the USPTO issued the Utility Examination Guidelines in 2001,280 
to  demonstrate  three  criteria  for  utility, which  are  specific,  substantial  and 
credible utility.281 In In re Fisher, the court held that to meet the requirement 
of  substantial  and  specific  utility  under  §101,  an  expressed  sequence  tags 
[ESTs]  invention application should have prompt and particular benefits  to 
the public; in the case at bar, the utility did not suffice. The court stated that 




















the utility  requirement was  largely  rejected  in  later  case  law.287 At present, 
patent  law  is widely  considered  an  inappropriate  tool with which  to make 
moral  judgments  about  science; 288  therefore,  morality  is  no  longer  an 
accepted  consideration  in  applying  the  utility  requirement.289   Accordingly, 
even though moral arguments on hESCs research have continued for over a 





The  novelty  requirement  is  set  forth  under  35  U.S.C.  §102,  in  order  to 
protect the information already in the public domain from being privatized. 





























However,  no  further  information  is  given  regarding  the  scope  and 
definition of a patentable composition of matter. The ambiguity is critical to 
biotechnological  inventions  since  they  already  exist  in  nature  and  have  a 
close  relationship  with  products  of  nature.  In  the  case  of  gene  sequence 






their  natural  environment  are  still  held  patentable  by  some  people  while 





non‐modified  hESCs  as  products  of  nature,  making  them  unpatentable. 














prior  art  in  the USPTO. The  litigation process  and  subsequent  result  of  the 
human gene case may influence hESC patents and redirect the main issue. At 
present,  artificial  interventions,  such  as  isolating  hESCs  from  an  in  vivo 






 Nonobviousness  requires  that  the  subject  matter  be  different  enough 
from  the prior  art  that  the  subject matter  as  a whole would not have been 
“obvious at the time the invention was made to a person having ordinary skill 
in the art.”298 
The  essential  question  is whether  success  is  “reasonably  predictable  on 
the basis of  the prior art”:  if  a person having ordinary skill  in  the art has a 
reasonable  expectation  of  success  in  achieving  the  invention,  the  invention 
fails  to meet  the  non‐obviousness  requirement.299 In  the  case  of Graham v. 
John Deere Co. of Kansas City  (1966),  the  court  held  that  both  primary  and 










instance,  long‐term  demand  in  the  market  and  commercial  success  of  an 
invention are both suggestive of nonobviousness.301  
There  is  one  important  question  in  the  obviousness  determination 
concerning  hESC  inventions:  whether  the  primate  (human)  stem  cell 
technique  is  obvious  to  a  person  having  ordinary  skill  in  the  art.  This 
question  was  brought  up  in  the  Wisconsin  Alumni  Research  Foundation 
[WARF]  patent  reexamination  proceedings,  where  it  was  argued  that  the 
patents  lacked  novelty  and  nonobviousness  because  the  technique  for 
isolating  and  culturing  murine,  porcine,  and  ovine  stem  cells  had  been 
disclosed in the prior art. The USPTO decided that considering the biological 
differences between species, and the  failure to apply the technique used on 
murine  stem  cells  to  isolate  ovine  cells,  the  technical  differences  between 





The  U.S.  Patent  Act  lacks  any morality  requirement,  though  historically, 
the federal courts took the issue of morality into account.303 However, courts 
today are  reluctant  to apply moral doctrine  to  judge patent applications.304 











However,  the USPTO has  adopted  a different policy.  The USPTO  tried  to 
introduce morality considerations  into  the utility  requirement.  In 1998,  the 
USPTO  issued  a  media  advisory  stating  that  inventions  directed  at 
human/non human chimeras are not patentable because they fail to meet the 
“public  policy  and  morality  aspects  of  the  utility  requirement.” 305  This 
statement  does  not  only  explicitly  affirm  the  morality  aspect  to  the utility 
criterion,  but  also  demonstrates  the  USPTO’s  opinion  on  patentability  of 
inventions directed toward humans. But the USPTO fully realized that it could 
not deny a patent based on morality beyond Congress’ statutes and relevant 
court decisions.306 This limitation on its power has been confirmed by the courts. 
The Federal Circuit ruled that the USPTO has no authority to issue substantive 
rules  because  35  U.S.C.S.  §  2(b)(2)  does  not  vest  the  USPTO  with  such 
power.307 Any attempt by the USPTO to impact patent applicants’ substantive 
rights is subject to judicial review according to 5 U.S.C. § 706.308 Meanwhile, 






far,  there  have  been  516  issued  patents  on  human  cells  with  41  of  these 
patents  being  related  to  hESCs.  In  addition,  there  are  80  published 























matter  claimed  in  hESC  related  patents.  The  list  includes  claims  on  hESCs, 
methods of culturing, maintaining, propagating,  isolating and differentiating 
hESCs, and cellular compositions comprising hESCs. 
o U.S.  Patent  No.  5,843,780  (Application  No.  08/591,246) 
Primate embryonic stem cells (issued on 12‐01‐1998) 
This  patent  claims  primate  embryonic  stem  cells  and  cell  lines  and 
methods of isolating primate embryonic stem cell lines. 





















Method of Producing Embryonic Germ Cells
Method of Using Pluripotent ESCs
Method of Producing GM Pluripotent ESCs
Method of Producing NM Pluripotent ESCs
Isolating Pluripotent ESC's from Blastocysts
Method of Maintaining NM ESCs
Method of Identifying NM ESCs
Method of Isolating NM ESCs
72 





also  totipotent.  ‘806  maintains  the  same  claims  as  ‘780,  but  focuses  on 
human stem cells while ‘780 embraces all primate embryonic stem cells.  




These  three  patents,  called  WARF  patents  as  a  whole,  are  claimed  by 
James Thomson  and his  research  team. The patents were  later  assigned  to 
the WARF, an organization  that manages  intellectual property assets of  the 
University of Wisconsin.312 WARF’s function is to file patent applications for 
discoveries  made  by  UW‐Madison  and  negotiate  with  companies  that  are 
interested in commercializing the patents in order to facilitate the use of UW‐
Madison  research  results.313 With  regard  to WARF  patents,  WARF  granted 
exclusive licenses to Geron Corporation to commercialize those products on 
certain  cell  types. 314  In  1999,  WARF  established  a  non‐profit  research 



















to  encompass  all  hESC  research  and  all  downstream  products. 317  The 
enforcement  of  theses  patents  has  triggered  problems  for  the  public  and 
other institutes which wish to gain access to hESCs for further research.318 To 
solve  this  problem,  WiCell  and  the  Public  Health  Service  of  the  U.S. 
Department  of  Health  and  Human  Services  [HHS]  signed  an  agreement  in 
2001, the Memorandum of Understanding [MOU].319  
Under  the  MOU,  WARF  cells  are  available  to  scientists  at  the  NIH  for 
teaching  or  basic  non‐commercial  research  programs.  In  exchange,  WiCell 
will  charge  transmittal  fees  for  expenses  related  to  the  cells’  supply.  In 
addition,  WiCell  agrees  to  allow  federal  non‐profit  institutes  access  to  the 
stem  cells  upon  the negotiation  of  similar  agreements.320 Because  the MOU 
only entitles a third party to non‐commercial use of the WARF materials, any 
























in  vitro,  comprising  deriving  and  maintaining  embryos  in  certain  culture 
mediums with  certain  amounts  of  recombinant  leukemia  inhibitory  factor, 
and a method of maintaining mammalian ESCs in vitro while retaining their 
pluripotency.  
o U.S.  Patent  No.  5,914,268  (Application  No.  08/343,686) 
Embryonic  cell  populations  and  methods  to  isolate  such  populations 
(issued on 6‐22‐1999) 








The  claims  of  this  patent  include  one  method  for  producing  human 
pluripotent  embryonic  germ  cells  in  described  culture  mediums,  and  a 
method  for  maintaining  human  pluripotent  embryonic  germ  cells  in  an 
undifferentiated state.  
o U.S.  Patent  No.  6,280,718  (Application  No.  09/435,578) 
Hematopoietic  differentiation  of  pluripotent  human  embryonic  stem 
cells (issued on 8‐9‐2001) 
75 
The  claims  in  this  patent  include  a  method  of  obtaining  human 
hematopoietic cells by manipulating hESCs and a method of transplanting the 
cells into a human host. 






o U.S.  Patent  No.  6,800,480  (Application  No.  09/530,346) 
Methods  and  materials  for  the  growth  of  primate‐derived  primordial 
stem cells in feeder‐free culture (issued on 10‐5‐2004) 
This  patent  claims  cellular  compositions  comprising  undifferentiated 
primate primordial stem cells and undifferentiated hESCs. The patent covers 
both totipotent and pluripotent stem cells, including human stem cells.322  
o U.S.  Patent  No.  7,297,539  (Application  No.  10/873,922) 
Medium  for  Growing  Human  Embryonic  Stem  Cells  (Issued  on  10‐31‐
2007) 
The  main  claim  of  this  patent  is  a  method  for  proliferating  hESCs, 
comprising  culturing  hESCs  in  the  presence  of  an  extracellular matrix  in  a 












Another  interesting  piece  of  information  conveyed  by  the  survey  is  the 
investment  sources  for  hESC  research.  This  can  be  inferred  from  patent 
ownership  because  usually  inventors will  assign  their  patents  to  investors. 
But  there  are  exceptions.  For  instance,  a  research  institute  as  an  investor 





Figure  4.3  demonstrates  the  present  number  of  patents  owned  by 
companies,  the  U.S.  government,  universities,  501(c)(1)  institutes  (tax 




significant  expense,  private  investors  are  reluctant  to  provide  financing  to 
                                                        
323 26 U.S.C. 501(c)(1) (2006) 









































in the  field. The usual arrangement  is  that research  institutes or companies 




of  the  patent.326 However,  in  most  situations,  to  prevent  employees  from 




that  some  inventors  do  not  sign  any  assignment  contract,  or  not  all 
assignments to research institutes by employees have been completed, which 
may explains the large number of individually owned patents. Figure 4.3 also 























of  natural  products  were  patentable  under  §101  of  the  Patent  Act,  on  the 
grounds that the pure culture of the claimed microorganism does not exist in 
nature;  instead,  it  is man‐made and only obtained under certain  laboratory 
conditions.329 This distinction is confirmed in Chakrabarty in 1980, in which 










The  WARF  patents,  usually  referring  to  U.S.  Patent  No.  5,843,780,  U.S. 
Patent  No.  6,200,806,  and  U.S.  Patent  No.7,029,913,  focus  on  pluripotent 
primate embryonic stem cells,  including hESCs. Before these patents expire, 
WARF  has  the  right  to  enjoy  all  royalties  earned  by  successful  medical 
products  or  procedures  based  on  its  hESCs  research.332 After  the  WARF 








California‐based  Foundation  for  Taxpayer  and  Consumer  Rights  [FTCR] 
challenged  the  validity  of  the  WARF  patents  for  lacking  novelty  and 
nonobviousness, and  filed a request  to reexamine these patents  in 2006. At 
first,  the  challenge was  upheld  by  the  patent  office,  and  some  claims were 
held invalid.333 Nevertheless, after WARF submitted its defense and amended 
some  claims  to  limit  the  patent  claim  scope  by  inserting  “pluripotent”  and 
“derived from a pre‐implantation embryo” to define human embryonic stem 
cells  in both patent  ’780 and  ’806 claims,334 these  two patents were upheld 
by  the  USPTO  on  the  grounds  that  they  then  satisfied  the  patent 
requirements  of  novelty,  nonobviousness  and utility.335 Later,  claims 1‐3  of 
patent  ’913  were  upheld  by  the  USPTO  as  well.336  On  the  question  of 
nonobviousness,  the  USPTO  asserted  that  there  were  distinct  biological 
differences among species like murine, porcine and human, so there was no 
reasonable expectation of success in deriving hESCs based on the prior art.337 



























5,166,065  [Williams]  issued  in  1992  described  and  enabled  methods  of 
isolating  mouse  ESCs,  which  could  have  potentially  been  used  to  isolate 
hESCs.  Even  though  the Williams method was  not  used  to  create  the  cells 
claimed in the WARF patent, this alone does not establish that the Williams 
method  could  not  have  succeeded  in  hESC  isolation.  Since  the WARF  ‘913 
patent  claims  hESCs  themselves  rather  than  a  process  for  producing  them, 
the  claim  was  rejected  for  obviousness. 338 However,  WARF  claimed  that 
Strategies  for  the  Isolation  and  Characterization  of  Bovine  Embryonic  Stem 
Cells, by Robert Cherny in 1994 [Cherny’s publication], negated “Williams,”339 
because  it  disclosed  a  failed  attempt  to use  the ESC  isolation  technique  for 
the murine model (mouse model) on domestic animals.340  
This  argument  did not  receive  support  from  the BPAI,  because Cherny’s 
publication only involved murine models but not humans or primates.341 As 
the  patent  applicant  with  the  burden  of  proving  the  novelty  and  non‐
obviousness when  the USPTO  thinks  otherwise, WARF  failed  to  prove  that 
the Williams method did not  apply  to  human embryos;  therefore, Williams 
anticipated hESC derivation, anticipating claim 1.342 The BPAI’s application of 
the  standard of non‐obviousness  in  this  case  implies  that  to achieve patent 
validity, inventors need to attempt very broad possibilities in the hESC field, 
rather  than  taking  predictable  steps  that  another  individual  with  ordinary 
skills in the art would be able to anticipate.343 Disagreeing with the examiner, 
the  BPAI  believed  the  evidence  demonstrated  that  the  techniques  for 












species.344 The  invention  at  bar  is  obvious  to  try  in  view of  the predictable 
options explicitly taught  in the prior art,345 inasmuch as the testimony from 
scientists in the art demonstrates that hESCs have been successfully derived 
from  embryos  by  following  the  existent  methods  for  mouse,  rat,  pig  and 
sheep ESCs.346  
WARF  may  request  a  rehearing  before  the  board  addressing  the  new 
grounds of rejection. Alternatively, it could reopen the prosecution before the 
examiner  by  either  submitting  new  evidence  to  the  original  examiner  or 





Recently,  a  Federal  District  Court  handed  down  a  judgment  ruling  that 
gene inventions, without artificial  intervention, are the same in bio‐context; 
they  are  products  of  nature,  therefore,  they  are  not  patentable.  The  court 
believed  that  the  patent  claims  at bar were  “improperly  granted”  because 
they were “directed to a law of nature.”349 In the opinion of the court, even the 
technique used to isolate them from the natural context does not change the 
quality  of  those  genes  and  does  not  change  the  fact  that  they  are 
discoveries.350 This case remains on appeal at this time. In October of 2010, 
the Department of  Justice  filed an amicus curiae brief  to the court declaring 
that isolated human genes without alteration or manipulation are a product 










structure  as  genes  in  the  human  body,  but  manipulated  genes,  DNA  and 






The  Constitution  grants  the  patent  authority  to  the  federal  government 
under  Article  1,  Section  8,  Clause  8.  Hence,  this  clause  deprives  state 
governments of patent authority. However, states have an alternative path in 






The  state  of  Michigan  has  adopted  a  prohibitionary  policy  on  human 
cloning. 352  However,  human  embryo  and  embryonic  stem  cell  research 
permitted  under  federal  law  can  be  conducted  in  Michigan  if  it  meets  the 
additional  requirements  in  Art.  I,  §27  of  the  Michigan  Constitution.  An 
example  of  this  would  be where  the  human  embryos  used  in  research  for 
stem  cell  derivation  would  be  no  more  than  fourteen  days  old  after  cell 
division begins,  the embryos were not  created  for  research,  therapeutic,  or 







The  Constitution  of  the  State  of Missouri  has  a  similar  statement  to  the 
Michigan Constitution. The right  to conduct hESC research  is confirmed the 
Constitution. Meanwhile, it stipulates requirements for lawful hESC research 
conduct,  such  as  the  fourteen  day  old  embryo  restriction,  researcher 
eligibility requirements, research conduct norms, oversight processes, etc. In 
order  to  enforce  these  requirements,  it  sets  forth  punishments—either 
imprisonment or fine or both—for any violation of the said requirements. 354 
The  Constitution  of  the  State  of  California  also  guarantees  the  right  to 
conduct  stem  cell  research  including  research  on  pluripotent  stem  cells, 
either  obtained  by  somatic  cell  nuclear  transfer  or  from  surplus  in  vitro 
embryos from fertility clinics.355  
The  above  constitutions  are  the  only  three  state  constitutions  that 
legitimize  hESC  research.  Even  though  the  Constitution  of  the  State  of 
California  does  not  explicitly  refer  to  human  embryonic  cells,  it  implies 
coverage of the embryonic stem cells because an embryonic stem cell is one 





Beyond  their  constitutions,  more  states  regulate  hESC  research  in  their 
statutes. While  supporting  hESC  research,  they  set  forth  certain  restriction 
related to the ethical controversy. 
In the Health and Safety Code of California (Annotated California Codes), 






accordance  with  the  Guidelines  for  Human  Embryonic  Stem  Cell  Research 
issued by the National Research Council and the Institute of Medicine of the 




an  embryonic  stem  cell  research  oversight  committee  and  further  defines 
“embryonic stem cells” and “eligible  institution”  for regulating hESC related 
research. 358 
In  Illinois,  embryonic  stem  cell  research  is  allowed  and  eligible  for 
government  funding  only when  it  complies with  the  research  policy  of  the 
State of Illinois.359 
Massachusetts is another state that has opened the door to hESC research. 
It  justifies  hESC  research  based  on  its  scientific  and  therapeutic  value:  any 
research  or  clinical  application  involving  the  use  or  derivation  of  hESCs  is 




New  Jersey  law  provides  that  research  involving  hESCs  and  clones  is 










supervision  of  a  review board  and  conducted with  consideration  of  ethical 
and medical issues.363 
Compared to these hESC research advocate states, Nebraska has adopted a 

















Inventions  involving  human  embryos  are more  controversial  than  those 
involving mere human cells. The debate over  embryo‐relate  inventions  can 
be divided  into  two questions based on  the  source  of  the human embryos: 







patentable,  and  whether  human  stem  cells  derived  from  surplus  embryos 
from fertility clinics are patentable.  




are  not  created  by  the  fusion  of  an  egg  and  sperm.366 In  addition,  the 
conception  of  human  beings  comprises  more  than  just  a  physical  human 




potential  to  be  born  as  infants  after  being  implanted  into  a  uterus.368 
According  to  the  U.S.  Constitution,  13th  Amendment,  “[n]either  slavery  nor 
involuntary  servitude,  except  as  a punishment  for  crime whereof  the party 
shall  have  been  duly  convicted,  shall  exist within  the United  States,  or  any 
place subject  to  their  jurisdiction.” Any conduct utilizing human embryos  is 
commercializing  human  beings,  which  therefore,  can  be  construed  to 
constitute  a  violation  of  the  Constitution. 369  Some  people  brought  this 
















As mentioned  in  the  previous  chapter,  the  status  of  embryos  and  other 
human tissues created by cloning is blurred. It not only involves science and 
technology, but also intersects with religion. Therefore, some scholars jump 
over  the  contentious  status  dispute,  and  target  a  more  essential  question: 
should the morality element be considered in the patent granting processes? 
Some assert  that over  the  last decades of U.S. patent  litigation,  courts have 
repeatedly  refused  to  make  moral  judgments  in  patent  cases  involving 
advancing technologies and limited the patent office’s power to its technical 
expertise.372 As an expert  in  technology,  the patent office  should only  focus 
on the classic patentability requirements and technology.373 
As mentioned above, morality has now been removed from the hand of the 
patent  office  by  case  law.  Therefore  it  is  left  to  Congress. 374 The  argument 
can  also  be  made  by  apagoge.  If  a  morality‐based  bar  is  applied  to  hESC 
innovations,  it  will  undermine  the  function  of  the  patent  system  by 
eliminating  the  exclusive  right  granted  to  the  inventors  and  depriving  the 
























patent  granting  process,  and  the  revocation  of  patents  will  not  only 
discourage the patentees, but also damage the interest of the public.378  
As morality is a pubic interest consideration, once the morality criterion is 
applied  to  the  patent  system,  the  patent  office  needs  to  factor  in  all  other 
public  interest  considerations,  such  as  human  health  benefits.379 Compared 




















act  as  “no  more  than  research  intermediates”382 or  do  not  provide  “an 
immediate, well‐defined, real world benefit to the public.”383 In that sense, a 
research  tool  should not  be patented  since  it  has no  substantial  or  specific 
utility.  Some people  consider  that hESCs are  research  tools;  therefore,  they 
are not  patent‐protectable.384 Research  tools  usually  have  foundational  and 
broad applicability; they are essential input that cannot be duplicated.385 For 
instance,  hESCs  have  irreplaceable  importance  in  understanding  cytology 
and  human  body  development. 386  Privatizing  research  tools  restricts 
researchers’ use of these materials,387 which will  impede further  innovation 
and  application.  In  addition,  it may  require  an  insurmountable  investment 
for  downstream  developers  to  simply  attain  the  research  tools  from  their 
inventors.388 Therefore, research tools should be available to the public and 
are excluded from patenting on the basis of patent exceptions in the common 
law.389 hESCs have no direct benefits  to  consumers. As  a necessary  tool  for 
research  and  development,  their  main  value  merely  lies  in  achieving  end 
products,  i.e. differentiated cells for repairing injured organs or cells.390 The 
broad  claim  scope  of  the  WARF  patents  hampers  researchers  because 





















even  though  the hESCs  they are using may be obtained by another method 
beyond  the  scope  of  patent  claims.391 Some people  assert  that  the  financial 
and  time  input  for  negotiation  impedes  the  research  process  more  than 
government  restriction  on  federal  appropriation  to  hESC  research. 392 
Therefore,  they  argue,  such  a  monopoly  over  essential  research  tools  is 
contrary to the antitrust laws and should be removed. 393 
In contrast, some commentators assert that patenting research tools may 
provide more  research and development  investments by attracting  funding 
from downstream  industry. 394 Other  arguments  are made on  the  empirical 
ground  that  very  few  cases  of  breakdown  or  delay  of  projects  caused  by 
access difficulty  to  the basic  techniques or negotiation over patent  licenses 
have occurred, while  it  is admitted  that patents on research  tools  impose a 
cost and limit access.395  
In  order  to  offset  the  side  effects  of  patenting  essential  resources  like 
hESCs  and  achieve  the  balance  sought  in  patent  law,  some  strategies  are 
proposed. One proposal is to grant a shorter patent term for such patents.396 
Another  is  to  enact  a  compulsory  licensing  scheme  to  ensure  researchers 




















 So  far, debates continue over whether hESCs should be protected  in  the 
patent  system.  However,  compared  to  the  U.S.  which  has  already  granted 






Chapter 5: Laws  regarding  hESCs  in  the  European  Patent 
Convention 
 
Europe  has  several  hierarchies  within  its  patent  system.  At  the  lowest 
level,  every  nation  in  Europe  has  its  own  national  patent  system.  Another 
facet  is  the  European  Patent  Organization,  set  up  by  the  European  Patent 
Convention,  which  establishes  a  European  patent  system,  within  which  a 
unified  application process  is  set  forth  that  simplifies  patent  application  to 
multiple  countries  in  Europe.  Nonetheless,  member  states  maintain  their 
own  national  patent  systems  and  have  jurisdiction  over  patent  right 












Historically,  patent  applicants  in  European  countries  submitted 
applications to their national patent agencies for examination under national 
patent  laws.  However,  since  procedural  and  substantive  laws  vary  in 
different  countries,  this mechanism was  time‐consuming  and  costly.  It  also 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substantive  laws,  created  a  centralized,  unitary  patent  application  process 
and  instituted  the  European  Patent  Organization  as  its  agency.  The  EPO 
granted  patents  on  behalf  of  its  member  states,  dramatically  reducing  the 
cost  and  time  associated  with  the  patent  application  process,  especially 
considering  that  applicants desiring protection  in multiple  states no  longer 
needed to deal with patent offices on an individual basis or spend money on 
language  translation.  This  also  eliminates  the  situation  wherein  varying 
scopes  of  patent  protection  are  granted  in  different  states.  However,  after 




Meanwhile,  the  European  Union  has  been  seeking  to  unify  the  patent 
system of its member states in order to reduce the processing and translation 
costs, stimulate patent activity and enhance its economic competitiveness in 
the  world.  At  present  the  EU  is  considering  establishing  a  European 
Community  patent  system  as  well  as  a  patent  court400 to  unify  the  patent 
litigation  system  (Unified  Patent  Litigation  System  [UPLS]).  However,  it  is 
still under debate. 
In  addition,  other  agreements  have  been  proposed  to  establish  an 







patent  litigation;  the European Patent Litigation Agreement  [EPLA] and  the 
London  Agreement  of  2000.401 The  EPLA’s  idea  was  initiated  in  the  Paris 
Intergovernmental Conference  in 1999, during which  the member  states of 
the  EPC  set  about  drafting  an  agreement  on  integrated  litigation  for 





EPC  member  states,  aimed  at  reducing  application  costs  by  eliminating 
states’  authority  to  require  translation  of  application  files  to  state’s 
languages, which paved the way for a community patent system.403 However, 
























individual  countries  in  which  the  applicant  desired  to  obtain  patent 
protection,  each with  distinct  procedures  and  different  languages.  In  1973, 
the  Convention  on  the  Grant  of  European  Patents,  also  known  as  the 
European  Patent  Convention,  took  effect  to  provide  a  unitary  system  for 
patent protection. It was initially ratified by 32 member states. According to 
the  EPC,  the  European  Patent  Organization  was  created  in  1977  as  an 
intergovernmental  organization  on  the  basis  of  the  EPC,  which  has  two 
bodies,  the  European  Patent  Office  as  its  executive  organ  and  the 
Administrative  Council,  a  supervisor  of  the  EPO.  In  2000,  the  EPC  was 
amended  to  keep  pace  with  the  TRIPS  Agreement  and  other  international 
treaties, which came into force in 2007. One main target of the amendment of 
2000  was  to  simplify  the  language  requirements  and  reduce  translation 




recognize  patents  granted  by  the  EPO.  To  gain  a  patent  from  the  EPO,  a 
patent  applicant must  file  an  application  in  one  of  three  official  languages, 
English,  French or German.405 The patent office  then performs a  formalities 
examination,406 completes a search report and publishes it.407 After the report 
is  published,  the  invention  will  be  published  and  go  through  substantive 












files  satisfy  the  written  description,  claims,  drawings  and  abstract 
requirements  (Article  83,  84  and  85).  However,  the  EPC  is  only  concerned 
with patent granting, not enforcement (Article 64(3)). As long as a European 
patent is granted by the EPO, it enters into the patent systems of designated 
countries on date  it  is  filed with  the European Patent Office,  transferring  it 







not  definitive.  Decisions  of  the  Receiving  Section,  Examining  Division, 




Opposition  Division  carries  out  the  examination  of  the  opposition  and 
reaches a decision to maintain or revoke the patent (Article 102). As long as 
the patent  is revoked in opposition proceedings,  the patent right  is deemed 
to not have existed in the first place.  
The European patent system and national patent systems are independent 








protection  under  the  national  patent  system. Additionally,  only  states  have 




procedure,  appeals  procedure,  common  provisions  on  procedure,412 impact 
on national  law,413 special  agreements,414 international  application pursuant 
to  the  patent  cooperation  treaty, 415  transitional  provisions 416  and  final 































Article  52  of  the  EPC  defines  the  scope  of  patentable  invention  by 
excluding  discoveries,  theories  and  mathematical  methods,  aesthetic 




essential  biological  processes  for  plants  or  animal  production,  and 
therapeutic  and  diagnostic methods  for  treatment  of  the  human  or  animal 
body.  But  the  EPC  attempts  to  narrow  these  exclusions  from  patentable 
subject  matter  by  including  some  restrictions  on  their  application.  For 
instance,  the  scope of ordre public  or morality  is not determined by  law or 
regulations  in  individual  states,  but  is  determined  by widely  accepted  and 
tradition‐rooted beliefs  and  conduct. Microbiological  processes or products 
do not  fall  into  the  scope of  plant  or  animal biological  process or products 
excluded  from  patentable  subject matters  Any  substances  or  compositions 
used  in  treatment,  diagnosis  or  surgery  on  human  or  animal  bodies  are 
patentable. 
The  EPC  does  not  explicitly  refer  to  patentability  of  the  human  body  or 
human tissues. This may be due to two reasons. First, at the time the EPC was 
first drafted and adopted, modern cellular research on the human body and 
tissues  was  too  young  a  practice  to  draw  the  member  states’  attention. 
Second, the EPC is a guideline of principles which is essential to the European 
patent  system,  i.e.,  it  consists  of  general  ideas  that  provide  direction  to 
member  states.  It  does  not  address  every  detail  in  the  patent  system 
considering  the  role  supplementary  documents,  such  as  regulations, 
100 






Articles 54, 55, 56 and 57 of  the EPC manifest  substantive  requirements 
essential  for  the  process  of  patent  development  and  approval:  novelty, 
inventiveness and industrial application. 
Article  54  defines  novelty  as  not  “part  of  the  state  of  the  art,”  which  is 
interpreted  in  the  next  clause  of  the  same  article  as  “everything  made 
available to the public by means of a written or oral description, by use, or in 
any other way, before the date of filing of the European patent application.” 
The  EPC  adopts  the  first  to  file  principle  in  novelty  requirement.418 Even 
though some substance is already in the state of the art, its new use may still 
be beyond the prior art.419  
Article  55  supplements  the  novelty  clause  by  regulating  the  non‐
prejudicial disclosures, which means that an invention that has been misused 











57;  it  requires  manufacture  or  use  in  industry,  including  agriculture,  and 
anything  not  producible  on  a  large‐scale  does  not  satisfy  this  requirement 
and cannot be patented. 
An  opposition  can  be  filed  on  the  grounds  of  non‐patentability  under 
Article 52 through 57,420 and a European patent may be revoked therein.421 
Besides  these  substantive  requirements,  patent  applicants  need  to  fulfill 
procedural  requirements  as  well.  The  Article  78  illustrates  the  application 
documents, which includes a request form, description, claims, and abstracts. 
To better implement the EPC and interpret it consistently in practice, the 
Administrative  Council  of  the  European  Patent  Organization  adopted  the 
Implementing  Regulations  to  the  Convention  on  the  Grant  of  European 
Patents  [the  Implementing  Regulation]  in  2006,  which  interprets  and 
explains  the  articles  under  the  Convention with more  detailed  and  specific 
instructions.  According  to  Article  164  of  the  EPC,  the  Implementing 
Regulations  and  all  protocols  are  integral  parts  of  the  EPC;  therefore,  the 
Implementing  Regulations  are  legally  binding,  too.  Corresponding  to  the 
structure  of  the  EPC,  the  Implementing  Regulations  consist  of  112  rules 
concerning  the  form  and  format  of  the  application,  administrative matters, 
the  examination  procedure,  opposition  procedure  and  appeal  procedure. 










The  Implementing  Regulations  explicitly  incorporate  some  articles  of 
Directive  98/44/EC,  and  considers  themselves  and  the  Biotechnology 
Directive “supplementary means of interpretation” of the EPC.422 
Rule 26(1) of the EPC423 defines the term “biotechnological inventions” as 
“inventions which  concern  a  product  consisting  of  or  containing  biological 




different. 424  Meanwhile,  Article  53  also  applies  to  biotechnological 
inventions,  but with more  specific  instructions, which  are  laid  out  in  other 
clauses. 
Rule 27 of  the EPC  (2000),  also known as Rule 23(c) of  the EPC  (1973), 
encompasses the general rule of patentable biological inventions. It confirms 
the  patentability  of  a  biological  material  if  it  is  “isolated  from  its  natural 

















c) uses  of  human  embryos  for  industrial  or  commercial 
purposes; 
d) processes for modifying the genetic identity of animals which 
are  likely  to  cause  them  suffering  without  any  substantial 
medical benefit to man or animal, and also animals resulting 
from such processes. 
According  to Rule  26(1)  of  the  EPC  (2000),  in  order  to  interpret Article 
53a  and  determine  whether  inventions  are  contrary  to  ordre  public  or 
morality under Article 53a, examiners shall resort to Rule 28 for more details 
in  the  case of  biotechnological  products  or processes. Rule 28(c)  stipulates 
that  any use  of  human  embryos  for  “industrial  or  commercial  purposes”  is 
considered to be contrary to the ordre public. This clause basically blocks any 
product or process regarding hESCs from patenting because it must concern 
the  use  of  human  embryos,  including  embryos  from  abortion, miscarriage, 
IVF  or  SCNT.  Another  technical  question  is  how  to  define  “industrial  or 
commercial purpose.” There is no further regulatory explanation of the term, 
but the Enlarged Board of Appeal [EBA] interprets Rule 28(c) in the case of 






discovery  of  human  body  elements  from  their  isolation.  The  former  is  not 
patentable, but the later is as long as the subject is isolated from the natural 




2.  Decisions  on  hESC  Patent  Applications  of  the  European  Patent 
Office under the EPC 
 
Figure 5.2  is a graph  illustrating the status of patent applications  filed  in 
EPO that are related to hESCs. Among those applications, eighteen are under 
























































Figure  5.3  demonstrates  claims  categories  of  hESC  related  EPO  patent 
applications,  including  those  intended  to  be  granted.  The main  category  is 
method  of  applying  pluripotent  ESCs  for  further  purpose.  There  are  four 
claims. One of them is intended to be granted.  
The  milestone  cases  concerning  hESC  inventions  in  the  EPO  are  the 
“Isolation, selection and propagation of animal transgenic stem cells” field by 
Edinburgh University  and  the  “Primate  Embryonic  Stem  Cells”  filed  by  the 




granted  in 1999 after  it was  amended  to  exclude  “human  cloning”  from  its 
claims. The claim first covered animal ESCs. After it was granted, it received 
oppositions  from  Italy, Germany, Netherland and  the European Parliament. 
The Opposition Division Claimed that the granted patent violates the Article 
53(a) and Rule 28 of the EPC. By the end, patent proprietor voluntarily added 



















Method of Producing Embryonic Germ Cells
Method of Producing NM Pluripotent ESCs
Method of Using Plurpotent ESCs
Isolating Pluripotent ESC's from Blastocysts
106 
because  the  English  word  “animal”  does  include  human  beings. 426  The 
amendment does not  change  the  scope of  the patent because even without 
the  wording  of  the  qualifier,  the  patent  does  not  include  human  cloning 
because  the  technique  is  not  disclosed  in  the  specification.  At  the  end,  the 
patent  claim  is  limited  to  non‐human  animal  ESCs  and  human  adult  stem 
cells;  the  claim  no  longer  involves  hESCs.  The  prosecution  history 
demonstrates  the  fact  that  the  EPO  is  cautious  about  patenting  inventions 
involving hESCs.   
Facing  the  issue  of  whether  Article  53(a)  of  the  EPC  excluded  the 
invention at bar, the Board interpreted the article narrowly, because Article 
53(a) is an exception to the general entitlement to a patent found in Article 
52(1)  of  the  EPC,  “given  the  EPC’s  underlying  objective  of  establishing  a 
comprehensive  patent  protection  between  the  contracting  states.”427  To 
interpret Article 53(a)  in a restrictive manner  is supported and  justified by 
previous decisions of  the Opposition Division and the Board of Appeal. The 
exception  to  patentability  only  applies  when  the  intended  exploitation  or 







At  the  end,  the  Board  emphasized  that  morality  standards  cannot  be 















Research  Foundation  [WARF]  claimed  cell  cultures  including  primate 
embryonic  stem  cells  (EP0770125,  application  number  196903521.1  ).  In 
2004,  the  Examining  Division  refused  to  grant  a  patent  based  on  the 
provisions  of  the  EPC  and  the  EU Biotechnology Directive.  Considering  the 
fact  that  the  disclosed  method  of  obtaining  stem  cells  involved  embryo 
destruction,  the  invention was considered  to be  the use of human embryos 
for industrial or commercial purposes and fell out of the scope of patentable 
subject matters, since the regulations banned inventions which are “contrary 
to  ‘ordre public’  or morality”  under  Article  53(a)  of  the  EPC  (2000).429 The 
applicant  appealed  to  the  Technical  Board  of  Appeal,  which  referred  the 
question to the Enlarged Board of Appeal [EBA] for legal points.430 The EBA 
reached its decision in 2008. 
The  EBA  interpreted Rule  28(c)  of  the  Implementing  Regulations  to  the 
Convention  on  the  Grant  of  European  Patents—Rule  28(c)  of  the  EPC 
(2000)—in  the  context  of  its  legislative  history  and  supplementary 
documents.  Since  the  Regulation  was  aligned  with  the  Biotechnology 
Directive (in this case, the specific article is Article 6(2) of the Directive), the 








mention  any  prohibition  regarding  the  use  of  human  embryos.  Later,  the 
Economic and Social Committee of the European Parliament proposed in its 
opinion  to  specifically  exclude  human  embryos  from  patentability,  which 
implies  the  committee’s  opposition  to  patents  misusing  human  embryos. 
After  hearing  the  opinion  of  the  Committee,  the  Commission  amended  the 
proposal by adding “methods in which human embryos are used” under the 
clause of unpatentable subject matters.”431 The language was amended later 
in  the  Common  Position  EC  No  19/98  adopted  by  the  Council  as  “uses  of 
human embryos for industrial or commercial purpose,” which is also the final 
version  of  the  Directive,  as  well  as  the  wording  in  the  Implementing 
Regulation. The EBA considered the language and its amendment history as a 
clear  intention  to  prohibit  commercialization  of  human  embryos.  The  EBA 
claimed  that  since  the  present  invention  was  not  for  therapeutic  or 
diagnostic purpose, it was not patentable unless it was for the benefit of the 
embryo, which was not true in this case either considering the embryos were 
destroyed.  To  answer  the  appellant’s  question  regarding  the  starting  point 
for defining the term “embryo.” the EBA leaned towards leaving the question 
to  the  fact  of  particular  patent  applications  since  both  the  EU  and  EPC 
seemed to make an effort to avoid any restrictive meaning of the word.432 
Finally,  the EBA concluded that Rule 28(c) of  the EPC (2000)  forbids the 
patenting of clams directed to products which are prepared exclusively by a 
method in which human embryos are misused, even if the method is not part 
of  the  claims.  In  other  words,  to  determine  whether  an  invention  is 
forbidden,  examiners  should  investigate  the  entire  technical  description  of 
the  application  as  to  how  the  invention  is  to  be  performed,  instead  of  the 






inventions,  there  is  no  need  to  discuss  whether  the  morality  requirement 
under Article 53 applies in this case. However, the EBA emphasizes that the 
decision  only  concerns  inventions  which  are  obtained  by  any  methods 
involving  destruction  of  human  embryos,  but  not  applicable  to  general 
inventions relating to human stem cells or human stem cell cultures. The EBA 
sustained  the rejection. Finally,  the application was withdrawn because  the 
applicants failed to reply.  
In  summary,  the  EPO’s  refusal  to  grant  patents  for  primate  embryonic 
stem  cells,  especially  hESCs,  is  based  on  moral  grounds. 433 However,  the 












of  the  EPC  (2000).  The  distinction  is  the  subject  matter.  The  “Euthanasia 
Compositions”  case  does  not  involve  human  beings  while  the  WARF  case 
directly  relates  to  human  embryos.  Generally  speaking,  to  determine 
whether  inventions are contrary  to  “ordre public” or morality under Article 
53(a),  the  Board  leans  towards  interpretation  of  the  exception  clause 
narrowly, applying it only to the publication or exploitation of the products. 




applies  automatically.  Any  product,  whose  preparation  method  or  process 






The  high  uncertainty  of  the  EPC  system  is  due  to  the  possible  different 
litigation outcomes achieved by national courts. While patents granted by the 
EPO are valid across all of  the states,  the courts’ decisions are only binding 
within  the  borders  of  the  state.  Once  entered  into  the  national  judicial 
system, the litigation cost, procedural laws, damage assessments, and quality 
of  adjunctions may  have  strong  variations  across  states.  Patentees  are  not 
only  facing  the  uncertainty  of  litigation  results,  but  also  the  high  litigation 
cost. 
The  European  Patent  Litigation  Agreement  started  with  the  Paris 
Intergovernmental  Conference  in  1999.  In  this  conference,  the  contracting 
state of the EPC set up a Working Party on Litigation, which was in charge of 
drafting  the  Agreement  on  integrated  litigation  for  European  patents.  The 
latest draft was submitted to the Working Party on Litigation in 2005.  
The  draft  Agreement  includes  substantive  patent  law,  such  as  the 
definition  of  infringing  acts  and  indirect  infringement,  burden  of  proof, 
procedural provisions, procedural remedies (appeal or petition to review of 
court decisions), as well as the remaining jurisdiction of national courts, and 
new  organs  of  the  European  patent  judicial  system—European  Patent 
Judiciary [EPJ], comprising the Court of First Instance, the Court of Appeal, a 
111 
Registry, and  the Administrative Committee. After  that, no  further progress 
has been made by the Working Party on Litigation.434  
In  2007,  the  European  Commission  proposed  a  document  named 
Enhancing the Patent System in Europe [COM (2007) 165] to  the European 
Parliament  and  Council,  suggesting  the  combination  of  the  EPLA  and  a 
community  jurisdiction  as  an  integrated  judicial  system.  Since  then,  the 
project  of  creating  an  integrated  judicial  system  has  been  shifted  to  the 








procedure, but  leaves enforcement and dispute  litigation  to member states. 
As  patents  are  subject  to  diverse  national  laws  and  procedures,  patentees 
bear the burden of litigation in a number of countries on one patent and the 
risk of variable or even contradictory results in different countries. Different 
rules  of  evidence,  cost  of  litigation,  speed  of  proceedings  and  even 
interpretation  and  application  of  substantial  laws may  give  rise  to  “forum 
shopping”.  The  lack  of  legal  certainty  also  has  an  impact  on  business 







Convention  on  the  Community  Patent  in  1975,  which  never  enters  into 
force. 436  In  2000,  The  Commission  proposed  the  Community  Patent 
Regulation to unify the complete patent process, including enforcement and 
dispute  resolution. 437  But  this  proposal  failed.  In  2009,  the  Council 
unanimously  adopted  a  document  regarding  enhancement  of  the  patent 
system by establishing a unified European Community patent system and the 
European  and  Community  Patent’s  Court  with  a  group  of  individuals  with 
legal  and  technical  expertise  in  patents.438 After  the  effectiveness  of  the 
Lisbon Treaty in 2009, which amends the Treaty on European Union and the 






patent  court  are  in  different  states  of  progress.  In  2010,  the  European 
Parliament  gave  its  consent  to  a  common  EU  patent  system  by  using  the 
enhanced co‐operation procedure.440 This procedure can only be used under 



















unanimous  agreement  is  required  to  adopt  new  rules  when  unanimity  is 
unreachable.441 After  consent  is  obtained  in  the  European  Parliament,  the 
Commission  will  submit  two  proposals  concerning  the  establishment  of  a 
single  patent  system  and  the  language  requirements  for  the  patent 
applications.442 
However, the establishment of a European patent court encountered some 
obstacles.  The  European  Court  of  Justice  conveyed  its  opinion  on  the 
compatibility  of  the  European  and  EU  Patent  Court  Agreement  with  the 
provisions  of  EU  treaties  on  Mar.  8,  2011,  stating  that  the  envisaged 
agreement fell outside the institutional and judicial framework of the EU, and 




of documents with different  levels of  legal effectiveness has been  issued by 
the  European  Parliament,  the  European  Community  and  the  European 
Council. Regulations are documents self‐executing in all EU institutes and all 
member  states  and  can  be  applied  directly.  Therefore,  regulations  have 
supreme  legal  effectiveness  over  other  EU documents  and national  laws  of 
member  states.  Directives  are  more  like  guidelines  or  model  texts  than 
binding documents. They leave the member states the freedom to adopt any 
















instruments  issued  by  European  institutions  to  solve  or  respond  to  any 
disputes or debates  in  the EU with  the  legal  ramification  affecting only  the 
member  states  to  which  they  are  addressed.444 In  addition,  the  European 
Court  of  Justice  [ECJ]  have  the  jurisdiction  to  give  preliminary  rulings  on 
interpreting treaties and agencies’ acts445, which become part of EU laws to 
promote the integration of European laws.446  The ECJ with the authority to 
apply  and  interpret  laws  ensures  the  laws  are  applied  and  interpreted 





The  Convention  on  Human  Rights  and  Biomedicine  took  effect  in  1999, 
setting  forth EU general policy on embryonic  research.  In Article 18 of  this 
convention, it entitles the authority of states to regulate embryo research, on 
two premises: “to ensure adequate protection of the embryo” and to prohibit 
“the  creation  of  human  embryos  for  research  purpose.”  The  Convention  is 
only binding in states that have ratified it. So far, it has received ratification 












2.  Announcement  of  the  European  Parliament  concerning  hESC 
Research 
 
The  European  Parliament  explicitly  demonstrates  its  attitude  towards 
hESC  research  in  the Patents  on Biotechnological  Inventions  and European 
Parliament  Resolution  on  Patents  for  Biotechnological  Inventions, 
promulgated  in  2006.  In  this  announcement,  it  underlines  support  of  stem 
cell research but rejects any research on human embryos which may destroy 
embryos.448 Reflecting  that  principle,  it  further  states  that  the  patenting  of 
procedures involving hESCs and derived from hESCs violates Article 6(2)(c) 
of the Directive, because the creation of hESCs inevitably leads to destruction 
of  embryos,  which  violates  the  principle  of  the  EU  and  the  Directive.449 It 
does  not  specifically  mention  the  patenting  of  hESCs  per  se,  but  it  can  be 
easily inferred from the text that Parliament would consider that patenting of 
human embryonic stem cells is a violation of the Biotechnology Directive for 
the  same  reason.  This  document  is  an  announcement  of  the  Parliament’s 
general  policies,  intend  to  reduce  the  uncertainty  surrounding  hESC 
patenting  issues.  Generally  speaking,  however,  announcements  of  the 





Considering  the  importance  of  stimulating  investment  in  research  and 
industry,  the  important  role  of  biotechnological  inventions  in  industrial 











Directive  in  1988  relevant  to  the  patenting  of  biotechnological  inventions, 
but this and was rejected by Parliament due to opposition from the Greens, 
an  animal  welfare  activist  and  environmentalist  group.  The  major  reason 
given  by  opponents  was  that  “it  failed  to  deal  adequately  (or  at  all)  with 
ethical  concerns  about  patenting  biotechnological  inventions” 450 and  “it 
should identify certain specific topics that, for ethical reasons, should not be 
patentable.”451 After  revisions,  a  new  draft  of  the  Biotechnology  Directive 
was  approved  by  the  European  Parliament  in May  of  1998  and  came  into 
force two months later.  
This  Directive  undoubtedly  has  succeeded  in  establishing  unitary 
guidelines  within  the  EU.  Even  though  it  is  a  directive  that  only  functions 
once  transferred  into  a  member  state’s  national  laws,  it  has  been  applied 
quite  well  in  the  EU.  There  are  two  reasons  for  this  success.  First,  the 
Administrative  Council  of  the  European  Patent  Organization  has  already 
introduced  the provisions  of  the Biotechnology Directive  implementing  the 
European patent laws. Rule 26(1) of EPC states: 
The  relevant  provisions  of  the  convention  shall  be  applied  and 
interpreted  in  accordance  with  the  provisions  of  this  chapter. 











EU.  This  rule  assures  legislative  consistency  between  the  EU  and  EPO, 
consequently  carrying  forward  the  implementation  of  the  Biotechnology 
Directive throughout most European countries.  
Secondly,  the  mechanism  of  the  EU  entitles  either  the  European 
Commission or an aggrieved person  the  right  to ask  the European Court of 
Justice  to  impose  a  penalty  on  a  member  state  that  fails  to  transpose  the 
Biotechnology Directive into national law.452 Besides that, the Court of Justice 
held that a state that fails to transpose directives is liable for all damages to 
individuals  or  companies  who  had  been  adversely  affected  by  the  lack  of 
implementation  or  faulty  implementation.453 Later,  the  European  Court  of 
Justice  developed  a  doctrine  of  direct  effect  holding  that  in  those  cases  of 
non‐implementation  or wrong  implementation,  directives  have  direct  legal 
force. 454  Legal  proceedings  for  failure  to  transpose  the  Biotechnology 
Directive  to national  law were  initiated  in 2003 before  the Court  of  Justice 
against  the  countries  which  had  not  transposed  the  Directive.455 Infraction 
procedures were opened in December 2004 against two new member states, 


















These  two  factors  ensure  the Biotechnology Directive will  function with 
real  effectiveness  and  enforceability  rather  than  being  just  a  trumpery 
recommendation.  
Generally speaking, the Biotechnology Directive is a compromise between 
the  European  Commission  and  Parliament.  On  one  hand,  it  gives  sanction 
endorsement to certain types of inventions relating to the human body, such 
as isolated or purified DNA sequences; on the other hand, taking parliament’s 
concern over ethical  issues  into account,  it prohibits patents on  the human 
body and parts of the human body considering the public order and morality.  
The  Biotechnology  Directive  sets  forth  the  basic  requirements  of 
patenting: novelty, inventiveness and industrial application as general patent 
rules.  However,  since  the  Biotechnology  Directive  is  is  concerned  with 
biotechnological  inventions,  it  focuses  on  the  patenting  issues  raised  by 







1.  The  human  body,  at  the  various  stages  of  its  formation  and 
development,  and  the  simple  discovery  of  one  of  its  elements, 
including  the  sequence  or  partial  sequence  of  a  gene,  cannot 
constitute patentable inventions. 
2. An element isolated from the human body or otherwise produced 






Inferring  from  the  text,  the  clauses  set  forth  a  special  standard  of 
patenting for the human body. An element derived from the human body by 
techniques  of  identification,  purification  and  multiplication  is  patentable 
even if it is identical to an element existing in nature, as long as it is novel,457 
inventive and industrially applicable.  









likely  to  cause  them  suffering  without  any  substantial  medical 
benefit  to  man  or  animal,  and  also  animals  resulting  from  such 
processes. 
To  clarify  the  exclusion,  Recital  42  reiterates  that  the  exclusion  of 
patenting human embryos for industrial or commercial purposes should not 
affect inventions for therapeutic or diagnostic purposes. These are the basics 
rules  governing  patentability  of  biological  materials  relating  to  the  human 








instance,  the  definition  of  human  embryo  and  the  scope  of  “industrial  or 
commercial purposes” have not been clarified.  
The statutes of the Biotechnology Directive do not unambiguously refer to 
hESCs.  Thus,  application  to  hESCs  is  left  to  adjudication  or  judicial 
interpretation.  
In  the  Commission  report  to  the  Council  and  Parliament  titled 
Development  and  Implications  of  Patent  Law  in  the  Field  of  Biotechnology 
and Genetic Engineering,458 the Commission  stated  that  the patentability  of 
totipotent  stem  cells  was  clear  under  Article  5(1)  of  the  Directive,  which 
precluded  the  patenting  of  the  human  body  at  its  various  stages,  because 
totipotent  stem  cells  had  the  ability  to  develop  into  human  beings. 459 
However, according to the document, the situation of pluripotent embryonic 
stem  cells  was  more  complex  since  they  lack  the  capacity  to  develop  into 
human  beings.  Despite  this  lack  of  capacity,  the  matter  still  raises  ethical 
questions, such as the status of human embryos, and the Commission thinks 
it is premature to unify the law in this area.460  
The  Board  of  Appeal  of  the  EPO  has  interpreted  Rule  53d(c),  which  is 
Article  6(2)(c)  of  the  Directive,  to  exclude  products  or  processes  that  are 
prepared exclusively by methods in which human embryos are used, unless 
intended  for  the  benefit  of  the  embryos  themselves.  That  interpretation 









The  European  Group  on  Ethics  in  Science  and  New  Technologies  to  the 
European Commission [EGE]  is an  independent group  in  the EU, comprised 
of  experts  appointed by  the Commission. The main  tasks of  the EGE are  to 
review ethical issues arising from science and new technologies and submit 
its advice on those issues to the Commission for legislation or policy making. 
As  an  advising  agency,  the  EGE  only  provides  expert  opinions  to  the 






Origin,  giving  some  comments  and  opinions  on  the  first  proposal  of  the 
Directive.  
Another  report,  Ethical  Aspects  of  Human  Stem  Cell  Research  and  Use, 
was issued on November 14, 2000. In this report, the EGE admitted that the 
embryonic  stem  cell  research  raised  certain  ethical  issues  and  different 
sources  could mean  different  ethical  acceptability.  Derivation  of  stem  cells 
from embryonic blastocysts raises the issue of the moral status of embryos. 
Considering  the decentralized  structure  of  the EU, member  states  have  the 
authority over human embryonic research with the obligation of protecting 
human dignity. For instance, making regulations on embryonic research and 
provisions  against  “arbitrary  experimentation  and  instrumentalisation  of 
human embryos.”461 Even though the embryonic stem cell research has great 








possibility  of  misuse  of  embryos  by  the  “proportionality  principle  and  a 
precautionary  approach.”462 However,  the  EGE  did  not  provide  a  line  of 
reasoning  to explain  to how  to balance  the benefits of  embryonic  stem cell 
research  against  any  risk  to  human  dignity  that might  be  impaired  by  the 
research.  
The  report  entitled  Ethical  Aspects  of  Patenting  Inventions  Involving 
Human  Stem  Cells,  released  in  2002 was  requested  by  the  Commission  to 





this  clause,  nor  is  the  patentability  of  cells  derived  from  embryos  directly 
addressed. To fill in the gap, several elements must be considered: content of 
patents, sources of stem cells, methods used to derive stem cells, protection 
of  the  donors,  socio‐economic  consequences,  and  implication  to  the  patent 
system.  
The  EGE  held  that  unmodified  stem  cells  are  not  patentable  for  several 
reasons.  First,  they  do  not  fulfill  the  legal  requirements,  especially  the 
industrial  application  requirement.  Second,  since  they have a  close  relation 




However,  stem  cell  lines  modified  by  in  vitro  treatment  or  genetic 
modification  with  specific  industrial  application  are  patentable.  As  to 








stem  cells  from  human  embryonic  origin  into  genetically  modified 
stem  cell  lines  or  specific  differentiated  stem  cell  lines  for  specific 
therapeutic  or  other  uses,  is  ethically  acceptable,  as  long  as  the 
inventions fulfill the criteria of patentability…464   
Based on  this  logic,  unmodified embryonic  stem cells  are not patentable 
because  they  lack  industrial  application  and  contradict  the  public  order, 
while modified embryonic stem cells with specific industrial application may 








either  the  EU  or  the  EPO.  The  European  courts  have  no  jurisdiction  over 
patent  disputes.  After  the  contracting  states  of  the  EPC  began  to  work  on 
drafting  the  European  Patent  Litigation  Agreement  [EPLA]  in  1999,  and 
proposed to establish a new jurisdiction for a European patent system—the 
European  Patent  Judiciary  [EPJ]—the  European  Commission  adopted  a 
document titled “Enhancing the Patent System in Europe” in 2007.  In it, the 









determinations  and  patent  enforcement  over  most  European  countries.465 





Since  the EPC does not  explicate  the patent‐eligibility of hESCs,  it  leaves 
room  for  countries  to  come  to  their  own  interpretation  in  patent  practice. 
Member states of the EPC have come to diverse decisions on the patenting of 
hESCs.  Some  countries  allow  both  hESCs  and  process  patents;  some  only 






Schedule  A2  of  the  Patent  Act  (1977)  precludes  certain  subject matters 
from  being  patented.  Paragraph  3  of  Schedule  A2,  similar  to  the  Directive, 
excludes from patentability the human body at  its various stages, processes 
of cloning human beings, processes  for modifying human germ lines, use of 
human  embryos  for  industrial  or  commercial  purposes  and  processes  for 
modifying the genetic identity of animals without bringing benefit to man or 
animals.  There  are  no  specific  rules  regarding  embryonic  stem  cells. 
However,  this  gap  is  filled  by  the  Examination  Guidelines  for  Patent 










In  the  UK  Examination  Guidelines,  Article  107  to  Article  113  concern 
hESCs.  The  Examination  Guidelines  exclude  the  patentability  of  any 
processes  for  obtaining  stem  cells  directly  from  human  embryos  and  stem 
cells  derived  from  human  embryos  are  not  patentable  either  under 
Paragraph 3(d) of Schedule A2, which bans  the patenting of uses of human 
embryos for industrial or commercial purposes. As previously stated, human 
totipotent  cells  have  the  potential  to  develop  into  human  beings,  and 
therefore, are not patentable under Paragraph 3(a) of Schedule A2. This also 
includes  the  processes  of  culturing  or  propagating  them.467  In  contrast, 
human  embryonic  pluripotent  stem  cells  that  cannot  develop  into  human 
beings  are  patentable  especially  considering  their  scientific  and  medical 
values.468 On the grounds that the EPO Enlarged Board of Appeal’s judgment 
in the WARF case—that the unpatentablity holding only concerns embryonic 




In  the newest Practice Notice of  Inventions  involving Human Embryonic 
Stem Cells, published in February of 2009, the UK Intellectual Property Office 















Neither  the  German  Patent  Office  nor  German  courts  have  issued  any 
official  statement  regarding  the  patentability  of  hESC‐related  application. 
However,  in  practice,  the  German  Patent  Office  has  granted  patent  DE 
10136702 B4, related to a process involving the use of pluripotent hESC’s.471 
Another  patent  DE  197  56  864,  claiming  methods  of  obtaining  progenitor 
cells from hESCs and the progenitor cells per se, is under appeal in Germany 




relevant  hESCs  or  hESC  lines  have  been  imported  legally  under  German 





















The  Swedish  patent  office  has  granted  a  patent  on  a  method  of 
differentiation  of  pluripotent  hESC’s  into  hematopoietic  cells.475 The  office 
explained  that  the  method  disclosed  in  the  patent  application  could  be 
performed  by  using  deposited  lines  without  causing  any  direct  damage  to 
human embryos, so it fell outside the scope of the exclusion in Article 6(2)(c) 
of the Directive.476  
Similarly,  the  Norway  Intellectual  Property  Office  has  granted  a  patent 
claiming  pluripotent  stem  cells  from  non‐embryonic  origins.  But,  how  that 
result affects  inventions of hESCs per se or  involving  the use of embryos  is 
unpredictable. 477  





Reproductive  Medicine  Act,  which  prohibits  any  use  of  “developmental 
potential  cells”  for  other  purposes  except  assisted  reproduction,479 there  is 
little  possibility  of  patenting  hESCs  since  their  derivation  contravenes  the 
laws. 
As new EU members, Estonia and Slovakia both adopted the content of the 












process  involving  the  utilization  of  human  embryos  for  commercial 
purposes.480 However,  the  application  of  these  clauses  in  practice  is  still 
unknown  
In  conclusion,  the  EPO  applies  Article  6(2)(c)  to  exclude  any  invention 
derived from embryos, but maintains silence in relation to hESCs attained by 
other means,  and  leaves  the definition of  embryo open  to determination  in 





develop  into  human  beings  and  patenting  or  commercializing  them  will 
jeopardize human dignity. hESCs which have no potential  to develop  into a 
human  being  of  their  own  at  the  blastocyst  stage,  are  pluripotent  stem 







Since  the  definitions  are  not  given  in  the  EPC,  different  interpretations  of 
words  can  drive  different  conclusions,  and  therefore,  different  scopes  of 












study  is  not  exhaustive.  Some  singnificant  scholoar  viewpoints may  not  be 
included in this section. 
First,  the  definition  of  “embryo”  is  not  clear.  The  scope  of  the  definition 
depends on whether the word is interpreted narrowly or broadly. Under the 
narrow  interpretation,  “embryo”  merely  includes  naturally  conceived 
embryos.    If  the narrow definition  is adopted, hESCs derived  from embryos 
produced  by  an  artificial  method,  such  as  IVF,  are  not  inhibited  by  the 
Directive  and  are  patentable482 because  they  lack  the  capacity  or  intent  to 
develop  into  adults.  Furthermore,  even  embryos  produced  by  therapeutic 
cloning may be patentable as well since the purpose of therapeutic cloning is 





















commercial  or  industrial  uses  of  embryos,  all  of  which  fall  into  non‐
patentable  categories  in  the  Directive.  Therefore,  according  to  this  view, 
totipotent ESCs are not patentable, but pluripotent or multipotent stem cells 
which cannot develop into an adult human being are patentable, albeit with 
deliberate  supervision  by  patent  agencies  to  ensure  those  patents will  not 
adversely affect embryos or totipotent stem cells.485  
There are some scholars do not agree with that interpretation. Some state 
that  the  therapeutic  use  of  stem  cells  is  thoroughly  different  from 
commercial  or  industrial  use.486 For  instance,  they  hold  that  utilizing  stem 
cells for therapy or treatment should not be considered commercialization of 
human embryos, especially when the embryos used are produced by SCNT, 
and  thus,  such  embryonic  stem  cells  should  not  be  excluded  from  patent 
protection.487  Some  argue  that  the  ultimate  goal  of  any  research  is  to 
commercialize the research results and apply them in industry. As long as the 
hESC  research  is  legal,  there  is  no  reason  to  reject  legal  protection  of 
research  results. 488  Others  allege  that  the  exception  clause  should  be 
interpreted  in a narrow way on  the grounds of  jurisprudence principles,489 
which are established by the case law of European Court of Justice.490 Some 
scholars  conclude  from  the  legislative  history  of  the  Directive  that  the 
amendment  changing  “methods  in which  human  embryos  are  used”  in  the 
draft  to  “for  commercial  and  industrial  purpose”  in  the  final  text manifests 













Third,  the  line  between Article  5(1)  and Article  5(2)  is  blurred. Webber 
claims  that  Article  5(1)  of  the  Directive  applies  to  various  stages  of  the 
human  body,  including  zygotes  and  totipotent  stem  cells  that  have  the 
capacity of developing into human beings; pluripotent and multipotent stem 
cells  are  not  governed  by  Article  5(1),  but  are  also  precluded  from  patent 
under Article  6(2)(c). 492 In  contrast, Hagen  and Gittens  argue  that  it  is  not 
clear whether 5(1) precludes the patentability of human stem cells that are 
not  a  natural  stage  in  the  development  of  a  human  body,  for  instance, 
embryonic  stem  cells  extracted  from  an  embryo  which  would  not  have 
developed into a mature human body on its own. Furthermore, if Article 5(1) 
prohibits  the patenting  of  isolated  totipotent  cells,  all  human  cells must  be 
excluded from patenting because they could develop into a mature human by 
SCNT  or  through  the  reprogramming  of  adult  cells.493 Aurora  Plomer  takes 
the  middle  ground,  concluding  that  Article  5(1)  governs  totipotent  hESC’s 
while  5(2)  applies  to  pluripotent  stem  cells;  in  other words,  the  former  is 
nonpatentable while the latter is patentable.494  




















“ruled  by  Li  and  run  by  Xing.”497In  the  Han  dynasty,  two  main  Chinese 
philosophic  schools  of  thought—Confucianism 498  and  Legalism 499 —
accomplished this combination:500 Han governers infused Confucianism with 
the  written  laws,  administrative  system  and  government  structure  of 
Legalism  by  using  Confucian  classics  to  create  and  interpret written  codes 
and  published  documents.501   In  the  Tang  dynasty,  this  characteristic  was 
more systemized.502 This legal system lasted for more than 1000 years until 
legal reform occurred during the Qing Dynasty in AD 1901. That reform was 


























other  countries,  especially  Germany  and  Japan.  During  this  short  period, 
China promulgated many new  laws,  for  instance,  a Constitutional  law, Civil 
Code, Criminal Code, Company law and Bankruptcy law. However, these laws 
did not last long due to the Xinhai Revolution in 1911.  





However,  that  legal  system  was  gradually  destroyed  during  the  “Anti‐
Rightist  Campaign”  (1950s  to  early  1960s)  and  “the  Great  Cultural 
Revolution”  (1966‐1976).  Therefore,  after  the  “Great  Cultural  Revolution,” 
President  Deng  Xiaoping,  emphasizing  the  importance  of  the  legal  system, 
signed a new Constitution (1978 Constitution) as well as some statutes such 
as  the  Criminal  Law,  the  Criminal  Procedure  Law,  the  Organic  Law  of  the 
People's Courts of the People's Republic of China and so forth.  
From  this  beginning,  China  embarked  on  the  arduous  process  of 
rebuilding the judicial branch and commensurate laws. Since 1978, China has 
promulgated the laws listed below among other legislations: 
• the Constitutional Law (1982) and  its  four amendments  in 1988, 1993, 
1998 and 2004; 
• the    Organic  Law  of  the  National  People’s  Congress  of  the  People’s 
Republic of China (1982) (effective); 
• the  Electoral  Law  for  National  People's  Congress  and  People's 
Congresses  at  Local  Levels  and  the  Organic  Law  of  the  Local  People's 
134 
Congresses  and  Local  People's  Governments  (1982)  (last  modified  in 
2004); 















the  Executive  and  the  Judiciary.  Unlike  the  “check‐and‐balance”  system  in 
western  countries,  the  Legislature, which  in  China  is  the  National  People’s 
Congress  [NPC],  has  the  highest  power.  The  State  Council  is  the  highest 
executive  agency,  assisted  by  many  departments  and  local  agencies.  The 



















initiating  statutes  when  it  is  not  in  session.  That  organ  is  the  Standing 
Committee  of  the  National  People’s  Congress505 [the  Standing  Committee], 
which possesses less power than the NPC. 
The  NPC  exercises  the  exclusive  power  to  enact  and  amend  the 
Constitution  and  criminal  laws,506  and  maintain  nonexclusive  legislative 
power to enact statutes. It has approval and removal rights over the heads of 
governmental institutions and maintains control of the state budget. It is also 















The  NPC  Standing  Committee  [Standing  Committee]  is  the  permanent 
body  of  the  NPC.  It  has  the  authority  to  stipulate  and  modify  all  statutes 
except  for  the Constitutional Law,  to  interpret all  laws, and  to supervise  the 
work  of  the  administrative  agencies  and  the  judiciary  as  well  as  other 
significant  activities which  are  essential  to  state  interests  or  governmental 
functioning.508 
The NPC members are elected by lower level regional congresses, whose 
members  are,  in  turn,  elected  by  still  lower  level  legislative  bodies.  Direct 
elections are held at the lowest tier of the People’s Congress system, i.e., at a 
town or municipal  level. Every citizen registered  in a  town or city over  the 
age of 18 with political  rights, has  the right  to vote  for  the deputies of  that 
area.509After  this  electoral  process,  the  deputies  of  provinces,  autonomous 
regions, municipalities, special administrative regions and the armed forces 
in turn are entitled to vote for the deputies to the NPC. Every minority ethnic 
group  is  entitled  to  appropriate  representation. 510  The  term  of 





















The  NPC  and  its  Standing  Committee  have  the  highest,  but  not  the 
exclusive,  legislative  authority.  There  are  many  local  People’s  Congresses 
established at various levels in provinces, municipalities, counties and towns, 
under  the  guidance  of  the  central  government,  with  comparatively 
independent power.514 Their authority includes enacting local regulations,515 
electing and removing governors, court presidents and chief procurators, and 
supervising  the  governments,  courts  and  procuratorates  at  the 
corresponding level.516 Since local congresses are elected from bottom to top 
rather  than  designated  by  the  upper  level  congresses,  theoretically, 
congresses  at  various  levels  should  be  independent  from  each  other. 
However, the authority of congresses at lower levels is subject to the upper 
level  congresses  to  some  extent.  For  instance,  the  regulations  they  make 
must not contravene statutes or regulations promulgated by the NPC or the 
Standing  Committee,  and  must  be  reported  to  the  Standing  Committee.517 
Local congressional members are elected either by direct election or by the 






There  are  two main  issues  that  have  been  questioned  regarding  China’s 
governmental  system.  One  criticism  is  the  relationship  of  the  Communist 









years,  Mr.  Jiang  Zemin,  the  former  President  of  China,  has  stated  that  all 
groups,  including congresses, governments, courts and procuratorates must 




the CPC  is  subject  to  laws  is  questionable.  The  influence  of  the CPC on  the 
judiciary  is  never  described  in  the  Constitution.  Instead,  the  Constitution 
stipulates that the judicial power of the people’s courts is independent from 
“interference  by  any  administrative  organ,  public  organization  or 
individual.”522 Nonetheless,  the  fact  is  that  the  judiciary  in  China  is  always 
subject to the leadership of the CPC.523 A lack of check and balance may cause 
corruption and abuse of power.524  
The  second  criticism, mainly  from western  countries,  is  China’s  rule‐by‐
law  instead  of  rule‐of‐law. 525  Rule‐by‐law  refers  to  “an  instrument 
conception of  law in which  law is merely a tool to be used as state sees fit” 


























power  and  the  CPC  has  large  influence  over  the  legislature  and  the 
judiciary.527 Others, realizing the progress that the Chinese legal system has 
made, classify China as in transition to rule‐of‐law.528 But, China believes that 
rule‐of‐law  is  determined  by  “national  condition  and  social  system.”  China 
adopts  a  different  definition  for  rule‐of‐law.  According  to  the  Chinese 
government, rule of  law means governing a country according to  law, along 
with  the  main  goal  of  establishing  a  consistent,  stable  and  authoritative 
system of  laws, and having “laws  to go by,  laws  that must be observed and 







Local People’s Governments,  all  of which are promulgated by  the NPC. The 
Constitution is at the top of the hierarchy of legal power.532 However, Article 
62 of the Constitution authorizes the Standing Committee of the NPC and the 
















it allows  the  legislative body  the ability  to amend the Constitution which  is 
the source of the legislative body’s authority.533 This contravenes one of the 
foundations of the modern constitution, which is that the power to establish 
a  constitution belongs  to  the people while  the  legislative power belongs  to 
the legislature.534 
According to the Constitution, the congresses and the Standing Committee 
represent  the  interests  of  the  public  and  the  public  oversees  them  by  an 
election  mechanism.  However,  whether  it  functions  as  well  in  practice  as 
stated in the Constitution is questionable. Theoretically, the NPC represents 
the  voice  of  the  people,  but  it  fails  in  practice  due  to  the  fact  that  the 
members of the NPC are indirectly elected. 
The  relationship  between  the  NPC  and  administrative  agencies  often 
triggers questions about whether  this mechanism works effectively  to  curb 
corruption and abuse of power.535 This system might not combat corruption 
or  power  abuse  effectively  because members  of  the NPC might  not  have  a 
chance  to  access  governmental  information  due  to  the  relative  non‐
transparency  in  administrative  agencies,  and  the  NPC’s  lack  of  ability  to 
investigate. 
Additionally,  even during  the  legal  reform process,  unlike Europe or  the 
United States,  the Chinese  legal system is not only a protector of  individual 
rights,  but  also  “a  mechanism  by  which  political  power  is  exercised  and 
protected.” 536 However, the same situation has ensued in western countries, 












questionable  detention  and  interrogation methods  in  the  name  of  national 
security.  Laws protect  an  individual’s  rights,  but  also maintain  the national 
security.  
The  Judicial  system of  China  also has deficiencies.  It  is  hard  to maintain 
the  neutrality  of  courts  and  procuratorates  because  of  the  influence  of  the 







statutes,  regulations  or  governmental  decisions  that  contravene  this 
document are invalid and will be annulled by the Standing Committee, rather 
than the courts.538 
Statutes  promulgated  by  the  NPC  or  the  Standing  Committee  apply  to 
either the whole country, or certain regions of the country with the exception 
of  autonomous  areas  and  special  administrative  regions. 539  No 














Similar  to  the  legislature,  the  executive  body  can  also  be  further  sub‐
divided  into  national  and  local  levels  and  is  a  vast  and  complex  system 
governed  by  the  Organic  Law  of  the  State  Council,  the  Organic  Law  of  the 
Local  People’s  Congresses  and  Local  People’s  Governments,  the  Law  on 
Administrative  Penalty,  the  Law  on  Public  Security  Administration 






Its  functions  include  adopting  administrative  measures  and  regulations  to 
implement  or  supplement  the  Constitution  and  statutes,  or  to  exercise 
administrative functions,541 submitting proposals to the NPC and its Standing 
Committee,  leading  local  executive  agents  by  producing  national  economic 
and social development plans and state budgets and directing and providing 
general guidance for its subordinate agencies.542 










Standing  Committee.543  A  single  term  for  each  office  is  five  years,  and 
incumbents cannot be reappointed after two successive terms. The Premier 
assumes  overall  responsibility  for  the  State  Council  as  director,  and  is 
assisted by Vice‐Premiers and State Councilors.544 
The  State  Council  is  a  giant  agency  with  many  commissions  that  have 
responsibilities  for  respective  fields.  These  commissions  have  authority  to 
issue  directives  and  rules  within  their  areas  of  competence. 545  All 
administrative  agencies  at  the  central  level  are  divided  by  function  into 
seventeen ministries and commissions, one special organization,546 eighteen 
organizations  directly  under  the  State  Council,  four  administrative  offices, 
fourteen institutions and ten bureaus.547 
The  seventeen ministries  and  commissions  perform  the  basic  executive 
functions  under  the  direction  of  the  State  Council.  They  are  established  to 
handle  different  responsibilities,  including  foreign  affairs,  national  defense, 
education,  science  and  technology,  industry  and  information  technology, 





















generally  supervises  state‐owned  enterprises  and  state‐owned  assets  in 




tourism and  transportation.  The  State  Intellectual  Property Office  is  one  of 
those organizations.  
The  fourteen  institutions  include  three  types  of  organizations  with 
oversight  functions.  The  Banking  Regulatory  Commission,  organizations  of 
special importance such as the Academy of Social Sciences, and organizations 
that  require  technical  or  scientific  specialty,  such  as  the  Earthquake 
Administration  are  charged  with  these  oversight  duties.  In  fact,  these 
institutions do not perform any administrative functions, nor have their acts 
governed  by  administrative  law.  Therefore,  strictly  speaking,  they  are  not 
administrative agencies. However, because of their importance to society and 
economy  in  administration,  they  are  organized  in  forms  analogous  to 
administrative agencies and under the direction of the State Council as well.  













Among  these  dozens  of  agencies,  biotechnological  research  and  the 
patentability of research results are governed by certain agencies. First,  the 
State Council is responsible for carrying out patent law in general and stating 
policies  and  regulations  on  scientific  research.  The  subordinate  agencies 
involved  include  the Ministry of Health  [MOH],  the Ministry of  Science  and 
Technology  [MOST],  the  State  Intellectual  Property  Office  [SIPO]  and  the 
State Administration for Industry and Commerce [SAIC].  
The MOH is involved because it administers activities essential to human 
health,  such  as  collecting  blood  and  bone  marrow,  abortion  and  other 
activities involving the human body.  
The MOST promotes, launches and supervises scientific research not only 
involving  biotechnology  but  also  other  subjects  as well.  The  SIPO manages 
the  protection  of  intellectual  property  rights  by  carrying  out  the  statutes 
including Patent Law, Copyright Law and Trade Mark Law, and drawing up 
regulations or guidelines for the interpretation of statutes, if necessary. SIPO 
also  bears  the  duty  of  examining  patent  application,  granting  patents  and 
resolving patent infringement issues. The SAIC is responsible for overseeing 
commercial  activities  and maintaining market  order.  Every  business  entity 
must  register  at  the  local  Industry  and  Commerce  Bureau  to  obtain  a 
business  license before  launching  its business activity. Any conduct beyond 
its  license  or  detrimental  to  product  quality  will  be  subjected  to 
administrative  investigation  and  penalty  or  even  a  criminal  sentence. 
Therefore,  as  long  as  commercialization  of  biotechnology  materializes, 
companies or factories must register in the Industry and Commerce bureaus, 




Besides  these managerial  agencies,  scientific  and  technical  organizations 
are also vital for biotechnology development. The more advanced research is 
done, the more globally competitive the achievements will be, and therefore, 
the  greater  the  potential  for  the  results  of  such  research  to  be  patentable. 
Only  if  the  research  is  conducted  can  the  patent  system  play  its  role.  The 
mission  of  conducting  research  rests  on  the  shoulders  of  these  research 
organizations involved. For instance, the Academy of Social Sciences not only 
pioneers  research  on  philosophy  and  social  sciences,  including 
jurisprudential  studies,  but  also  offers  a  platform  for  exchanging  and 
publishing academic achievements, from which one might not only discover 
the  latest  research  results,  but,  also  the  fiercest  debates.  The  Academy  of 
Sciences  conducts  research  in  basic  and  technological  sciences  and 
undertakes surveys on natural resources and the environment, which direct 
Chinese  scientific  and  technical  research.  In  addition,  the  Academy  of 
Engineering  works  to  initiate  and  conduct  scientific  studies,  to  provide 
consultancy  services  for  decision‐making  on  key  national  issues  in 
engineering and technological sciences and to promote the development and 
undertaking  of  these  sciences.  Although  the  Academy  of  Sciences  and  the 




One  other  agency  is  worthy  of  special  mention.  This  is  the  Legislative 
Affairs Office, one of the administrative offices. The Legislative Affairs Office 
is  not  a  policy‐maker;  nevertheless,  it  is  essential  to  all  the  regulations 





There  are  various  levels  of  local  governments,  which  are  the  executive 
agencies  of  the  congresses  at  the  corresponding  levels.553 They  exercise 
executive  authority  by  producing  orders,  promulgating  regulations,  and 
conducting  other  administrative  activities. 554  Unlike  congresses,  the 







the  central  government.  The  local  government  is  composed  of  one  general 
office, and several bureaus, commissions, and specialized offices. The general 




are  under  a  dual  supervision  system.  They  are  subject  to  both  levels  of 
people’s  congress  as  well  as  the  upper  level  of  government.  Local 
governments are the executive bodies of local congresses, so they are subject 
to  the  supervision  of  local  congresses.556Meanwhile,  because  there  are 









the  lower  agencies  based  on  a  request  for  administrative  reconsideration 
made by citizens, legal entities or any other organization.557 
There are some exceptions  to  the dual‐supervision system. The eighteen 
organizations mentioned  above  are  exclusively  supervised  under  the  State 
Council.  Because  some  affairs  are  so  essential  and  vital  to  the  national 
economy,  for  example,  customs,  foreign exchange,  taxation,  and  intellectual 
property  rights,  they  need  to  be  unified  across  the  state  and  taken  under 
direct control of the central government to avoid any intervention from local 
congresses.  
The  patent  agency  is  different.  The  patent  administration  system  is  not 
vertical  like  the  other  seventeen  organizations mentioned  above.  The  local 
Intellectual  Property  Offices  are  subordinate  to  the  corresponding  local 
congress as part of  local agencies, but  they have very  limited authority and 
no  authority  over  patent  examination  or  review.  The  state  Intellectual 
Property  Office  is  the  only  agency  that  accepts  and  examines  patent 
applications,558 defines the scope of patent rights and the patentable subject 
matters  and  determine  patent  infringement  by  interpreting  statutes  or 
drawing  up  and  implementing  regulations  and  rules.559 Thus,  it  exclusively 
controls the pathway to patent. Local patent agencies, under authorization of 
the  State  Intellectual  Property  Office,  are  entitled  to  provide  patent 
consultations,  deal  with  patent  infringement  disputes  and  other 
administrative  services  concerning  patents,  but  are  incapable  of  granting  a 











effectiveness  of  patents,  it  is  necessary  to  unify  the  standards  and 
requirements for patents in order to prevent unfairness and injustice. 
However, this system does not work efficiently because central control of 
patent  application means  that  all  applicants must  submit  their  application 
forms  directly  to  SIPO,  which  is  extremely  inconvenient  for  applicants 
considering the vast territory of China. To solve this practical problem, SIPO 
sets up patent application receiving offices at Intellectual Property offices at 
provincial  levels,  to  perform  certain  duties  of  SIPO,  such  as  receiving 
application  documents  and  fees.    So  far,  26  receiving  offices  have  opened 
across  the  country  since  1985, which  have  accepted more  than  2/3  of  the 
patent  applications.561 However,  SIPO  is  still  the  only  agency  to  examine 
claims and issue patents. 
Nevertheless,  the  receiving  offices  cannot  replace  the  role  of  SIPO  in 
patent  application.  First,  the  receiving  offices  have  restricted  jurisdiction. 
They are only available for national residents of China, not for foreigners or 
legal  entities  from  Taiwan,  Hong  Kong  and  Macau.  Therefore,  all  foreign 
enterprises  or  other  foreign  organizations,  whether  having  habitual 
residences  or  business  offices  in  China  or  not,  must  submit  applications 
directly  to  the  state  Intellectual  Property  Office  in  Beijing,  in  person  or 
through the Internet. The only difference between foreigners with residence 
or  offices  in  China  and  those who  are not  is  that  the  latter must  appoint  a 
patent  agency  designated  by  the  state  to  process  applications,562 while  the 













these  8  regions  process  patent  applications?  They  must  either  submit 
materials  online,  or  turn  to  receiving  agencies  in  other  regions.  However, 
most  of  the  regions without  receiving  agencies  are  comparatively  poverty‐





As  mentioned  above,  administrative  regulations  or  rules  must  not 
contravene any statute promulgated by the NPC or the Standing Committee. 
Administrative  rules  created  by  departments  or  commissions  must  not 
contravene regulations of the State Council. All regulations or rules made at 
the national level direct the local regulations.  
The  State  Council  has  the  right  to  alter  or  annul  inappropriate  orders, 
directives,  regulations  and  rules  issued  by ministers,  commissions  or  state 

















provincial  level,  Intermediate  People’s  Courts  at  the  municipal  level566and 
Basic  People’s  Courts  at  the  town  or  county  level.  Courts  exercise  judicial 
power  independently  and  are  not  subject  to  interference  by  any 
administrative  agents  or  public  organization.567 However,  courts  are  not 
independent  from  people’s  congresses.  As  stated  in  the  Constitution,  the 
Supreme  Court  is  responsible  to  the  National  People’s  Congress  and  its 
Standing Committee; local people’s courts at different levels are responsible 
to  the  corresponding  organs  of  state  power,568 which means  local  people’s 
congresses. Theoretically speaking, courts are not supervised or reviewed by 
the people’s  congress. However, because  congresses are  the most powerful 
organs,  in practice, their policies or attitudes may influence the decisions of 
courts in an indirect way. 
All  judicial  decisions  can  be  appealed  to  the  next  level  in  the  judicial 















Each  court  level  has  its  own  jurisdictions.  For  instance,  death  penalty 
judgment must be reviewed by the Supreme Court before they take effect;571 
the  Basic  People’s  Courts  have  no  jurisdiction  over  custom  or  patent  right 
disputes.572 
The  constitution  provides  that  the  People's  Procuratorates  are  state 
organs  of  legal  supervision  and  prosecution. 573 The  procurator  offices  are 
implemented  in  several  different  layers  of  the  administration 
hierarchy.574 The  highest  level  of  the  procurator  offices  is  the  Supreme 
People's  Procuratorate  which  is  tasked  with  supervising  and  directing  the 
work of the lower level offices.575 Each office has a procuratorial committee 
which  is  expected  to  institute  the  system  of  democratic  centralism  and 
discuss  important  cases.  The  role  of  these  committees  can  loosely  be 
compared with that of a legal consultant group.  
Procuratorates  functions  include  exercising  procuratorial  authority; 
reviewing  cases  investigated  by  the  public  security  organs  and  deciding 
whether  to  prosecute;  investigating  cases  involving  graft,  infringement  of 
citizens’  democratic  rights  or  dereliction  of  duty  and  deciding  whether  to 
initiate  prosecution;  supervising  criminal  trials  in  the  courts;  reviewing 





















the procuratorate department.  It  is highly doubtful  if  the procuratorate can 
maintain  a  neutral  position  while  functioning  as  a  prosecutor  and  a 
supervisor  at  the  same  time.  However,  there  is  no  sign  of  change  on  the 
system  in  the  short  term.  Another  concern  is  the  internal  influence  on  the 
judicial  decision‐making process. Other  judges  and  even higher  courts may 
review the judgment before they are issued576 in order to minimize conflicts 
between judicial decisions and the possible reversal  later.  In that sense, the 
people’s  courts  closely  resemble  a hierarchy  rather  than being operated as 
independent  agencies.577  A  third  concern  is  the  external  impact  on  the 
judiciary  system.  The  impact  of  the media  and  public  voice  as  well  as  the 
pressure  from  higher‐level  courts  and  the  CPC  on  the  judiciary  is  also 
criticized.578 It not only distracts courts from applying laws as the sole base 
of  their  judgment,  but  also  sends  the  public  the  message  that  courts  “are 
easily  manicured.”579 The  CPC  also  has  influence  on  judicial  independence 
since most  of  the  senior  judges  are members  of  the  CPC.580 These  external 
impacts need to be removed to ensure the  independence of  the  judiciary. A 
fourth  criticism  concerns  the  immense  gap  of  legal  professional  levels 
between developed areas such as Shanghai and Beijing, and underdeveloped 
regions such as small the cities in Western China.581 This situation has been 

















The  NPC  and  the  Standing  Committee  have  authority  over  the 
interpretation of laws. However, sometimes courts will still find some vague 
or  ambiguous  language  in  laws  when  they  are  applied  in  practice.  In  that 
situation,  the  trial  court  will  submit  the  specific  issue  concerning  the  law 
application  to  the upper  court until  it  reaches  the Supreme Court, which  is 
the  only  court  with  judicial  interpretation  power.  Judicial  interpretation 
issued by the Supreme People’s Court is binding.583 
 

















insisted  on  supporting  therapeutic  cloning  while  opposing  reproductive 
cloning. After this vote, China stated: 
 
Different  countries  varied  in  their  understanding  of  the  text’s 
inherent moral, ethical and religious aspects, and it was regrettable 
that  the  Declaration  failed  to  give  effect  to  the  concerns  of  those 
countries.  The  prohibitions  contained  in  the  text  could  be 
misunderstood as covering all forms of cloning. Having voted against 
the Declaration,  the Chinese Government would continue  to adhere 






laws  and  policy.  There  is  no  law  explicitly manifesting  China’s  advocacy  of 





In  the  Eleventh  Five‐year  Plan,  promulgated  in  2006  by  MOST,  it  is 
disclosed that one goal is to establish a human embryonic stem cell bank, as 
well  as  a  bank  for  non‐human  primate  stem  cells.  It  also  recommends 
establishing a model of embryonic stem cells differentiation and promoting 
research  on  both  tissue  engineering  and  animal  cloning.  However,  as  it  is 








ii.  Ethical  Guiding  Principles  for  the  Research  of  Human 
Embryonic Stem Cell (2004) 
 
In  the  Ethical  Guiding  Principles  for  the  Research  of  Human  Embryonic 
Stem Cells, disseminated by MOST and MOH in 2004, is a guideline for hESC 
research  under  internationally  recognized  ethical  criteria  and  Chinese 
specific  conditions,  in  order  to  promote  healthy  development  of  hESC 
research. According to the Principles, the hESC mentioned include stem cells 
originated  from human embryos,  stem cells originated  from germ cells and 
those obtained by SCNT.  
It regulates only four methods of obtaining hESCs: from a surplus gamete 




implanted  into  any  human  being  or  other  animal.586 No  purchase  of  germ 




















the  Invention Right  and  the Patent Right was  issued  in 1950,  but  the  state 
owned  these  inventions.589 During  the  Cultural  Revolution  from  1966  to 
1975,  patent  rules  hardly  functioned.590 A  new modern  Chinese  patent  law 
was  adopted  by  the  Standing  Committee  of  National  People’s  Congress  on 
March 12, 1984, and became effective on April 1, 1985. The patent law was 
amended in 1992, in order to carry out the Memorandum of Understanding 
signed  by  the  United  States  and  China  in  1992,591 which  commits  China  to 
provide  improved  protection  in  the  patent,  copyright  and  trade  secret 
areas. 592  A  second  amendment  was  made  in  2000,  to  implement  the 
obligations committed to in WTO accession.593  
Different from the first two amendments, which were forced by relations 















raising  the  bar  of  novelty  requirement594 and  improving  the  protection  of 
human  genetic  resources.  It  was  intended  to  advance  the  development  of 
scientific  research  and  lead  to  a  transition  of  China’s  economy  from 
technology import model to technology innovation model.595 Among the total 
76 articles, the following articles are worthy of attention.  
Article  2  classifies  and  defines  three  categories  protected  under  Patent 































This  law  excludes  some  categories  from  being  patented  as  general 




with  different  definitions.  Novelty  means  the  invention  has  not  been 
disclosed  in  the  prior  art,  nor  a  priority  claimed  before  the  filing  date. 
Inventiveness means  that  compared  to  the  technology  existing  in  the prior 
art,  the  new  invention  has  prominent  substantive  features  and  represents 
notable progress. Practical applicability means the invention can be made or 
used  in manufacture with  effective  results.  The  revised Article 22  adds  the 
definition  of  prior  art,  which means  any  publicly  known  technology  in  the 
country  or  abroad  before  the  filing  date.  This  clause  enhances  the 
requirement  of  novelty  and  inventiveness  and  broadens  the  scope  of  prior 
art.596 
However,  Article  24  introduces  an  exemption  clause  to  novelty 
requirement, which gives a six‐month grace period to a patent which loses its 
novelty before the filing date, when it was first exhibited at an international 
exhibition  recognized  by  the  Chinese  government,  first  made  public  at  an 






Patent  applications  must  be  filed  with  a  request  form,  a  written 
description, an abstract and claims,597 and a claim of right of priority if there 
is one.598 
All  applications  must  progress  through  a  preliminary  (format) 
examination  and  substantial  (content)  examination.  After  preliminary 
examination,  the  application  will  be  published.599During  the  substantive 
examination,  the  patent  office  will  inspect  the  application’s  novelty, 
inventiveness and practical applicability, then reject the application or grant 
the patent right.600 
Once a patent  is granted,  the duration of patent right, which  is 20 years, 
tracks back to the filing date.601 Any individual or entity which does not agree 
with the result may appeal to the Board of Patent Appeals and Interferences 
[BPAI] and request    that  the patent  to be annulled.602 Any party  (either  the 
applicant  or  the  appellant) who  is  dissatisfied with  the  BPAI  decision may 
bring  a  lawsuit  to  the  courts  within  three  months  of  receipt  of  the 
notification.603 Any  decision  declaring  a  patent  invalid  relates  back  to  the 
time of  tis  issue.604 However,  the  invalidation of a patent has no retroactive 




















which  compulsory  licenses  may  be  ordered  for  patented  drugs.  There  are 
three types of licenses: qualified compulsory license,606 domestic emergency 
compulsory  license 607  and  cross  compulsory  license. 608  The  patent 
administrative  department  may  also  grant  a  compulsory  license  for 
manufacturing  and  exporting  drugs  patented  in  China  to  designated 
countries  or  regions,  which  include  least‐developed  countries,  or  WTO 
member countries or regions with no or insufficient capacity to manufacture 
the  patented  drug,  if  the  public  health  interest  in  those  countries  so 
requires.609 
Any  patent  infringement  disputes  may  be  solved  by  negotiation  or 
litigation.610 Trial judgment is appealable.  
There are five exceptions to patent infringement: exhaust of patent right, 


























obtained  from  a  patented  processes  sold  by  the  patentee  or  with  the 
permission of the patentee, anyone can resell or import the product to China 
without  infringing  the  patent  right.  This means  that  as  long  as  a  patented 
product is sold, the patent right on that product exhausts.  
Unlike  the  United  States,  China  has  adopted  the  first‐to‐file  principle, 
which means that no matter who practices an  invention  first, whoever  files 
the  application  first  acquires  the  patent.  It  would  seem  unfair  to  those 
individuals  who  generated  the  idea  first, 612  but  it  enhances  the 
administrative  efficiency  and  certainty  of  the  patent  holder.613 In  order  to 
mitigate the unfairness to the first creator, the patent law provides the users 
before  the  filing  date  a  grace  period.614 In  addition,  people  who  made  the 
same  products,  practiced  the  same  methods,  or  even  made  necessary 
preparations before the filing date are still entitled to make such products or 
use such processes within their original scope of use. 615 
The  research  and  experimental  use  exception  to  patent  infringement  is 
important  to  stimulate  scientific  development  while  maintaining  patent 
















patentee’s  exclusive  right  to  commercialize  his  patent  while  encouraging 
scientific and technologic innovation.617 
Any  person  convicted  by  effective  judgment  of  patent  infringement will 
have an administrative penalty imposed,618 be required to pay compensation 
under  the  Patent  Law,  and  incur  other  civil  or  criminal  penalties  in 
accordance with other statutes. Judicial decisions must be enforced. The Civil 









Lilly  and  Company  (“ELI”)  on March  26,  2003,  with  the  patent  number  of 
961066350,  and was  effective  at  the  time  of  the  trial.  In  2002,  the  Gan  Li 




to  register  the  new  medicine  during  the  study.  In  accordance  with 
descriptions  of  the  preparation  in  GAN  LI’s  application  data,  the  active 










with  medicinal  excipient  vehicles  or  carriers  including  distilled  water, 
hydrochloride,  zinc  oxide,  glycerol,  m‐cresol,  phenol,  disodium  hydrogen 
phosphate  and  protamine  sulfate.  GAN  LI  promulgated  introductory 
materials  concerning  the  aforesaid  new  medicine  on  its  website 
http://www.ganli.com.  









process  for  registration,  and had not yet  coming onto  the market. GAN LI’s 
behaviors—initiating a clinical study and filing an application for production 
approval—were meant  to meet  the medicinal  registration  requirements  of 
the SFDA, and were not for the purpose of making profits by direct sale, and, 
therefore,  were  not  deemed  to  be  patent  infringement  under  Article  69  of 
Patent  Law.  Nor  was  propagandizing  the  new  medicine  recognized  as  the 
behavior  of  offering  for  sale.  Thus,  the  court  denied  ELI’s  claim  for  patent 
infringement.  
In summary, the Patent Law introduces general ideas and principles of the 
patent  mechanism,  including  definitions  of  invention,  patentable  subject 
matters,  and  the  requirements  for  patenting—novelty,  inventiveness  and 
utility. It is also the primary source of law addressing the patentability issue 
of biotechnological  inventions,  especially hESC  research  results.  It does not 
explicitly  outlaw  the  patenting  of  hESCs  and  the  preparation  processes 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thereof.  However,  there  are  so  many  undefined  words  in  the  statute  that 
other documents must be referred to in these situations.  
 
b.  The Detailed Rules  for the Implementation of  the Patent Law 
(2010) 
 
The  Detailed  Rules  for  the  Implementation  of  the  Patent  Law  [Detailed 
Rules],  promulgated  by  the  State  Council,  is  an  implementing  guideline  for 
the Patent Law. It further explains vague and ambiguous language or fills in 
the loopholes in the statute. It also regulates more details of the procedure of 
patent  examination  and  approval,  for  instance,  the  conditions  of 
circumvention, 620  documents  required  for  reexamination  of  an 
application, 621 and  documents  required  for  requesting  a  compulsory 
license.622 
Article  10  explains  Article  5  of  the  Patent  Law  regarding  the 
unpatentability  of  certain  inventions  that  are  contrary  to  national  laws  or 
social morality, or detrimental  to  the public  interest.  It  states  that Article 5 
only  applies  to  the  inventions  themselves,  but  not  the  use  of  them  that 
violates the law. In other words, Article 5 only precludes the patentability of 
inventions  with  illegal  purposes;  for  instance,  a  method  or  instrument  to 
counterfeit  bills.  Inventions  that  have  both  legal  and  illegal  applications, 
depending on what  the original use  is, may  still be patentable according  to 
Article 5. Some chemical substances could be used in medical treatment, but 
also  in  drug  addiction.  Their  legitimacy  depends  on  the  situation  in which 











Conditions  for  dismissing  patent  applications  during  substantive 




By  analyzing  these  rules,  one  cannot  deny  that  hESCs’  preparation 
processes  fall  into  the  scope  of  invention,  which  is  defined  as  a  “technical 





By  this  interpretation,  hESC  research  does  not  violate  any  law,  and  the 
results  of  such  research  constitute  patentable  subject  matter  because  the 













offices  to carry out  their  functions more effectively by answering questions 
patent  offices  have  encountered  while  applying  Patent  Law  and  Detailed 
Rules.  Since  the  Examination  Guidelines  is  promulgated  by  SIPO,  a 
department  under  the  State  Council,  the  legal  force  of  it  is  lower  than  the 
Patent  Law  and  Detailed  Rules.  The  authority  clause  for  the  Examination 
Guidelines is Article 121 of the Detailed Rules that the patent administrative 
agency created in accordance with Patent Law and Detailed Rules. The 2006 
version  is  the  latest version. But, a new version  is expected  to be delivered 
due to the implementation of the new Patent Law.  
There  are  five  parts  in  the  Examination  Guidelines.  Part  1  covers 
preliminary  examination,  Part  2  covers  substantive  examination,  Part  3 
covers  examination  of  international  applications  entering  China,  Part  4 





The  first  part  of  the  Examination  Guidelines  addresses  the  principles, 
procedures,  and  document  requirements  for  patent  application  covering 
utility models  and  design,  as well  as  classification.  Different  rules  apply  to 
different categories,  for instance,  inventions and utility models enjoy longer 
patent right periods  than designs, and  in  their application documents, even 
substantive  requirements  are  different.  Sometimes  the  lines  between  the 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three  categories  are  vague,  and  therefore,  the  classification  is  essential  to 
both  applicants  and patent  examiners.  The  classification of  designs  is  dealt 
with  in  Chapter  3  of  the  same part.  Therefore,  Chapter  4  is  only  about  the 
classification  of  inventions  and  utility  models.  The  classification  scheme 
helps  to  establish  properly  categorized  patent  application  files  for  patent 
researching,  and  distributes  patents  into  corresponding  examination 
departments for more efficient work.623  
Generally  speaking,  the  classification  should be based on  the  invention’s 
technical  subject,624 which  is  determined  by  the  claims,  descriptions  and 
drawings  if  they  are  present.625 The  technical  subjects  could  be  products, 
apparatus,  or  the  processes  used  or  created. 626  In  determining  the 






clarifies  the  scope of  invention defined  in Article 2 of  the Detailed Rules.  It 
emphasizes  that  an  invention  must  adopt  a  technical  means  to  solve  a 
technical  problem  and  achieve  a  technical  effect.  Any  solution  without 












Rule  3  reiterates  the  unpatentable  subject matter  under Article  5  of  the 
Patent  Law,  as  “contrary  to  national  laws,  social  morality  or  that  is 




NPC  and  the  Standing  Committee  except  administrative  regulations.  Any 
invention  contrary  to  the  laws  is  not  granted  a  patent,  such  as  gambling 
facilities, devices or  instruments, drug‐taking appliances,  and apparatus  for 
counterfeiting currencies, official documents, certificates, seals or others. But 
any  invention  with  a  legal  purpose  whose  application  may  be  contrary  to 
laws is still patentable. Examples would be intoxicants, anesthetics, sedatives 
and analeptics. 
Rule  3.2  refers  to  social  morality  as  rules  generally  recognized  and 
accepted by the public  in China.  It depends on the cultural background and 
changes  with  time  and  social  progress.  Certain  anti‐social  morality 
inventions include an artificial sexual organ or its substitute not for medical 
use, a method of mating a human with an animal, a process for modifying the 
germ  line  genetic  identity  of  human  beings  or  a  human modified,  a  cloned 




cause  harm  to  the  public  or  society  or  disrupt  the  order  of  the  State  and 




or  delete  the  contravening  part;  otherwise  the  whole  invention  must  be 
denied patent protection.629 
Rule  4.1  to  4.5  further  interprets  the  five630 categories  of  unpatentable 
subject matter under Article 25 of the Patent law. It differentiates invention 
from  discovery  by  inputting  intervention  by  human  beings.  It  also 
exemplifies  mental  activities  as  thinking  movements,  such  as  traffic  rules, 
schedules,  competition  rules,  business  methods,  calculation  methods, 
methods of  editing  a dictionary,  searching  information or  classifying books 
and  computer  programs.631 Diagnostic  methods  or  disease  treatments  are 
not patentable for ethical reasons. Besides, those methods or treatments that 
are  utilized  on  humans  or  animals  tend  to  be  unsuited  for  industrial 
application.632 But Rule 4.3.1.2 precludes the patenting of certain inventions 
that are not diagnostic methods, including methods of pathological anatomy 
practiced  on  dead  humans  or  animals,  and  methods  with  the  purpose  of 
obtaining information from the testees or processing such information. Rule 
4.3.2.1  exemplifies  diseases  treatments,  and  Rule  4.3.2.2  exemplifies 
inventions not constituting methods of treatment. Rule 4.3.2.3 also mentions 
that methods of surgery on living humans or animals are not patentable. But 
the  patentability  of  surgery  on  a  dead  body  depends  on  its  purpose.  Any 















 Rule 4.4 defines  “animal”  in  the Patent Law as a  life  form which  cannot 
synthesize  carbohydrate  and  protein  by  itself,  but  maintains  life  only  by 
absorbing carbohydrate and protein, but not a human being. Even though the 
processes of  producing  animals  and plant  varieties may be patented under 
Article  25  (2),635 those  processes  refer  to  non‐biological  processes  rather 
than  essentially  biological  processes.  One  way  to  decide  processes  is  to 
determine  whether  the  human  technical  involvement  in  the  process  is 
dominant or decisive.  
Chapter  2  concerns  the  requirements  of  description  and  claims.  Unlike 
Part 1, which deals with format requirements, this chapter in Part 2 is about 
the  content  of  those  sections  and  whether  they  satisfy  substantial 
requirements. For instance, a description must be clear, complete and enable 
a  person  skilled  in  the  art.  The  definition  of  “person  skilled  in  the  art”  is 
referred  to  Chapter  4,  Rule  2.4  in  the  same  part. 636 The  Examination 
Guidelines  further  explains  the  clarity,  completeness  and  enablement 
requirements  of  the  description.  It  also  mentions  that  the  abstract  is  a 
summary of the description; it provides helpful information but has no legal 
effect.637 Claims can be either product or process related. They are based on 


















the  Guideline  adopts  the  doctrine  of  equivalents  rather  than  the  literal 
doctrine. 
Chapters  3,  4  and  5  introduce  definitions  and  examination  standards  of 
novelty,  inventiveness  and  industrial  applicability.  Since  the  regulation  of 
novelty was modified in the Patent Law in 2008, some changes to Chapter 3 
are expected.  Section 4 of Chapter 3  in Part 2 addresses  the priority  rights 
under  the Patent Law  for  inventors who  first  filed  for a  foreign patent.   To 
qualify for priority rights, the application filed in China must solve the same 
technical problem  in  the same way and with  the same anticipated result as 
the application  first  filed  in a  foreign country.640 Section 5  is a grace period 
rule.  It  also  clarifies  the  difference  between  grace  period  and  priority.  The 





Whether  an  invention  is  inventive,  which  includes  both  substantive 
features and notable progress, should be evaluated on the basis of a person 
skilled in the art. The method of evaluating substantive features is similar to 
the  American  mechanism:  determining  the  prior  art  and  features  of  the 









person  skilled  in  the  art;  in  other  words,  whether  there  is  a  technical 
suggestion  in  the  prior  art  that  gives  a  person  skilled  in  the  art  enough 
information  to  reach  the  same  invention.642  The  assessment  of  notable 
progress is determined on social basis, that is, whether the invention would 
bring  any  social  benefits. 643  Other  factors  that  suggest  an  invention’s 
inventiveness should also be considered, for instance, solving a long‐standing 
but  unsolved  problem,  overcoming  a  technical  prejudice,  producing 
unpredicted  technical  results,  or  achieving  commercial  success  due  to 
technical features.644 
Industrial  applicability,  unlike  the utility  requirement  in U.S.  patent  law, 
requires  that  an  invention  be  capable  of  being  manufactured  or  used  in 
industry with positive effects. It emphasizes reproducibility of the invention, 
and manifests that methods of surgery on human or animal bodies for non‐
treatment purposes  are  examples  of  unpatentable  subject matters,  because 
they are not industrially applicable.645 
Chapter  10  of  Part  2  introduces  special  rules  for  chemical  products, 
including biotechnology. In Section 9 of Chapter 10 in Part 2, the Examination 
Guidelines lays out rules for examination of invention application in the field 
of  biotechnology.  In  the  beginning,  the  definition  of  “biological material”  is 




the  Patent  Law  as  unpatentable  subject  matters.  Embryonic  stem  cells  of 







the  public  interest  and  social morality  clause Article  5.646 Human bodies  at 
the various stages of their formation and development, including germ cells, 
zygotes, embryos and even an entire human body are unpatentable under the 




Rule  9.1.2.1  addresses  the  patentability  of  microorganisms,  including 
bacteria,  actinomycetes,  fungi,  viruses,  protozoa  and  algae,  etc.  Generally 
speaking,  microorganisms  are  patentable  because  they  fall  outside  the 
exclusion clause in Article 25.1(4) of the Patent Law because they are neither 
animals  nor  plants.  This  section  also  defines  the  differences  between 
invention  and  discovery.  A  microorganism  existing  in  nature  without 
artificial involvement is a scientific discovery, which is not patentable. But if 
it is isolated from its natural environment and has a particular industrial use, 
it  could  be  patented.  Therefore,  as  for microorganisms,  the  involvement  of 
isolation  or  purification  techniques  and  industrial  applicability  are  two 
requirements  of  patenting.  But  this  section  does  not  mention  the 
requirement of novelty. 
Rule  9.1.2.2  concerns  the  patentability  of  genes  or  DNA  fragments, 
including  those  isolated  from  microorganisms,  plants,  animals  or  human 
bodies, or by other means. The method to determine whether a gene or DNA 
fragment is patentable subject matter or a scientific discovery is to examine 
whether  it  is unknown in  the prior art and definitely characterized (novel), 
isolated  or  extracted  from  nature  for  the  first  time  (inventive)  and  can  be 
exploited  industrially  (industrial  applicable).  In  other  words,  genes  and 





these words, one can  imply  that  isolation of partial genetic sequences  from 
known  full‐length  sequences  could  be  patentable  if  it  is  the  first  time  to 
characterize  the  sequences  or  its  functions.  Full‐length  genetic  sequence 
contains  patented  partial  sequences  and  is  still  patentable  if  new 
characteristics  and  functions  are  found.  However,  this  section  does  not 
explain  how  to  identify  infringement  between  two  sequences  that  are 
overlapped.  
Rule 9.1.2.3  contains  rules governing  the patentability of  animals, plants 
and  constituent  parts  thereof.  The  definition  of  “animal  varieties”  includes 









Since  some  European  countries  and  the  United  States  have  allowed  the 
patenting of genetically modified organisms, China will  lose  its  competition 
position in the international trade market, and will also lose benefits derived 
from  a  patent  regime  such  as  the  impetus  for  promoting  innovation  and 
economic growth. 
Rule  9.2.2  covers  about  genetic  inventions  relating  to  “genetic 
engineering,”  which  means  the  technology  of  manipulating  genes  through 
gene recombination and cell fusion. These inventions include genes, vectors, 
transformants,  proteins,  monoclonal  antibodies  and  the  processes  of 
176 
producing  these  products.  They  can  be  patented  as  long  as  they meet  the 
requirements of novelty, inventiveness and industrial applicability. 
Document  procedural  examination  is  governed  under  Rule  9.3,  while 
substantive examination is governed under Rule 9.4. Specific requirements of 





Part  3  promulgates  the  procedures  for  international  applications  in  the 
national  phase,  Part  4  discusses  invalidation  requests  and  reexamination 
procedures,  and  Part  5  concerns  a  special  aspect  of  application  processing 
and  procedure.  Since  procedure  is  not  the main  topic  of  this  article,  these 
three parts will not be discussed here. 
It  is  quite  clear  that  the  Examination  Guidelines  explicitly  preclude  the 
patentability of hESCs and preparation processes under the morality clause 
of Article 5 of the Patent Law. However, as introduced before, departmental 
regulations  have  limited  legal  force.  Besides,  this  interpretation  is 
inconsistent with the SIPO decision, which has already granted one patent on 
a hESC culture system and preparation process. The Examination Guidelines 





























































Method of Using Pluripotent ESCs
NM Pluripotent SCs
Method of Producing NM Pluripotent ESCs
Method of Identifying NM ESCs
GM Pluripotent SCs
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Figure  6.2  demonstrates  the  status  of  all  the  hESC  related  patent 
applications in China. There are five issued patents related to hESCs in China. 
The  claims  are  mainly  for  methods  or  culture  media.  As  stated  in  the 
Examination  Guidelines,  no  hESC  is  granted  patentable  according  to  the 
morality  clause  in  Article  5  of  Patent  Law.  But methods  of  producing  non‐
modified pluripotent embryonic stem cells are patentable, which is contrary 
to the current state of the Examination Guidelines. Thus, patent examination 







As  demonstrated  in  Figure  6.1,  there  are  twenty‐five  applications 
currently  under  examination.  Four  applications  have  been  rejected,  six  are 
deemed  to  be  withdrawn,  and  three  applications  have  been  recently 
published.  One  item  worth  mentioning  here  is  that  there  are  three 
applications claiming on non‐modified pluripotent embryonic stem cells and 
none  of  them was  filed  by  domestic  institutes  or  companies.  Among  those 
applications,  one  was  rejected  (CN1350059),  one  was  deemed  to  be 




WARF  also  filed  five  patent  applications  in  China  and  one  was  already 




5,843,780  is  unclear.  Possibly  it  is  because  at  the  time  5,843,780 was  first 












There  are  very  few  articles  that  discuss  patenting  of  hESCs  in  China  at 
present.  The  main  reason  may  be  that  the  Examination  Guidelines  has 
already  precluded  the  patentability  of  embryonic  stem  cells  and  their 
production processes on the grounds that “they are contrary to morality and 
public interest.”648 The human body at the various stages of its formation and 
development,  including  germ  cells,  zygotes,  embryos,  and  entire  human 














There are some articles  that discuss  the ethical  issues surrounding hESC 
research.  The  following  overview  is  necessarily  general  in  character  and 
therefore subject to significant exceptions.  With realizing the importance of 
protecting  medical  ethics,  some  schorlars  support  hESC  research  for 
therapeutic  purposes,  however,  these  activities  should  be  conducted  in 
accordance  with  the  law.652  It  is  admitted  that  science  is  complex  and 
unpredictable, and ethical rules should be updated with the development of 
scientific  research.653 It  is  belived  that  thics  could  be  used  to  guide  the 
direction  of  scientific  progress,  and  position  the  bottom  line  of  scientific 
research; scientific research could be regulated by ethics, but not restricted. 
The more advanced the science is, the more mature ethical rules will be.654 
It  is  also  emphasized  that  reproductive  cloning  and  therapeutic  cloning 
need to be distinguished to implement scientific research: the former creates 
a person while the later only creates a blastocyst which will never have the 























rules  in  their  patent  laws,  and  then  explores  the  reasons  behind  the 
differences. As an effective method to promote  innovation  in biotechnology 
research  and  the  pharmaceutical  industry,  patent  law must  be  adjusted  in 
order  to  embrace  modern  hESC  related  research.  A  model  law  will  be 
proposed  below  to  answer  the  unsettled  questions  about  the  patent‐
eligibility of hESCs. 
 
A.  Differences  of  Laws  and  Judicial  Practices  among  the United  States, 
Europe and China including Reasons for Differences 
 





member  state of  the WTO  including  the US,  the European Union and China 
must  accept  the  WTO  agreements  encompassing  the  TRIPS  Agreement, 
which  contains  a  minimum  threshold  of  intellectual  property  protection, 
including patent protection in international trade. Therefore, national patent 
laws  are  similar  at  a  threshold  level,  but  vary  in  some  substantive  legal 
aspects.  In  today’s  world,  international  organizations  are  still  working  on 














utility/industrial  applicability;  all  require  a  description  in  the  patent 
application;  all  open  the door  to  biotechnological  inventions  as  long  as  the 
inventions  are  isolated  and  purified  from  their  natural  environment  and 
subject  to  human  intervention.  These  three  regions/countries  vary 
dramatically in their history, culture and legal systems; therefore, differences 
in patent  law are  to be expected. Many distinctions are maintained  in both 
legislation and legal practice. Each region/country’s law has been introduced 







Both  Chinese  and  European  patent  laws  have  specific  articles  for 
patentable  and  non‐patentable  subject  matter,  while  the  American  patent 
law  does  not.  In  U.S.  patent  law,  any  process,  machine,  manufacture, 
composition of matter and improvement can be patented.658 The U.S. Patent 
Act  does  not mention  any  unpatentable  subject matter.  However,  case  law 
restricts  the  scope  of  patentable  subject  matter  with  the  rule  that 




abstract  intellectual  concepts”  are not patentable,659 because  they are basic 
tools  of  science  and  technology  and  they  should  not  be  monopolized.660 
However,  methods  of  practical  application  or  implementation  with  new 
devices  of  law  of  nature,  abstract  ideas  and  mathematical  formulas  are 
patentable. 661  Methods  of  treatment  or  diagnosis  that  are  tied  to  a 
machine/apparatus or transform a particular article into a different state or 
thing  are  patentable.662 Life  forms modified,  isolated  or  purified  by  human 
intervention  are  manufactures  /  composition  of  matter  under  the  statute, 
and  therefore  are  patentable.663 Any  naturally  occurring  phenomenon  that 
does not occur in an isolated form in nature is patentable, including DNA and 
human  cells.664 The  U.S.  has  the  broadest  scope  of  patent  subject  matters 
among the three regions/countries, partially because its courts are reluctant 
to narrow the scope of patentable subject matter. The court restricts its task 
in  interpreting  statutory  language  and  leaves  policy  consideration  to  the 
legislature.665  
In  China  and  the  European  Patent  Convention  [EPC],  explicit  rules  are 
present regarding unpatentable subject matter. Article 52(2) of the European 
Patent  Convention  specifies  that  discoveries,  theories  and  mathematical 
methods,  aesthetic  creations,  schemes,  rules  and  methods  of  mental  acts 


















been  patented  in  the  US,  but  are  considered  unpatentable  in  the  EPC. 




some  technical  character  such  as  “performing  or  supporting  an  economic 
activity.”667  
Besides the listed categories in Article 52 of the EPC, additional examples 
of  unpatentable  subject  matters—such  as  surgery,  therapy  and  diagnostic 
methods  for  humans  or  animals—are  illustrated  in  the  Guidelines  for 
Examination in the European Patent Office, which is the executive body of the 
European  Patent  Organization.  Article  53(a)  generally  exempts  inventions 
against ordre public  or morality  from being patented. This  is  a general  rule 
for  unpatentable  subject  matter  separate  from  the  listed  categories  under 
Article 52,  thus  leaving  the European Patent Office  the power  to determine 
the  patentability  of  subject  matter  outside  that  excluded  in  Article  52. 
Implementing  Regulations  to  the  Convention  on  the  Grant  of  European 
Patents further enumerates unpatentable categories under the Article 53(a) 

















and  genetically  modifying  the  human  germ  line  as  unpatentable  subject 
matter contrary to morality. This is also incorporated into the Biotechnology 
Directive (98/44/EC) under Article 6(c). Rule 29 (1) excludes human bodies 
from  being  patented,  which  is  encompassed  in  Article  5(1)  of  the 
Biotechnology Directive.  
Chinese patent  laws have similar regulations. Article 5 of Chinese Patent 
Law  creates  the  general  principle  of  exclusions  from  patentability  of  those 
inventions/creations  that  are  contrary  to  national  laws,  social  morality  or 
that are detrimental  to  the public  interest. This  is  similar  to a clause  in  the 
EPC but with different wording. In the EPC, “ordre public and morality” is the 
only  criterion;  while  in  China,  laws  and  public  interest  are  also 
considerations.  According  to  the  morality  clause,  human  embryo  and 
embryonic  stem  cell  related  products  trigger  breaches  of  public  order  and 
social  morality  because  they  involve  destruction  of  human  embryos; 
therefore they are not patentable. However, Article 10 of the Detailed Rules 
for  the  Implementation  of  the  Chinese  Patent  Law  (2010)  imposes  a 
patentability requirement based on the legal use intention of the invention. If 
the  invention was  originally  designed with  an  illegal  purpose  in mind,  the 
invention  is  not  patentable.  It  should  be  noted  that  in  some  cases  the 
invention, while being designed with a legal purpose in mind, can be used in 
an  illegal manner.  In this case the  invention  is still patentable. According to 
this rule, human embryonic inventions should be patentable as long as they 
are used  for  therapeutic purpose rather  than reproductive cloning. But  this 
conclusion  conflicts  with  the  current  regulations  contained  in  the  Patent 
Examination Guidelines of China, stating that human embryos and embryonic 
stem cells are not patentable.  
Chinese  patent  law  also  has  a  clause  regarding  unpatentable  subject 
matter:  scientific  discoveries,  mental  activities,  diagnoses  or  treatments, 
animal  and  plant  varieties  and  substances  obtained  by  nuclear 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transformation.  Among  these  categories,  both  the  EPO  and  China  consider 
treatment and diagnosis to be unpatentable for public benefit, but this is not 
the  case  in  the  U.S.  Nuclear  transformed  substances  is  a  unique  Chinese 
category of unpatentable subject matter, but not one that is seen in either the 
U.S.  patent  laws  or  the  EPC. While  the  EPO  and  the  U.S.  started  patenting 
business  methods  and  computer  programs,  China  chose  another  road. 
Business  methods  and  computer  programs  per  se  or  their  recorded 
representations are rules and methods for mental activities and therefore are 
not  patentable  according  to  Article  25(2)  of  the  Chinese  Patent  Law.668 
Instead, these innovations are protected under Chinese copyright law in the 
Regulation  for  Computer  Software  Protection.669 By  contrast,  if  computer 
programs  have  technical  features  and  constitute  technical  results,  they  are 
patentable  under  the  Examination Guidelines.670 While  the U.S.  and Europe 
have  abandoned  the  technical  feature  requirement,  China  continues  to 
maintain  this  requirement  and  therefore  provides  computer  programs  less 
patent protection. 
The scope of patentable subject matter in the U.S. has the largest coverage 
closely  followed  by  the  EPC.  Chinese  patent  laws  protect  a  much  smaller 
scope  of  patentable  subject  matter,  especially  in  regards  to  the  aspect  of 



















has  not  addressed  this  matter  with  legislation. 672  However,  President 
William J. Clinton announced his opposition to patenting human clones, and 
President  George  W.  Bush  urged  Congress  to  promulgate  laws  to  ban 
patenting  human  beings.  The  USPTO  also  stated  his  policy  about  human 
being  are  not  patentable  subject  matter.673 Nonetheless,  there  is  no  single 
morality  requirement  in  the  U.S.  patent  law.674 People  still  consider  that 
patent  law  is  an  inappropriate  tool  for  making  moral  judicial  decisions 
concerning matters of science.675  
By contrast, the legislatures of both China and the EPO are more morality‐
minded  when  it  comes  to  patent  law.  Both  have  morality  clauses  in  their 
laws, and even more detailed articles concerning morally excluded categories 
in light of ambiguous definitions of morality and ordre public.676 Because the 
definitions  vary  from country  to  country,  the  scope of  the patent  exclusion 
clause in the Chinese and the European laws is slightly different. 
Article 53(a) of the EPC contains the general rule regarding morality and 
ordre  public:  any  invention,  the  commercial  exploitation  of  which  violates 
morality and ordre public should not be patented. Rule 28 of the EPC consists 












53(a),  and  includes  processes  that  using  human  embryos  for  industrial  or 
commercial purposes. The application scope of the morality and ordre public 




iintended  purpose  and  the  direct  result  are  the  only  considerations;  other 
potential applications or processes which may contravene morality or ordre 
public do not trigger the morality and ordre public clause and do not affect an 
invention’s  patentability.  This  interpretation  is  similar  to  the  scope  of 
morality and ordre public clause in Chinese patent law. However, the scope of 
the morality  and  ordre  public  clause  has  been  broadening  in  the  EPO.  Not 
only  must  the  teachings  and  disclosures  of  the  invention  comply  with  the 
law,  but  also  any  process  enabling  the  invention.678 In  the WARF  case,  the 
patent application was rejected based on commercial exploitation of human 
embryos  contrary  to  the morality  clause  in  the  EPC.679 Although  the  direct 
basis  of  the  rejection  is  not  Article  53(a),  but  Rule  28(c),  Rule  28(c)  is  a 
subcategory  of  Article  53(a);  the  interpretation  of  Rule  28(c)  indicates  the 
interpretation of Article 53(a). There is a tendency to extend the application 
of  morality  and  ordre  public  requirement  to  manufacturing  processes  that 
enable inventions as well as the inventions themselves. 
The  definitions  of  ordre  public  and  morality  are  different.  The  EPO  has 
distinguished  ordre  public  and  morality  in  Decision  T  356/93.  The  EPO 
defines ordre public as societal peace and quiet, encompassing public security 










behaviors  are  right  whereas  some  are  wrong.  These  behaviors  should  be 
culturally  dependent,  conventionally  accepted,  and  deeply  rooted  norm  in 
European  civilization.680 According  to Article  53(a)  of  the  EPC, ordre public 
and  morality  are  not  determined  by  the  criteria  in  national  laws.  The 
European Parliament also agrees that hESC inventions violate Article 6(2)(c) 




it  is  obtained,  even  if  such  processes  are  not  claimed  in  the  patent 
application. 
In  Chinese  patent  law,  there  is  a  corresponding  clause  that  bans  the 
patentability  of  hESCs  and  preparation  methods.682 China  admits  that  the 
definition  of  national  laws,  morality  and  public  interest  is  very  broad  and 
may vary with time and social progress.683 It  limits the definition of  laws to 
those  formulated  by  the  NPC  or  its  Standing  Committee,  but  excludes 
administrative  regulations  or  local  legislation,684 and  defines  morality  as 
“ethical  or  moral  norm  and  rules  generally  recognized  as  justifiable  and 
accepted by  the public.”685 With respect  to  the public  interest,  it  represents 
benefits and good order of the state and society, including the environment, 
the  sentiment  of  the  people  or  ethnic  group,  and  the  health  and  life  of  the 
people.686 
The scope of the general exception rule in China is broader than the rule in 













such  a  culture‐and‐tradition‐based matter.  The most  important  point  to  be 
emphasized is that no matter how the Biotechnology Directive is interpreted, 
it is impossible politically to satisfy and resolve all issues of morality among 
the  member  states  of  the  European  Union.  Attitudes  toward  embryonic 
research  differ  widely.  Therefore,  the  EPO  must  adopt  the  minimum 
requirement for morality in order to be accepted by all member states.  
In conclusion, in the EPO and China, hESC patent applications are usually 
rejected  under  morality  clauses,  though  hESC  derivation  or  production 
processes  may  be  patentable  and  the  application  of  the  morality  clause 
remains  undetermined,  especially  on  the  grounds  that  the  morality 
connotation is changing due to the technological and scientific development. 
American patent law leaves the discretionary power of patenting hESCs and 
preparation methods  to  the  USPTO  and  courts.  Nonetheless,  PBAI  and  the 






utility.  The  U.S.  utilizes  utility,  while  China  and  Europe  employ  industrial 
applicability.  The  difference  not  only  exists  in  terminology,  but  also  in 
content.  
U.S. laws do not have a morality proviso, but that does not mean morality 
has  never  been  considered  in  patent  examination.  As  a  matter  of  fact, 
historically it was included as part of the utility requirement. In case law, the 
courts  customarily  held  that  inventions  should  not  be  detrimental  to  the 
192 
well‐being  or  morals  of  society,  but  should  be  morally  useful.687 But  later, 
courts  began  to  abandon  the  moral  requirement  to  patent  inventions.688 
After the Supreme Court broadened the scope of patentable subject matter in 
the  Diamond  v.  Chakrabartycase  in  1980689  and  started  a  new  era  for 
biotechnological inventions, the USPTO considered reemploying the morality 
requirement690 but  did  not  ultimately  introduce  morality  as  a  basis  for 
rejection. Today,  the  conception  that patent  law  is  an  inappropriate  tool  to 




benefit  to  society.693 As mentioned  above,  since  the  Supreme Court  opened 
the  patent  door  to  “anything  under  the  sun  that  is  made  by  man”  in  the 


























patentable  inventions  must  be  made  or  used  in  industry.  Scientific 
achievement  or  research  value  does  not  necessarily  equate  to  industrial 
application.698 There is more content in the industrial application clause than 
in  the  clause  related  to  utility, 699  and  the  industrial  application  clause 
excludes more subject matters than the utility requirement. For instance, to 
some  scholars,  business  methods  as  such  are  not  patentable  bound  to  the 
industrial application and technical effect requirements.700  
 Chinese  patent  law  has  a  similar  “practical  application”  clause  which 
requires  an  invention  to  be  made  or  used  industrially,  solve  a  technical 
problem or achieve effective  results.701 This  clause has  stricter  implications 
than  the  corresponding  clause  in  the  United  States.  It  is  significant  to 
substances naturally existing. One way to differentiate patentable substances 
found  in  nature  from  non‐patentable  counterparts  is  that  only  substances 
which  can  be  isolated  or  extracted  from  their  natural  environment  and 




















difference  between  these  three  countries  relative  to  the  enforcement  of 
patents  is  patent  right  exemption. When  inventions  are widely  used  in  the 
arts as a research tools, a research use exception can impact significantly on 
enforceability of  issued patents.703 Especially under U.S.  law,  the exemption 
only applies  to uses  “for amusement,  to  satisfy  idle  curiosity, or  for  strictly 
philosophical inquiry.”704 A use is disqualified from the exemption if it is for 
commerce  or  for  a  legitimate  business  objective, 705  which  includes  a 
university  educating  students,  enhancing  the  status  of  the  institution, 
competing for grants, and attracting students and faculty.706  
In the European countries, using the experimental use exemption to block 




most  European  countries  have  similar  clauses  of  experimental  use 
exemption 707  such  as  the  German  Patent  Act,  which  excludes  from 















exemption  is  broader  than  that  in  the  U.S.  because  experiments  even with 
ultimate commercial intention may trigger the exemption clause.710  
In China, exemption clauses exist as well. Article 69 of the Chinese Patent 
Law  sets  forth  several  situations  as  non‐infringing.  One  clause  states  that 
using  patents  only  for  scientific  research  and  experimentation  does  not 
constitute  patent  infringement.  There  is  little  explanation  about  the 
experiment exemption, either in laws or judicial rulings. With respect to the 
literal meaning of “only,” it suggests that the exemption may apply narrowly 
to  scientific  research  and  experiments.711 Since  there  is  so  far  no  case  or 
dispute  over  the  scope  of  the  research  and  experiment  exemption,  it  is 
unclear if the scope of the experiment exemption in Chinese law leans more 
towards  the  American  scope,  blocking  all  uses  for  legitimate  business 
objective,  such  as  in  a  university  setting  to  educate  students  or  research 
institutes for gaining grants, or toward the European scope, applying to any 




and  public  welfare,  a  broad  approach  to  the  experimental  use  exemption 
should be supported.713  
From  the  analysis  above,  it  can  be  concluded  that  the  U.S.  is  relatively 
stricter  with  experimental  use  exemption  than  European  countries,  which 
















The  differences  in  patent  law  concerning  hESC  inventions  are  further 
evidenced by the experience of one WARF patent in the EPO and the USPTO. 
Since  the moral  issue  is  not  relevant  during  patent  examinations  in  the 
U.S.,  the WARF patents, U.S.  Pat. No.  5,843,780, U.S.  Pat. No.  6,200,806  and 
U.S.  Pat.  No.  7,029,913  were  granted  by  the  USPTO,714 albeit  with  some 
challenges. The Public Patent Foundation [PUBPAT] and the California‐based 
Foundation  for  Taxpayer  and  Consumer  Rights  [FTCR]  challenged  the 
validity of these WARF patents for lack of novelty and non‐obviousness, and 






and  formed  a  correlation  to  the  derivation  of  hESCs.716 Furthermore,  the 
maintenance time difference between the methods claimed and the prior art 
was  indistinguishable,  and  therefore  that  the  application  failed  to meet  the 
novelty  requirements  to  justify  patentability. 717  With  respect  to  the 










that  the  claimed  hESCs  involved  human  preparation  and  differed  from 
naturally occurring stem cells.718 Unlike the EPO, the U.S. reexaminer focused 
on  the  obviousness  and  novelty  of  the  said  claims  rather  than  the 
patentability  of  the  subject matter  or  public  policy  issues.  The  patent  was 
first rejected for lacking novelty and obviousness,719 and later upheld by the 
reexaminer.720 Similar situations occurred with Patent ’806.721  
Unfortunately  for  Patent  ’913,  after  the  reexaminer  confirmed  the 
validity,722 the  challengers  appealed  the  holding  on  patent  validity  to  the 
BPAI which overruled  the patent validity.723 Again,  the pinpointed  the non‐
obviousness  requirement  and  its  application  in  the  present  case.  The BPAI 
held  that  the  patentees  had  the  burden  to  prove  the  non‐obviousness  of 
patents, which the patentee failed to prove.724 Based on the evidence at hand, 
the  prior  art  disclosed  the  derivation  and  preparation  of  hESCs  in  general 
and thus anticipated the patent at bar.725  
The  differences  between  the  USPTO  and  the  BPAI  also  lie  in  the 
interpretation  of  non‐obviousness.  The  USPTO  asserted  that  the  prior  art 






















a  broad  application  of  the  prior  art  techniques  to  other  species  implies  its 
success on human beings, therefore making it obvious to apply the technique 




or  technology  in  a  new  area  of  research.728 In  the  case  of  WARF  patents, 
evidence  shows  that  people  with  ordinary  skills  in  the  art  did  not  have  a 
reasonable  expectation of  success  in  generating hESCs  from  the  techniques 
then available  in  the prior art.729 Moreover,  there are  secondary  factors  for 
non‐obviousness  determination,  such  as  long‐term  need,  failure  of  others, 
unexpected  results, unexpected properties,  licenses of  the  invention and so 
forth.730 All  of  these  factors  indicate  the  non‐obviousness  of  the  WARF 
patents.731  
In 1996, WARF also filed an equivalent application with the EPO, Primate 


















invention and  the  related commercial  exploitation of  embryos were  factors 
to be considered as well.732 In order to use the said invention, it must first be 
created; making the product is usually one step necessary to commercialize 
or  industrialize  the  invention.  In  this  case,  the  teaching  of  the  invention 
involves  the use and destruction of human embryos. The EBA regarded the 
unavoidable destruction of human embryos  in  the process as a violation of 
Rule  28(c).  The  EBA  further  clarified  that  Rule  28(c)  could  not  be 




However,  the EBA leaves the definition of embryo blank;  it  is not known 
whether  Rule  28(c)  applies  to  inventions  involving  human  embryos 
produced  by  other  routes, which  avoid  the  destruction  to  human  embryos 
resulting  from  fertilization.734 Even  if  the  EBA  precludes  the  application  of 
Rule 28(c) to the above situations in future litigation, which, according to the 
statement  of  the  EBA  case  at  bar,  is  very  possible,735 Article  53(a)  is  still  a 
potential bar to the hESC‐related invention applications. As a general public 
policy,  it  may  exclude  any  inventions  whose  commercial  exploitation  is 
contrary  to  ordre  public  or  morality,  including  but  not  limited  to  those 
involving  human  embryo  destruction.  Article  53(a)  requires  inventions  to 













Remarkably,  the  mechanism  of  the  EPO  leaves  its  member  states 
alternative.  Even  if  the  EPO  excludes  hESCs  from  patentability,  member 
states still may grant patent protection on such innovations. 



























courts  make  case  law,  to  the  extent  that  their  judgments  are  cited  as 
precedent  in future cases.738 Due to this, courts and judges can easily direct 
the  law in the relevant area. Consider Diamond v. Chakrabarty  (1980) as an 
example.  The  U.S.  Supreme  Court  held  that  no  further  restriction  from  the 








the  binding  sources  of  law  in  China  are  the  Constitution,  statutes, 
administrative  regulations,  local  regulations,  autonomous  regulations  and 
special  rules.741 Besides  that,  judicial  interpretation  issued  by  the  Supreme 
People’s Court has legal effect and can be used as a source of law under some 
conditions.742 No other source can be used as a legal basis of the courts, not 


















Court  is  the  only  court  that  has  judicial  interpretation  power  to  interpret 
ambiguous  laws or  legal  loopholes  found  in  litigation,  before  legislatures—
the  National  People’s  Congress  and  its  Standing  Committee—have  time  to 
respond.  Other  than  that,  China’s  legal  system  does  not  recognize  prior 
judgments  as  precedents.  Decisions  and  judgments  of  courts  have  no  legal 
force.744 Even  though  in  practice  certain  decisions  of  the  Supreme  People’s 
Court have already been repetitively cited as precedents by courts at  lower 




The  limited  legal  sources  restrict  the  patentable  subject  matter  to  the 
categories  listed  in  statutes,  regulations  or  rules.  Even  after  a  patent  is 
granted by the patent office, any individual still has the right to challenge the 
validity  of  the  patent  before  the  courts,  and  judges  may  revoke  a  patent 
under  current  codified  laws;  but  judges  have  no  discretionary  power  to 
broaden the scope of patentable subject matter. The only way to broaden the 
patentable  subject  matter  scope  is  to  create  laws.  However,  it  is  always 
convoluted and time‐consuming process to modify an existing law or enact a 
new  one.  A  new  law  or  modification  must  be  approved  by  the  legislature 













any  invention  contrary  to  public  interest,  national  laws  or  morality  from 
being  patented.  Besides  that,  no  law  either  excludes  or  authorizes  the 
patenting of hESCs and their production process. The Examination Guidelines 
do  exclude  hESCs  and  their  preparation  on  the  grounds  of  Article  5  of  the 
Patent  Law.  But,  this  is  simply  an  administrative  rule  implemented  in  the 
patent office for patent examination; it has no legal force in the courts. Courts 
maintain discretion  regarding  the  review of patent  validity  referring  to  the 
Examination  Guidelines  or  not  as  they  choose.  Since  there  is  no  such 
litigation  challenging  the  validity  of  the  Examination  Guidelines  or  the 
validity  of  granted  patents  on  hESC  making  processes,  it  is  too  early  to 
predict what the courts’ response will be. The courts may optionally refer to 
the  Examination  Guidelines,  or  submit  a  request  to  the  Supreme  People’s 
Court  for  judicial  interpretation  or  proposal  of  legislation.  But  the  judicial 
interpretation  is  still  subject  to  the  oversight  of  the  Standing  Committee, 
which has the ultimate law interpretation power.747  
The  legal  system  in  the  EPO  is  more  complicated.  The  decisions  or 
opinions of  the EBA “de facto” bind the corresponding Board of Appeal and 






of  human  cells  at  present,  the  decision  would  have  very  limited  effect  on 
other  patent  applications  or  patent  cases.  In  order  to  widen  the  subject 







the  EPC;  the  EPO  has  no  authority  over  such  changes.  With  regard  to 
controversial  topics  such  as  hESCs  patentability,  it  is  always  difficult  to 
achieve  a  consensus  among  member  states  because  of  the  ethical 
implications  of  such  topics  and  the  various  standpoints  of  the  countries, 
especially  considering  that  the  legal  status of hESC  research  is unsettled  in 
the  EPO.  It  is  a more  formidable  task  to  patent  hESC’s  in  the  EPC  than  in 




court.  In a  recent opinion  issued by  the European Court of  Justice,  it  stated 
that the European and EU Patent Court Agreement was not compatible with 
EU  treaties. 749  However,  this  is  not  the  final  decision.  If  the  proposed 
European  patent  court  is  established,  it  will  change  the  judicial  system  on 
patent issues in the European Union. 
From  the  foregoing  analysis,  it  can  be  seen  that  the  legal  system  of  a 
country impacts its patent scope heavily, especially on controversial subjects. 
In  common  law  countries,  policy  and  law  can  be  decided  or  changed  by 
judges  through  judicial  decisions,  which  favors  the  broadening  of  subject 
matter  scope  to keep pace with  technological developments.  In  contrast,  in 
civil  law  countries,  any  change  or  extension  of  patentable  subject  matter 









to  those  areas  authorized  by  the  people.750 Because  the  United  States  is  a 
comparatively  new  country,  there  is  no  lengthy  history  of  feudalism  to 
impede  the  social  revolution.751 Also,  possibly  because  of  its  geographic 
independence,  it  did  not  suffer  from  the  continuing  influence  of  European 
colonists’  native  cultures  on  its  own  social  values:  democracy, 752 
autonomy,753liberty and equality.754 Individual rights play an essential role in 
American moral vocabulary.755 Government’s authority is restricted.756  
Property  and  liberty  are  not  independent  from  each  other.757 Congress 
confirmed  a  patent  has  the  attributes  of  property, 758  and  some  courts 
consider a patent right to be a property right too.759 As an individual right,760 
patent  rights  entitle  patentees  to  exclusive  control  over  their  works.761 
Meanwhile, the public has a right to access information in the public domain. 































expired  patents.762 Another  example  is  the  excluded  subject  matter  not 




knowledge.  There  are  two  ways  to  solve  the  conflict  between  individual 
rights  and  public  rights.  One  is  to  control  the  threshold  of  patenting;  the 
other is to set the patent duration.763 The former includes the requirements 
of  patenting,  for  instance,  the  scope  of  patentable  subject matters,  and  the 
criteria of novelty, non‐obviousness and utility. These determine the scope of 
the  individual  right  against  the  common  wealth  available  to  the  public. 
Compulsory licensing is a power of the government to force the patentee to 
license  his  patent  to  a  third  party  for  using  or  selling  the  product  under 






















considered  less  flexible  than  patent  pools. 767  In  addition,  it  stifles  the 
inventors’ incentive to develop technology.768  
In  contrast,  China  has  a  different  history.  Historically,  China  was  a 
“bureaucratically  organized  country”  which  emphasized  the  good  of  the 
country and  the authority of  the government.769 After  the  foundation of  the 
People’s  Republic  of  China,  a  system  called  “democratic  centralization  of 
authority”  was  adopted,  which  shares  some  features  with  the  traditional 
Chinese  bureaucratic  system. 770  Over  many  years,  state  interest  was  a 
dominant factor in almost all social and economic activities. The government 
played  an  essential  role  in  economy.  State‐owned  corporations  were  the 
main investors and participants in the market.771 The decision‐making power 
was  in  the  hands  of  the  state.772 In  recent  decades,  China  has  gradually 
encouraged private economy to develop. Various apects of a private economy 























state  interest,  societal  interest,  collective  interest,  pubic order  and national 
security.775 Public interest and public order occupy a very important position 
in Chinese society and the state  is  the guide to public  interest.776 Individual 
rights are subject to the state interest test.777  
It  is  also  true  in  patent  laws,  inferring  from  the  rules.  Article  5  of  the 
Patent  Law  stipulates  an  exclusion  of  patenting  certain  inventions  for 
reasons of public  interest  and  social  ethics. This  is  an example of weighing 





significance  compared  with  another  invention  or  utility  model  for 
which a patent right has been granted earlier and the exploitation of 
the  later  invention  or  utility model  depends  on  the  exploitation  of 
the  earlier  invention  or  utility  model,  the  patent  administrative 


















patentee  and  other  researchers  cannot  achieve  an  agreement  to  remove 
patent obstacles, provided that the patent is critical to further study or future 
innovations in some extreme cases.  
The  concern  for  public  interest  leads  to  caution  in  the  scope  of  patent 
subject  matter  and  patentability  of  hESCs.  hESC  research  and  inventions 
involve  contentious  ethical  issues  in  Chinese  law. 778  Patenting  the 
innovations  not  only  confirms  the  legal  status  of  conducting  such  research 
and  making  related  products,  but  also  legally  monopolizes  the  research 
results  through  the  patent  system.  hESCs  and  derivative  productions  have 
such  tremendous  importance  to  human  beings  for  diagnosis,  disease 
treatment  and medicinal  development  that  nobody  should  exclusively  take 
advantage of the benefits by excluding the public from using them. Compared 
to  the  lives  waiting  to  be  rescued  by  applying  new  techniques  and 
applications  of  hESCs,  the  individual  patent  right  of  the  patentees  is 
negligible.  The  research  on  hESCs  is  still  encouraged  in  China.779 But  the 
research result is not protected in patent law.  
Like  China,  the  EPC  has  similar  public  order  and  morality  clauses.  For 
instance,  Article  53(a)  of  the  EPC  sets  fort  the  general  public  interest  rule, 
and Rule 28  and Rule 29 provide  specific  rules  regarding public  order  and 
morality.  The  European  patent  office  excludes  hESCs  in  patent  law  due  to 
their  close  relation  to  human  embryos  and  fear  that  the  commercial 
exploitation of hESCs results in commercialization of human beings.780 Since 











In  conclusion,  the  U.S.  focuses  on  rewarding  hESC  inventors  for  their 
efforts by entitling the inventors to patent law protection as an incentive for 
scientific  innovation.  By  contrast,  the  EPO  and  China  focus  more  on  the 
impact  of  patents  on  the  public  interest.  For  instance,  avoiding  the 
commercialization of humans  including human embryos  in order to protect 





continually  broadening  patent  monopoly.  Since,  in  the  U.S.,  the  perception 
has  already  been  created  that morality  should  be  the  concern  of  Congress 
rather  than  the  patent  office,782 both  the  courts  and  patent  office  avoid 
mentioning  morality  in  cases.  Instead,  courts  and  the  patent  office  have 
exhibited  the  trend  of  becoming  stricter  with  other  requirements  of 
patenting.  A  Federal  District  Court  issued  a  judgment  declaring  that  gene 
inventions, without human modification, are still products of nature and that 
isolation  is not sufficient  to distinguish a human element  from a product of 




recent  decision  in  2010,  on  the  grounds  of  lacking  non‐obviousness.  It 
reached this decision by applying a different criterion of non‐obviousness—






obviousness  standard.  The BPAI  believed  that  the  patent  at  issue  does  not 
satisfy the non‐obviousness requirement because the technique it employs is 
obvious  to  try  based  on  the  techniques  disclosed  in  the  prior  art.784 These 
two decisions apply different  requirements,  one  is novelty and  the other  is 




even  in  the  absence  of  a  morality  clause.  After  the  WARF  patents  were 
granted,  Geron  Corporation  acquired  exclusive  license  on  three  significant 
cell types: neural cells, cardiomyocytes (heart muscle tissue), and pancreatic 
islet  (insulin‐producing)  cells  made  from  embryonic  stem  cells.  Thus,  all 
individuals  seeking  to  use  these  particular  stem  cells  must  contract  with 
Geron.785 This  creates  a  perfect monopoly  on  hESCs  in  the  hands  of WARF 
and  Geron.  Even  though  WARF  signed  a  Memorandum  of  Understanding 
[MOU] with the Public Health Service of the U.S. and the HHS to supply WARF 
cells  to scientists at  the NIH  for  teaching or basic non‐commercial  research 
programs,  and  allows  federal  non‐profit  institutes  access  to  the  stem  cells 
upon  the  negotiation  of  similar  agreements,786 this  only  entitles  such  third 
















office’s  concerns  as  well.  I  speculate  that  after  noticing  the  voice  of 
opposition  to human genes and hESCs patents,  the patent office and courts 
gradually realized the side effects of the monopoly on the public welfare and 
subsequent  research  programs.  While  Congress  still  has  not  taken  any 
measures to preclude such patents, the courts and patent office are using the 
requirements  of  novelty  and  non‐obviousness  as  a  shield  to  clear  the 
obstacles  and  monopoly  for  hESC  and  other  scientific  research.  It  will  be 
interesting  to perceive  the policy orientation behind  the decisions. The end 
result  is  that hESCs and other human element patents  are  restricted  in  the 






hESC  research  in  the  regions  under  study.  The  U.S.  receives  the  most 
applications and patents on hESC related inventions.  
Figure  7.1  shows  the  top  ten  countries  that  own  the most  hESC  related 
patents  issued respectively  in the U.S.,  the EPO and China.  It  illustrates that 
the U.S. is the top country, owning the most patents in relation to hESCs. It is 
also the country that issues the most patents applied for by foreigners. It also 









The  status  and  development  of  hESC  research  affects  states’  policies 
because  the  more  hESC  research  achievements  in  a  country,  the  more 
competitive  the  country  is  in  the  hESC  related  pharmacy,  research  and 
therapy  fields of  the global market and  the more motivation  it has  to  issue 
protective  policies  and  laws  in  order  to  safeguard  and  utilize  its  research 
advantages.  In  contrast,  if  a  country  has  only  minimal  hESC  research 
programs  or  the  research  it  has  is  comparatively  lagging,  it  will  tend  to 
remove  any monopoly  protection  on  research  result,  so  as  to  share  in  the 
research progress,  and prevent  other  countries with higher  research  levels 
from taking take advantage of the patent system.  
The U.S. has the most advanced hESC research in the world. Although the 
policy  of  the  federal  government  on  hESC  research  is  shifting,  state 
governments  and  private  research  institutes  have  never  stopped  their 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Comparatively,  in China, very few other companies or institutes have the 










the  government  and  the  innovation  results  are  in  the  hands  of  the 
government, there is little domestic benefit to be achieved through the patent 
law,  which  aims  “to  protect  patent  rights  for  inventions‐creations,  to 
encourage  inventions‐creations,  to  foster  the  spreading  and  application  of 
inventions‐creations,  and  to  promote  the  development  of  science  and 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right  is  only  a  territorial  right,  the  government  can  always  turn  invention 
applications  from other countries down  for national patent  laws regardless 
of the patent regulations in other countries. It does not have to worry about 
the  research  results  or  resources  being  monopolized.  Thus,  within  the 
territory of China, there is no scientific research demand or market needs for 
patenting hESCs. 
Regarding  the  European  Patent  Office,  the  policy  making  is  more 
independent  from  research  progress  motivations  than  is  the  case  in 
individual countries with national patent systems. As a regional organization, 
the EPO has a neutral policy‐making process and administrative office; as a 
result,  the  EPO’s  patent  rules  are more  independent  from  the  objective  of 
stimulating research development.  
Due to  the different  levels of hESC research progresses and the different 














legislation  and  policy  concerning  biotechnology  is  to  bring  China  into  the 
competition in scientific study and the end‐product industry.  
Because of its cultures and transitions, China has a tendency to maintain a 
conservative  view  toward  any  ethical  or  controversial  issues.  Wherever 
negative  impacts  are  possible,  China  may  tend  to  be  very  careful  and 
cautious.  This  general  tendency  applies  to  biotechnological  inventions,  too. 
Current Chinese patent legislation regarding biotechnology covers almost the 
entire  field  of  biotechnological  research  and  expresses  China’s  stance  on 
some  ethically  controversial  issues,  such  as  hESC  research  and  its 
patentability. However, the current legal system is not perfect. It is the main 
goal of this dissertation to analyze the legal issues, especially in patent law, in 
relation  to  hESC  research,  in  order  to  unify  the  laws  on  hESC  innovation 
among countries. 
The main goal of patent law is to grant monopolies to inventors in order to 
promote  science  and  technology.789 The  degree  of  monopoly  is  the  main 
factor  to  be  adjusted  through  patent  law  in  order  to  stimulate  scientific 
innovation while maintaining a market with free competition.790 But the line 
is difficult to draw. With respect to essential tools of discovery and research 
in  biotechnology,  the  main  concern  is  over  the  side  effects  of  patenting—
stifling  further  developmental  innovations  due  to  the  high  costs  of 
licensing.791 In  the  meantime,  lack  of  adequate  patent  protection  may  also 
cause stagnation  in scientific research. Without patent  law, research results 










and  shared with  the  public.792 Thus,  it  is  accepted  that  while  patent  rights 
promote  innovation,  they should not  restrain research on essential  tools.793 
However,  there  is  no  consensus  on whether patent  law  should be used  for 
hESC innovations and if so how.  
Considering  the  importance  of  hESCs  to medicinal manufacture,  therapy 
and  diagnostic  research,  each  country  should  be  concerned  regarding  the 
patent  status  of  hESCs,  because  the  fields  of  industry  and  science  are 
impacted.  To  some,  patent  law  may  not  seem  critical  because  it  has  only 
territorial  jurisdiction.  Nonetheless,  the  world  faces  greater  and  fiercer 
industrial  and  scientific  competition  and  an  enlarging  globalized  market. 
Thus, it is crucial for countries to consider the place of hESCs in patent law in 
order to allow the patentees to have the advantage of an initial monopoly and 
to  avoid making decisions  that will  negatively  affect  industry  and  scientific 
research. As for the U.S., hESCs are presently patented. If these patents were 
to be considered invalid and opened to the public in the future, the licensees 
who  spent  tremendous  time  and  money  negotiating  license  agreements 
would be negatively impacted, which would, in turn, stifle the enthusiasm of 
research pioneers and bring about  instability of  the  industry as well  as  the 
market. On  the other hand, with  respect  to  states  that ban  the patenting of 
hESC  innovations such as China,  if  the ban  is ultimately removed, countries 
that had previously allowed the patenting of hESCs, such as the U.S, will have 
the  advantage  due  to  the  international  priority  right  of  their  inventions. 
Europe and China will lose not only the market for hESCs, but also the market 









China  as  in  the  US.  The  main  reason  for  this  is  that  most  of  the 
biotechnological  research  in  China,  especially  hESC  research,  is  conducted 
and supervised by national  research  institutes or public universities due  to 
the  fact  that  such  research  is  costly  and  requires  highly  professional 
researchers. This type of research could hardly be conducted by individuals 
or small enterprises.  
Three major benefits  are  realized  from  this  situation.  First,  the  research 
findings  are  primarily  under  the  control  of  the  government,  which 
diminishes  the  possibility  of  misuse  or  illegal  conduct.  Second,  it  dispels 
worries about  future research being  impeded by high royalties and  lengthy 
negotiations  because  the  government  will  supervise  licensing  and  assign 
activities  for  the  maximum  benefit  of  the  country  as  a  whole;  therefore, 
people do not need to worry about a research monopoly hampering further 
downstream development. Third, research results can be utilized and applied 
under macro‐control  for the public  interest.  In case of emergencies, such as 
those situations in which public safety is at risk, decisions can be made more 
quickly and measures can be implemented more thoroughly.  







social  values,  and  religion,  the  model  law  below  is  created  for  general 
situations  overall  and  not  specific  nations.  In  the mean  time,  all  countries 
219 





There are different types of rights  in a  legal system. These rights  include 
but  are  not  limited  to  the  right  to  freedom,  physical  property  rights,  and 
intellectual property rights. In order to protect and use the intangible values 
of intelligence and biotechnological techniques, intellectual property law is a 
good  option.794 This  category  includes  patent,  trade  secret,  copyright  and 
trademark  areas.795 Compared  to  trade  secret  protection  that  enables  the 
developer of an  invention  to maintain “an advantage over competitors who 
do  not  know  or  use  it”  as  long  as  the  information  is  a  secret,796 patent 
protection has more advantages in protecting and promoting hESC research.  





























Second,  a patent  right has  a  term period. An  appropriate  term of patent 
protection  can  guarantee  a  patentee  the  benefit  of  his  exclusive  right  and 
yield  profit  from  his  investment.  Meanwhile,  it  also  ensures  the  public’s 
access to the innovation by public disclosure, which is not required in trade 







Third,  given  the  experiences  of  countries  around  the  world,  patent  law 
appears  to be  the best  option  for biotechnology  innovation protection. The 
U.S. utilizes patent law to protect research findings on hESCs. The European 
Union  also  chose  patent  law  to  protect  biotechnological  innovations  by 
issuing  Directive  98/44/EC. 801  hESC  research  is  merely  a  category  of 
























Chinese  and  European  patent  laws  have  specific  non‐patentability  clauses 
while the exclusion of patentable subject matter in the U.S. is contained in the 
case  law.  They  all  have  a  definitive  clause  enumerating  broad  patentable 
categories, limited by a list of exclusions. This is mainly because the scope of 
eligible subject matter for patenting is  fairly broad and it  is easier to define 
the  scope  of  subject  matter  by  exception  rather  than  illustration.  Today, 
compositions  of  matter,  living  or  not,  and  processes  and  improvements 
thereof  are  eligible  for  patenting.  With  the  development  of  biotechnology, 
this  scope  is  broadened  to  include  more  highly  developed  animals  and 
related products, such as human tissues and materials. 
The  sources  of  the  nonpatentability  clauses  are  different  between  the 
countries  studied,  with  European  and  Chinese  exclusions  adopted  in 






unpatentable  categories  in  common,  such  as  scientific  discoveries, 
phenomena of nature, mental activities, and mathematical formulae. But they 
also  have  some  categories  that  differ  due  to  different  laws.  However,  each 
country’s  list  of  unpatentable  substances  is  consistent  with  the  patent 
requirements  in  its own laws. Subject matter  is not patentable because  it  is 
either not novel, or has no specific and substantial utility, or,  in  the case of 
the  EPO’s  practice  and  Chinese  patent  laws,  is  contrary  to  social  norms  or 
public interest. The clauses enumerating specific exceptions to patentability 





Whether  to  include  morality  requirements  within  patent  law  is  a 
contentious  question.  The  TRIPS  Agreement  gives  member  states  the 

















The  U.S.  refuses  to  consider  morality  in  patent  law  because  patent 
examination is about technique and science, not ethics.806 I am in favor of this 
opinion  that  patent  law  should  focus  solely  on  technical  requirements  and 
leave  the  moral  and  ethical  issues  to  the  legislature  or  relevant 
administrative  agencies,  not  only  because  patent  officers  are  technical 
experts, not ethicists or politicians, but also because states should allow them 








Second,  the patent system  is  incapable of adequately governing research 
conduct.  States  should be  fully  aware  that  the patent  law  is  a poor  tool  for 
governing  inventions  or  research  contrary  to  morality  or  public  order.  A 
patent  can  be  considered  a  negative  right.  Once  a  patent  is  obtained,  an 
inventor  can  reap  the  benefits  of  his  creation  and  has  the  right  to  exclude 
others from using his invention without permission. But patent law is neither 
appropriate, nor designed,  to supervise  inventions on a basis of morality.  If 
the  patent  law  incorporates  morality  considerations  and  rejects  some 












them.  This  result  contradicts  the  original  intent  of  the  morality  clauses. 
Therefore, patent law is the wrong tool to govern morality. 
Therefore,  excluding  the  patentability  of  hESCs  in  a  patent  regime  is 
ineffective in accomplishing the goals of those who advocate such exclusion. 
The  suggestion  is  that  countries  should  remove  the  morality  clause  from 
patent  law. China  should  remove Article 5 of  its Patent Law, and European 
Patent Convention should eliminate its Article 53(a) and corresponding Rule 
28.  Instead,  they should set  forth  in public  law or administrative  law direct 





The  novelty  clause  involves  the  requirement  of  being  new,  not  used, 
known, or  filed  for  in a patent application by a  third party before  the  filing 
date  of  the  patent  application.  One  distinction  between  invention  and 





law,  the novelty requirement  for biotechnological  innovation  is  that  it must 
be  separated  or  isolated  from  its  original  natural  environment,  with  its 
structure or physical characteristics revealed and a viable method to obtain it 
provided. However, novelty should require more than that. In order to meet 







that  does  not  exist  in  the  nature  world.  This  criterion  should  apply  to  all 
kinds of human materials such as human genes, and human cells. 
With respect to hESCs, as long as they are manipulated, isolated or refined 
by  people,  and  demonstrate  a  new  stage,  new  characteristics  or  new  use 
compared  to  the  prior  art,  they  meet  the  requirement  of  novelty.    hESCs 
isolated from embryos and cultured in specific media are novel because after 
being  cultured  in  an  artificial  environment,  the  molecular  structure, 
characteristics and even chromosomal structure may be changed and differ 
from  the  cells  of  the  embryos  from  which  they  were  derived.810  hESCs 
obtained  with  SCNT  that  have  unstable  and  irreversible  gene 
representation811 and iPSCs are created with human manipulation. They are 
novel  only  if  they  comprise  distinctive  characteristics  from  naturally 
occurred  human  cells.  Genetically  altered  hESCs  are  even  more  artificially 
modified. They have distinctive  characteristics  that differentiate  them  from 







The  general  value  in  research  and medicine  is  so  unique  and  irreplaceable 






industry.812 This  problem  can  be  solved  by  setting  up  the  requirement  of 
industrial  applicability;  merely  scientific  or  research  utility  should  not  be 
sufficient for patenting.  
The  requirement  of  industrial  applicability  means  that  first,  inventions 
being considered for patenting must have a practical, immediate, specific and 





Mere  scientific  achievement  or  research  value  does  not  satisfy  this 
requirement because it does not have immediate, specific and practical value. 
Methods for treatment by surgery or therapy and diagnostic methods cannot 
be  industrially  applied  because  they  are  based  on  patients’  personal 
situations  and  everyone’s  reaction  to  a  medicine  or  treatment  may  vary; 
therefore, they have no industrial value, but they do have clinical use. Nor do 
business methods meet the industrial application requirements.816 Regarding 
biotechnological  inventions,  any  product  or  process  that  utilizes  random 
mutation under  chemical  or physical  conditions  that  cannot be  repeated  in 
manufacture is not industrially applicable, and as a result, is not patentable.  
The same criterion applies to methods of using or producing hESCs. hESC 














achieve  concrete,  substantial  and  practical  results.  Only  when  they  meet 
these requirements, can they be patented. 
Non‐modified hESCs per se have no present direct and concrete technical 
results  in  the  real  world.  Their  utility  relates  to  the  process  of  their 
differentiation  into  multipotent  stem  cells,  or  their  existence  in  a 
transformed  state.817 In  terms  of  practical  and  specific  use,  therefore,  they 
have no immediate benefit to the public. The main use of hESCs is to utilize 
their  pluripotent  properties.  This  is  similar  to  the  expression  “biological 
properties,” which  is nebulous and general.818     In conclusion, non‐modified 





As modern developments  in  industry and  technology emerge,  the patent 
system is evolving beyond the primitive industry for which it was originally 
conceived.819 Instead,  it covers new  industries,  such as biotechnology, semi‐





Non‐obviousness  means  that  an  invention  is  so  original  that  it  is  not 








prior  art.  In  the  USPTO,  there  are  two  different  interpretations  of  non‐
obviousness:  “obvious  to  try”  and  “obvious  to  achieve.” 821  These  two 
standard should be applied together.  
First, patent offices should determine whether an invention is “obvious to 
try”  based  on  the  current  technique,  which  includes  several  factual 




factors,  such  as  the  failure  of  others,  the  needs  of  the  market  and  any 
commercial success achieved.822  
This  requirement  was  the  main  divergence  between  the  BPAI  and  the 
patent office on WARF patent ‘913. On the issue raised in that case, the first 
considerations  should  be  how  different  the  embryonic  stem  cell‐deriving 
techniques  employed  on  other  mammal  species  are  from  the  derivation 
technique  claimed  in  the  present  patent;  whether  the  difference  is  large 
enough to be obvious “to try” to people practicing the art with ordinary skill 
and creativity; and whether the technique at bar solves problems known in 
the prior  art.  These  are  technical  questions,  and need  to be determined by 

















Based  on  the  above  analysis,  example  rules  articulating  patent 
requirements,  taking  into  account  the  new  developments  in  biotechnology 
follow: 
Article  1.  In  order  to  encourage  inventions,  to  foster  the  spread  and 
application of inventions, and to promote the development of science and 
technology,  this  law  is  enacted  to  protect  inventors’  exclusive  rights  on 
creations  that  are  new,  inventive  and  industrially  applicable,  including 
process, products, or any improvement thereof for up to 20 years. 
Article  2.  No  patent  right  shall  be  granted  for  any  invention  that  is 
contrary to the laws; inventions shall not be deemed to be contrary merely 





(2)  Inventions shall not be considered new  if (a)  the  invention was  in 
use by others in public, or patented or described in a printed publication 








An  invention  shall  be  considered  to  be  susceptible  to  industrial 
application if  
(1)  it  can  be  made  or  used  in  one  or  more  industries,  including 
agriculture, and 
(2)  it  can  be  made  or  used  with  substantial,  concrete  and  practical 
results.  
Article 5. Inventiveness 
(1)  An  invention  should  be  considered  inventive  compared  to  the 
technology  existing  in  the  art  to  which  it  pertains  if  the  differences 
between  the  invention  and  the  prior  art  are  so  substantive  that  the 
invention would not be obvious with reasonable expectation of success to 
a  person  having  ordinary  skill  in  the  art  at  the  time  the  invention  was 
made. 
(2)  Other  elements  should  also  be  considered  in  determining  non‐
obviousness of the invention, such as the needs in the market, commercial 
success, and long‐term attempts but failure in the art. 
There  is no need to  list all of  the unpatentable categories  in  law because 
they all fail to meet at least one of the patenting requirements. According to 
the rules in the model law, discoveries should not be regarded as inventions 
because  they  fail  the  creation  element  in  Article  1  and  the  novelty 
requirement in Article 3. 
However, to be clear, states can incorporate this content in implementing 
rules,  i.e.,  Implementing  Regulations  to  the  EPC,  Detailed  Rules  for  the 
Implementation of the Patent Law in China. 
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Rule  1.  Presentations  of  information,  scientific  theories, 
mathematical  methods, aesthetic  creations, schemes,  rules  and 
methods  for  performing  mental  acts,  methods  for  treatment  of  the 
human or animal body by surgery or  therapy and diagnostic methods 
practiced on  the human or animal body are not patentable  since  they 
do  not  possess  industrial  applicability.  They  either  cannot  be 
manufactured,  or  do  not  achieve  substantial,  concrete  and  practical 
results. 
Rule 2. Human embryonic stem cells, human genes and other human 
cells without modification are not patentable even  if  they are  isolated 
or purified from human body, or created with the somatic cell nuclear 
technique.  However,  methods  of  isolating,  purifying  or  modifying 
human  materials  are  patentable.  Induced  pluripotent  stem  cells  are 
patentable  if  they meet  the  requirements  of  novelty,  industrial  utility 
and inventiveness.  
Rule  3.  Computer  software  is  protected  by  copyright  therefore 
should not be  subscribed  to patent  law. Plant  and animal  varieties or 
essentially  biological  processes  and  should  not  be  subordinate  to 




apply  the  criteria.  Additionally,  courts  and  the  USPTO  can  adopt  the 
reasoning  in Ass'n  for Molecular Pathology v. United States PTO (2010)  that 
















interpreted  very  narrowly,  merely  for  non‐business  purposes,  which  is 
defined very narrowly. Other uses, even for legitimate business purposes, are 
considered  infringement.  In  the EPC,  patent  enforcement  is  left  to member 
states as well  as  the  interpretation of  the  infringement exemption.  In  some 
European  countries,  the  exemption  is  given  broad  interpretation.  The 
exemption for experimental use is based on the idea that no direct profit will 
be gained.824 This  interpretation of  the exemption clause  is broader  than  in 
the  U.S.  because  experiments,  even  with  commercial  intention,  are  also 
protected under such interpretation.825 In China, Article 63(4) articulates the 













ultimate  goal.  Most  research  activities  have  a  business  purposes  to  one 
degree or another,827 either to enable the creation of a downstream product, 
or  to  apply  a  technique  or  composition  in  practice  to  solve  a  practical 
problem. Therefore, it is suggested that in order to keep pace with the needs 










For  instance,  states  can  rule  that  in  the  case of  a  national  emergency or 
other extraordinary  circumstances,  or where  the public  interest  requires,  a 
compulsory  license should be granted  to use or exploit  relevant patents.  In 
addition, whenever an  invention of  technical significance requires access  to 
another  patent  granted  earlier,  and  the  exploitation  of  the  later  invention 
depends  on  the  exploitation  of  the  earlier  invention,  a  compulsory  license 
should be granted upon the request of the later patentee. 
Patents  on  hESCs,  relevant  processes  and  certain  downstream  products 





and  pharmacy,  the  enforcement  of  patents  related  to  hESCs  should  be 
subordinated  to  the  compulsory  license  clause;  states  should  adopt 
compulsory licensing measures on hESC’s relating patents if it is necessary to 




Europe  and  China  both  include  morality  requirements  in  patent  laws, 
while  the U.S.  patent  law does  not. Whether  to  consider morality  issues  in 
patent law is essential to the patentability issue of hESC innovations, because 
patenting  hESCs  can  easily  be  considered  contrary  to  social  morality  and 
ethics  since  it  involves  commercializing  the human body, monopolizing  the 
commons and diverting essential facilities and research tools from the public. 
At  the  same  time,  hESC  research  is  encouraged  at  the  government  level  in 
China,  most  countries  in  Europe,  and  to  some  extent  in  the  U.S.,  and 





To discuss the morality  issue,  there  is one fundamental prerequisite that 
needs  to  be  clearly  understood:  the  starting  point  of  personhood.  Does  it 
begin at fertilization, birth, or some point in between? As introduced before, 
this  is  a  complex  question  not  only  involving  biology  and  science,  but  also 











Most  people  support  hESC  research  on  extra  embryos  left  over  from 
fertility  clinics.828 The  reason  is  that  these  embryos  are  no  longer  needed; 






Reproductive  technology,  which  assists  infertile  couples  to  achieve  their 
dream of pregnancy, also creates some unexpected difficulties. It has caused 
custody disputes during divorce proceedings. When a couple divorces, who 
has  custody  of  unused  frozen  embryos  and who  has  the  final word  on  the 
disposition of  these embryos? Since there  is no  law directly addressing this 
issue,  courts  have  taken  four  paths  to  answer  it:  considering  embryos  as 
persons,  as  potential  human  life,  somewhere  between  tissues  and  human 
beings,  and  mere  property. 830  Because  there  is  no  consensual  way  to 















litigation  regarding  this  issue.  But  a  similar  issue  occurs  in  the  case  of 
ownership  of  research  results  and  profits  derived  from  biological material 
taken from patients.  
The  current  practice  is  that  cells  and  tissues  removed  from patients  are 




court  states  that  the materials  removed  from  the  patients  are  “inter  vivos 
gifts”;  after  the  donation  is  performed,  the  patients  lose  their  right  to 
repossess or  transfer  the materials.833 Tissue  from human bodies  is  slightly 
different from the embryos because unless discarded, frozen embryos belong 
to the parents. By discarding the embryos, the parents give up the ownership 
interest  as  well  as  the  future  profits  that  may  be  generated  from  the 
embryos.  Instead,  the  clinics  have  the  right  to  claim  the  embryos,  launch 
research  activities  and  reap  the  profits  thereafter.  However,  research 













such  as  SCNT‐produced  embryos,  the  main  issue  is  whether  the  SCNT  is 
permissible.  In  the  United  Nations  Declaration  on  Human  Cloning,  human 
cloning  is prohibited out of  consideration  for human dignity, women rights 
and  human  life.834 But  there  are  several  countries  that  voted  against  the 
Declaration  because  it  arbitrarily  bans  on  all  forms  of  human  cloning, 
including therapeutically cloning. 835 These countries include China and most 
of the European Union members.836 The U.S. voted in favor of the Declaration. 
However,  the  document  is  a  non‐binding  political  statement,  which means 
that  countries  still  have  the  freedom  to  maintain  their  individual  attitude 
towards  therapeutic  cloning.  Regarding  the  different  purposes 837  and 
processes838 of  reproductive  cloning  and  therapeutic  cloning,  the  former 

























technique  is  to  induce  embryonic‐like  stem  cells,  which  have  similar 
characteristics  to  ESCs,  from  somatic  cells.  The  farther  away  the  research 
source  is  from  human  embryos,  the  lower  the  chance  it  will  bring  about 
ethical  controversy.  To  date,  iPSC  research  has  achieved  some  progress. 
IPSCs may  ultimately  be  a  replacement  for  hESCs  for  research  or  therapy, 




research  achievements  attained  so  far,  the  importance  of  hESC  research  is 
undeniable  and  the  future  of  hESC  research  is  inevitable.  In  order  to  fully 
utilize such a precious resource  for human welfare  to  the  full extent  that  is 
ethically  allowed,  the  research  would  benefit  if  the  limits  were  explicitly 
defined in laws. States should promulgate law on hESC research to clarify the 





federal  government  used  to  prohibit  the  funding  of  hESC  research  entirely 
because of  its damage  to human embryos and,  for  the same reason,  it  later 
funded only that hESC research conducted on cells derived from sources that 










programs  who  are  trying  to  obtain  already  received  federal  governmental 
support,  it  also  impedes  and  slows  research  progress  because  policies  are 
changing  back  and  forth.  For  the  sake  of  hESC  research,  the  U.S.  federal 
government  should  adopt  a  consistent  and  stable  policy  standpoint  by 
consulting  Congress  and  Judiciary  in  order  to  gain  the  support  from 
legislative and judicial branches and achieve consistency in the long run. 
There  are  three  aspects  that  should  be  emphasized  in  hESC  research  in 
distinguishing  legal hESC research activities  from illegal activities. First,  the 
research must have a legal aim. The state should consider the purpose of the 
programs.  If  the  goal  of  research  programs  is  to  extract,  culture  or  derive 
cells  from  human  embryos,  they  should  be  allowed  due  to  their  legal 
purpose.  As  to  the  concern  that  the  ultimate  purpose  is  difficult  to  predict 
from  the  beginning  of  research  work,  it  should  be  left  to  government 
agencies to oversee research conduct. Second, the state should supervise the 
embryo  source  of  hESC  research  because  the  source  of  the  embryos  is  the 
main key to the legality of the research program. Human embryos produced 
through  reproductive  cloning  should  be  prohibited;  hence  research 
conducted  on  cloned  embryos  or  human  beings  should  be  banned  as well. 
Similarly, embryonic research on material from unknown sources should be 
suspect; unless the researchers can prove the legal origin of embryos used in 
the  program,  the  research  should  be  banned.  If  the  embryos  are  obtained 
from  fertility  clinics,  the  researchers  should  present  the  consent  of  the 
parents  or  proof  of  embryo disposition.  Third,  states  should  issue  codes  of 
research conduct, for instance, the blastocysts used in research should be no 
more than 14 days old after their creation by in vitro fertilization or nuclear 











Human  embryonic  stem  cell  research  is  an  essential  branch  of 
biotechnology  due  to  its  critical  therapeutic  and  medical  values.  While  a 
substantial amount of research has already been accomplished, there are still 
many  aspects  of  hESCs  that  are  not  completely  understood  which  leaves 
some  properties  and  potentials  unclear.  In  addition,  there  is  an  open 
question  regarding  the  ability  to  use  other  types  of  stem  cells  as 
replacements  for  the therapeutic and medicinal values attributed to hESC’s. 
Because  of  the  tight  bond  between  hESCs  and  human  embryos,  hESC 
research  receives  opposition  from  both  religious  and  ethical  perspectives. 
Although  this  dissertation  is  focused  on  the  legal  aspects  of  hESC  patent 
protection, certain religious and ethical  issues are presented as background 
due to their large influence on the law‐making process. There are a number 





policies  toward  hESC  research.  The  United  States  has  a  history  of  federal 
appropriation  policy  changes  swinging  between  supporting  and  opposing 
viewpoints  on  hESC  research.  In  contrast,  China  has  been  very  consistent 
with  its  policy  of  supporting  hESC  research.  Considering  the  variation  in 
legitimacy and progress on hESC research in member states of the European 





in  the  U.S.  and  China  is  not  always  consistent  with  their  hESC  research 
policies.  
Historically,  the  U.S.  government  hesitated  and  was  reluctant  to 
appropriate  hESC  research  funding  due  to  ethical  concerns,  though  the 
situation  has  changed  recently.  However,  the  long  held  policy  of  the  U.S. 
patent office confirming the patent‐eligibility of hESCs results in making the 
U.S.  the  country  that  accepts  and  grants  the  most  hESC  related  patent 
applications.  
This situation is beginning to reverse. The federal government started to 
allow  federal  appropriations  for  hESC  research  after  President Obama was 
elected.  At  the  same  time,  the  validity  of  some  hESC  patents  has  been 
challenged  for  lacking  non‐obviousness  and  novelty  in  recent  cases.  At 
present,  the  validity  of  one WARF  human  embryonic  stem  cell  patent was 
denied for lacking non‐obviousness. The final outcome is uncertain and will 
depend  on  whether  the  inventor  decides  to  appeal  the  denial.  In  the 





isolation  and  purification  is  essential  to  distinguish  isolated  human  genes 
from  the  native  genes  in  the  human  body.  A  U.S.  federal  district  court 
invalidated  two  isolated  human  gene  patents  because  it  found  them  to 
constitute a mere product of nature. Following this, the Department of Justice 
filed an amicus curiae brief and declared that human genes without alteration 




Despite  its  positive  attitude  toward  hESC  research,  China  is  fairly 
conservative  with  regard  to  its  patent  laws  related  to  hESC  innovations. 
China excludes the patentability of hESCs and production citing the morality 
clause, yet encourages hESCs research at a national  level. The gap between 
patent  law  and  laws  governing  hESC  research  is  not  compatible  with  the 
essential  motive  of  the  patent  system—promoting  science.  This  apparent 
conflict  confuses  hESC  researchers  and  investors.  The  result  is  in  direct 
conflict  with  the  ideas  behind  patent  law  and  counteracts  the  facilitating 
function normally associated with patent  law.  In China,  the  consequence of 
having conflicting hESC research laws and patent laws is reflected in a lack of 
legal  protection  for  research  achievements.  This  lack  of  protection  directly 
stifles  the  normal  impulse  towards  scientific  development.  China  has  been 
improving  its  patent  protection  during  the  past  thirty  years  since  China 
entered  the  WIPO  in  1980.  From  2008  to  2009,  the  number  of  patent 
applications  in most countries grew slowly, with an average growth rate of 
2.6%, while  China  reported  a  growth  rate  of  18.2%.841 In  2009,  China  had 
7946 patent applications through the PCT, which places it fifth in the world; 
representing  a  growth  rate  of  29.7%.842 As  of  April  of  2010,  China  had 
received 6,095,949 applications, and granted 3,369,718 patents.843 While the 
national  average  for  overall  patent  issuance  is  close  to  50%,  hESC  related 
inventions lack patent protection due to the adopted patent policy. Currently, 
the consequence of this shortfall to hESC inventions may not seem so critical 


















Union  and  the European Patent Office  are  regional  organizations  that  have 
less  authority  than  sovereign  states.  In  the  EU,  the  patent  system  is  still 
under  construction  and  has  not  yet  been  established.  With  respect  to  the 
European patent office, it does have the power to grant European patents but 
it  lacks  jurisdiction  over  patent  enforcement.  In  addition,  the  European 
Patent  Convention  establishes  an  autonomous  patent  examination  system. 
Unfortunately,  it  leaves  the  national  patent  offices  with  the  authority  to 
revoke these patents within their national  jurisdictions. The EPO ruled that 
the hESC  invention at bar was not patentable because  it violated the clause 
under  the  EPC  that  any  commercial  or  industrial  use  of  hESCs  was 
considered  a  violation  of  the  public  order  and  morality.  This  leaves  the 
definitions  for  patentability  ambiguous.  It  is  understandable  that  as  a 
regional  organization,  the  EPO  has  avoided  wading  into  controversial 
debates over ethics, and there will not be a hard rule on hESC inventions in a 
short  period  of  time  considering  the  variety  of  cultures  and  traditional 
backgrounds in member states of the EPC. Since the EPO’s decisions are not 
binding  on  the  patent  offices  in  member  states,  how  the  member  states 
accept  that  ruling  is  of  interest. With  the deficiencies present  in  the patent 
system  governed  by  the  EPO,  a  new  patent  system  is  warranted.  The 
European Union infrastructure is being designed to mitigate the majority of 
the problems present in the EPO system.  
This  dissertation  studied  and  compared  the  main  requirements  of 
patenting in the United States, China, and the EPO. Patents need to meet the 
requirements  of  novelty,  non‐obviousness  and  utility  to  be  issued  in  all 
countries, but the wording and specific requirements of patenting are slightly 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different,  which  makes  the  scope  of  patentable  subject  matter  vary.  This 
dissertation  further  examined  the  hESC  patent  prosecution  history,  hESC 
patent litigation process, and scholarly opinions on the patentability of hESCs 
in  each  country  or  region  studied  in  Chapters  4,  5,  and  6  respectively.  In 
Chapter  7,  after  studying  patent  principles  and  exploring  the  reasons  for 
rejecting or confirming the patentability of hESC inventions in the U.S., China 
and the EPO, it  is determined that hESCs, per se, are not patentable because 









comprises  two  levels  of  obviousness:  obvious‐to‐try,  and  if  so,  obvious‐to‐
succeed to a person with ordinary skill and ordinary creativity  in the art. A 
utility  clause  indicates  the  invention  should  be  able  to  be manufactured  in 
industry  and  have  a  concrete  and  specific  industrial  application.  Morality 
should  not  be  incorporated  into  patent  law  because  only  technical  issues 






utility  in  industrial  development—especially  the  internationalization  of  the 
patent  market  and  trade  market—eventual  convergence  of  patent  rules 
246 
around  the  world  is  inevitable.  However,  considering  the  complexity  and 
controversy  of  hESC  research,  it  will  be  a  long  time  before  countries 







































Ethical  Guiding  Principles:  Ethical  Guiding  Principles  for  the  Research  of 
hESC of PRC (2003) 
EU: European Union 
Examination  Guideline:  Examination  Guidelines  for  Patent  Applications 






Guidelines  for  Human  Stem  Cell  Research:  National  Institutes  of  Health 
Guidelines for Human Stem Cell Research of the U.S. (2009) 


























SCNT:  somatic  cell  nuclear  transfer,  a  process  by  which  the  nucleus  of  a 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